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ABSTRACT 
 
The cardiac sarcomere is a complex matrix of molecular machinery that is 
responsible for contraction of the heart. Proper contractile function relies on maintenance 
of rigid stoichiometry of myofilament proteins and multiple protein quality control (PQC) 
pathways. Though PQC is undeniably essential to sarcomere protein homeostasis 
(proteostasis), there are many gaps in our knowledge of factors that regulate turnover of 
sarcomere proteins. Mutations in many of these proteins cause hypertrophic 
cardiomyopathy (HCM), which is often designated a “sarcomeropathy.” HCM and is 
characterized by thickening of the left ventricular free wall and intraventricular septum, 
myocardial fibrosis, and diastolic dysfunction. The most commonly mutated gene in HCM 
is cardiac myosin binding protein C (MYBPC3). The primary pathogenic mechanisms 
associated with MYBPC3 mutations remain unresolved. PQC and protein turnover are 
central to two hypotheses with the most supportive evidence: haploinsufficiency of 
MYBPC3 in the sarcomere, and proteotoxicity of truncated MYBPC3 protein products. 
However, very little is known about how MYBPC3 interacts with PQC networks in either 
physiological or pathological conditions. The goal of this thesis was to investigate 
pathogenic mechanisms associated with different MYBPC3 mutations, explore the roles 
of protein homeostasis and turnover with respect to these mechanisms, and identify PQC 
factors which are involved in MYBPC3 turnover. 
xvi 
 
Using affinity purification-mass spectrometry, we identified several molecular 
chaperones as potential novel interactors with MYBPC3, including αB-crystallin and 
HSP27, and the inducible and constitutive isoforms of the ubiquitous heat shock protein 
70kDa family (HSP70 and HSC70, respectively). We then confirmed that HSP70 
chaperones regulate proteasomal degradation of MYBPC3 by modulating their 
expression and activity and observing effects on MYBPC3 protein half-life in a primary 
cardiomyocyte culture system. This represents to our knowledge the first identification of 
a chaperone associated with MYBPC3. 
To determine the extent to which proteotoxicity of truncated MYBPC3 contributes 
to HCM pathogenesis in isolation from haploinsufficiency, we explored the effects of acute 
and chronic expression of truncated MYBPC3 on cardiomyocyte PQC using primary cell 
culture and a transgenic mouse model, respectively. We reported no deleterious effects 
of truncated MYBPC3 expression on proteostasis in vitro or in vivo.  Further, chronic 
expression of a truncating MYBPC3 transgene in mice up to 12 months of age was not 
sufficient to elicit hypertrophic remodeling. These results challenge the hypothesis that 
truncated MYBPC3 is directly proteotoxic and suggest a “poison peptide” mechanism may 
not be relevant to HCM pathogenesis without concurrent MYBPC3 haploinsufficiency. 
Lastly, we investigated the locus-dependency of protein stability in non-truncating 
MYBPC3 mutations. Novel analysis of genotypes using the Sarcomeric Human 
Cardiomyopathy Registry (SHaRe) of HCM patients uncovered putative clusters of 
missense mutations in the C3, C6 and C10 domains of MYBPC3. We identified a 
consistent pattern in C10 mutants of lack of sarcomere incorporation and markedly rapid 
degradation. This was in contrast to C3 and C6 mutants, which were generally equally 
xvii 
 
stable as WT MYBPC3 and localized correctly within the sarcomere. These findings 
demonstrate that mutation locus significantly influences protein stability and turnover, and 
further dissect pathogenic mechanisms associated with non-truncating mutations. 
With these studies, we have moved toward clarifying pathogenic mechanisms in 
MYBPC3-linked HCM, which will inform future development of targeted interventions for 
patients with different genotypes. Furthermore, we have identified new potential 
therapeutic targets to restore normal stoichiometry to haploinsufficient sarcomeres. 
Finally, we have contributed to our understanding of the enigmatic process of sarcomere 
protein quality control. 
 
 
 
Parts of this chapter represent a published review article: Glazier AA, Thompson A, Day SM. Allelic imbalance and 
haploinsufficiency in mybpc3-linked hypertrophic cardiomyopathy. Pflugers Archiv : European journal of 
physiology. 2018 
1 
 
 
CHAPTER 1 
 
Introduction 
 
1.1 Hypertrophic Cardiomyopathy: presentation and etiology 
1.1.1 Characteristics of hypertrophic cardiomyopathy. Familial hypertrophic 
cardiomyopathy (HCM) is the most common form of the inherited cardiomyopathies, 
occurring in about 1 in 500 individuals[Maron 1995, Zou 2004]. HCM is a monogenic disease with 
autosomal dominant inheritance, and is primarily considered a sarcomeropathy, as the 
vast majority of HCM mutations occur in proteins of the cardiac sarcomere. HCM is 
therefore distinct from hypertrophy associated with extrinsic factors such as hypertension. 
The primary feature of HCM is hypertrophic remodeling of the left ventricle and 
intraventricular septum to a thickness ≥15mm[Jacoby 2013]. In contrast to physiologic 
hypertrophy in which the LV chamber volume increases along with LV wall thickness, 
pathologic hypertrophy in HCM leads to a reduction in LV chamber volume.  
Functionally, HCM is characterized by diastolic dysfunction associated with 
impaired myocardial relaxation and reduced filling. LV outflow tract obstruction also 
frequently occurs in HCM as a result of septal hypertrophy and mitral valve 
abnormalities[Maron 2002, Shah 1969]. These features can lead to heart failure, arrhythmias and 
sudden cardiac death. Histological analyses of HCM hearts reveal interstitial fibrosis and 
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myocardial disorganization[Teare 1958, Yutani 1987]. This disorganization extends to the 
ultrastructural level; transmission electron microscopy of HCM tissue shows disordered 
myofilaments and out-of-register Z-disks[Razzaque 2013]. 
HCM is noted be a particularly heterogeneous disease in several aspects, such as 
age of onset, magnitude of hypertrophy, cardiac morphology, and severity of symptoms. 
Mutations are often incompletely penetrant within families, with some mutation carriers 
developing severe phenotypes while others remain asymptomatic. The disease has been 
found to first manifest in both children and octogenarians with a median onset at ~45 
years of age[Ho 2018]. HCM most commonly presents as asymmetrical LV hypertrophy with 
the intraventricular septum disproportionally affected, but concentric, apical, and other 
morphologies can occur[Baxi 2016].  Broad heterogeneity of clinical presentation in HCM 
makes it difficult to anticipate who will develop disease and which therapeutic 
interventions to employ. Currently available treatment options include beta-blockers, Ca2+ 
channel inhibitors, implantable cardioverter-defibrillators for patients vulnerable to 
arrhythmias, and heart transplant for end-stage HCM that has progressed to heart failure. 
1.1.2 Genetics of hypertrophic cardiomyopathy. The sarcomere is the basic 
contractile unit of muscle. HCM-associated mutations occur in the genes for almost all 
the key contractile and regulatory cardiac sarcomere proteins including cardiac myosin 
binding protein C (MYBPC3) β-myosin heavy chain (MYH7), ventricular myosin essential 
and regulatory light chains (MYL3 and MYL2), α-actin (ACTC1), α-tropomyosin (TPM1), 
cardiac troponin C, T, and I (TNNC1, TNNI3, and TNNT2), and titin (TTN)[Kimura 2016]. A 
number of genes encoding Z-disk associated proteins, such as obscurin (OBSCN), four-
and-a-half LIM protein-1 (FHL1), and muscle LIM protein (CSRP3)[Marston 2017, Theis 2006], and 
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proteins related to Ca2+ signaling such as phospholamban (PLN)[Landstrom 2012] also carry 
HCM mutations. Despite the increasingly long list of HCM-associated genes, no 
mutations are detected in about half of HCM cases, though many variants of uncertain 
significance have been identified. Of cases where a mutation is found, MYBPC3 
mutations constitute about 50%[Alfares 2015]. While multiple studies have aimed to 
differentiate disease severity, progression, and phenotype with specific sub-classes of 
mutations; there is currently no consensus regarding MYBPC3 mutations being predictive 
of any particular phenotype or prognosis[Lopes 2013]. Likewise, it has not yet been shown 
that the location of truncating mutations or missense mutations within MYBPC3 are 
predictive of clinical outcomes. The majority of patients with MYBPC3-linked HCM are 
heterozygous for the causative mutation. Compound heterozygotes occur rarely, and are 
associated with worse clinical outcomes[Hodatsu 2014, Wessels 2015]. Homozygous individuals 
typically develop severe cardiomyopathy as neonates that is typically lethal by age 1; 
heart transplant is the only treatment option[Xin 2007, Zahka 2008]. 
1.1.3 History of research into hypertrophic cardiomyopathy. Physicians as far 
back as the early 18th century made records of occurrences of sudden death with 
ventricular hypertrophy or dilation discovered post mortem, likely caused by HCM or 
DCM[Coats 2008]. However, the underlying cause of this cardiac remodeling remained 
elusive well into the 20th century. Physicians noted that this condition often ran in families, 
and was not associated with hypertension or aortic valve defects, known stimuli of cardiac 
hypertrophy. Several terms were proposed as names for the disease, including “idiopathic 
cardiac hypertrophy,” “familial cardiomegaly,” and “muscular subaortic stenosis”, each 
reflecting prominent aspects of HCM, but none capturing the whole picture[Coats 2008]. 
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Finally, a modern understanding of HCM was first clinically described by pathologist 
Donald Teare in 1958 based on examination of eight case histories of patients aged 14-
45 years with asymmetrical cardiac hypertrophy identified post mortem[Teare 1958]. His 
description includes many of the hallmarks of HCM which are still today used as 
diagnostic criteria: hypertrophy primarily of the intraventricular septum and left ventricular 
free wall, extensive myocardial fibrosis, myocyte disarray, and arrhythmia. Additionally, 
one patient had evidence of outflow tract obstruction and seven of the eight patients 
experienced sudden cardiac death. More evidence of the inheritability HCM came when 
the sudden death of one of the patients’ brothers revealed highly similar pathologies in 
both siblings. Subsequent studies of the initial patient’s and additional families with 
histories of heart disease and sudden death supported an autosomal dominant mode of 
inheritance, and took note of incomplete disease penetrance and significant 
heterogeneity of symptoms[Emanuel 1971, Hollman 1960, Pare 1961]. 
In the late 1980s, genetic linkage analysis of affected families identified likely loci 
for causative mutations in HCM on several different chromosomes [Jarcho 1989, Solomon 1990]. 
A locus found on chromosome 14 contained the genes for cardiac α and β myosin heavy 
chains[Saez 1987], which were compelling and logical targets to investigate for HCM-causing 
mutations. In 1990, β myosin heavy chain (MYH7) was the first gene confirmed to harbor 
mutations which segregated with HCM in affected families[Geisterfer-Lowrance 1990]. Mutations 
in cardiac troponin T (TNNT) and α-tropomyosin (TPM1) were the next  to be conclusively 
associated with HCM, suggesting HCM was a disease of the sarcomere related to 
aberrant function or expression of mutant cardiac contractile proteins[Thierfelder 1994]. 
MYBPC3 was proposed to be another affected sarcomere protein after its gene was 
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mapped to a region on chromosome 11 which overlapped with another HCM locus[Carrier 
1993, Gautel 1995]. Subsequently, the first MYBPC3 mutations found to be inherited in families 
with a history of HCM were discovered[Bonne 1995, Watkins 1995], which led to complete 
sequencing of the MYBPC3 gene and protein product[Carrier 1997, Gautel 1995]. Since the initial 
discovery of the molecular etiology of HCM, over 900 individual disease-causing 
mutations have been identified in at least 15 genes, with the majority encoding sarcomere 
proteins[Alfares 2015]. MYBPC3 mutations are found in approximately 50% of gene test-
positive patients, making MYBPC3 mutations the most common cause of HCM[Alfares 2015].        
1.1.4 Mutations in MYBPC3. The MYBPC3 gene is uniquely affected mostly by 
nonsense, frameshift, and splice site mutations that produce premature stop codons, 
compared to other sarcomere genes. While most other genes involved in HCM, especially 
sarcomere genes, have >90% non-truncating mutations, the reverse is true for MYBPC3, 
in which >90% of mutations prematurely truncate the protein[Alfares 2015, Morita 2008]. Still, 
certain non-truncating mutations are highly prevalent, including the Arg502Trp mutation 
found to be the single most common mutation in HCM[Page 2012, Saltzman 2010], and the 
Pro1210Cysfs*58 mutation present in up to 4% of the South Asian population[Kuster 2014]. 
Truncating and non-truncating mutations are hypothesized to act through separate 
mechanisms which will be discussed below. 
 
1.2. Function of MYBPC3 in cardiac muscle: a key regulator of contraction 
1.2.1 Sarcomere localization and structural roles of MYBPC3. MYBPC was 
initially identified as an impurity of intermediate molecular weight in preparations of 
myosin from rabbit skeletal muscle[Starr 1971]. MYBPC was first isolated simply as an 
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attempt to generate more pure preparations of myosin, but its strong interaction with 
myosin made it of physiological interest[Offer 1973]. Microscopy studies showed that MYBPC 
localized to a limited region within the A-band and confirmed that it corresponded to 7-9 
transverse stripes spaced 43 nm apart in the A-band previously observed in electron 
microscopy analyses of striated muscle[Craig 1976, Pepe 1975]. The segment of the sarcomere 
containing MYBPC is referred to as the C-zone. The stoichiometric ratio of MYBPC to 
myosin molecules has been determined to be approximately 1:7-9[Craig 1976]. This 
stoichiometry suggests only a relatively small percentage of potential cross-bridges are 
affected by MYBPC under physiological conditions[Stelzer 2006].  
  MYBPC3 is expressed exclusively in cardiac muscle, while the two other isoforms 
MYBPC1 and MYBPC2 are only found in skeletal muscle[Weber 1993]. Additionally, 
MYBPC3 is expressed throughout development, unlike some sarcomere proteins which 
have specific fetal isoforms[Gautel 1998]. Importantly, this means loss of MYBPC3 
expression cannot be compensated for by developmental or non-cardiac isoforms.  
MYBPC3 has eleven domains connected by linker sequences: eight immunoglobulin-
like and three fibronectin III-like referred to as C0 through C10[Gautel 1995, Okagaki 1993]. The 
C0 domain is unique to cardiac MYBPC3, as is a 30-amino acid sequence in C5, and 
the “LAGGGRRIS” sequence found within the M-motif, which contains phosphorylation 
sites not present in skeletal muscle isoforms[Gautel 1995, Kasahara 1994]. MYBPC3 interacts with 
a number of other sarcomere components, including the S2 region of myosin heavy 
chain[Starr 1978], light meromyosin[Moos 1975], F-actin[Moos 1978], titin[Furst 1992, Soteriou 1993], and 
four-and-a-half LIM domain protein 1 (FHL1), a protein of undetermined function which 
may regulate hypertrophy signaling pathways[Liang 2018, McGrath 2006]. Specific locations of 
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interactor binding sites can be found in Figure 1.1A. Broadly speaking, the C-terminal 
domains (C7-C10) are thought to act by anchoring MYBPC3 to the thick filament, while 
the N-terminal domains (C0-C2) are hypothesized to switch back and forth between 
myosin S2 and actin in a phosphorylation dependent manner, thereby acting as a 
regulator of contraction. Interactions with certain specific titin super-repeats may be 
responsible for limiting localization of MYBPC3 to the C-zone [Furst 1989, Tonino 2017]. The 
function of the interior domains is not well understood, but the cardiac-specific insertion 
of the C5 domain is hypothesized to act as a mobile “hinge” sequence and may have 
intramolecular interactions with other domains[Idowu 2003, Moolman-Smook 2002]. Further, 
evidence of missense mutation clusters within C3 and C6 points toward important but 
unknown roles of these domains (See Figure 1.2) (Thompson et. al., manuscript in 
preparation). 
1.2.2 Interactions of MYBPC3 with myosin and the thick filament. Evidence 
strongly suggests that MYBPC3 acts as a molecular “brake” on contraction. In vitro 
motility assays have demonstrated that the velocity of actin filaments sliding along 
native thick filaments decreases when actin reaches the C-zone[Previs 2012]. In the 
absence of MYBPC3, the velocity remained constant across the entire thick filament. 
Similarly, in ex vivo papillary muscles from MYBPC3 knockout mice, the duration of the 
cross-bridge cycle was found to be accelerated when compared to muscles from wild-
type mice, suggesting the presence of MYBPC3 normally restrains cycling[Lecarpentier 2008]. 
The myosin S2 binding domain (C1C2 fragment) appears to be sufficient to produce this 
inhibitory effect both in vitro and in skinned cardiac fibers[Kampourakis 2014, Kunst 2000, Razumova 
2006]. The exact molecular mechanism of the “braking” effect has not been conclusively 
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shown, but recent findings suggest MYBPC3 may stabilize the super-relaxed (SRX) 
conformation of myosin heads. In the SRX state, the myosin heads are tightly bound to 
the thick filament backbone and display an extremely slow ATP turnover rate, thereby 
severely restricting formation of cross-bridges[McNamara 2015]. Hearts of MYBPC3 knockout 
mice were shown to have a significantly smaller proportion of SRX myosin as opposed 
to disordered-relaxed (DRX) or active myosin when compared to wild-type 
hearts[McNamara 2016]. A reduced SRX:DRX ratio has also been observed in myocardial 
tissue from HCM patients with MYBPC3 mutations[McNamara 2017]. Reduced expression of 
MYBPC3 would hypothetically destabilize SRX myosin, making more myosin heads 
available to form cross-bridges. The physiologic purpose of stabilizing SRX myosin has 
been speculated to be to maintain a reserve population of myosin heads which can 
become active when necessary, such as under β-adrenergic stimulation[Mamidi 2017, 
McNamara 2015, Nagayama 2007]. Therefore, the effect MYBPC3 exerts on myosin directly is 
likely critical for precise regulation of cardiomyocyte contraction. 
1.2.3 Interactions of MYBPC3 with actin and the thin filament 
 While MYBPC3 has traditionally been designated a thick filament protein, its 
association with actin may be equally as important as its interactions with myosin. 
MYBPC3 interacts with actin at its N-terminus (C0-M domain), in a region which overlaps 
with the C1C2 myosin S2 binding region [Squire 2003]. The C1C2 fragment was found to 
retain the “brake” function in filament sliding assays with only myosin S1 present, 
indicating that MYBPC3’s interaction with the myosin S2 domain is not the only factor in 
its function[Saber 2008, Shaffer 2007]. In these studies, C1C2 co-sedimented with actin, but not 
myosin S1. Additionally, sarcomere incorporation of C1C2 results in conformational 
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changes in the troponins associated with thin filament activation even in the presence of 
blebbistatin, which prevents formation of strong cross-bridges and inhibits force 
production. This indicates MYBPC3 also interacts directly with the thin filament to alter 
contractile function, independent of myosin’s conformation. Partial extraction, full 
ablation, and mutation of MYBPC in several experimental models has repeatedly been 
shown to increase calcium sensitivity of force generation of the sarcomere[Cazorla 2006, 
Hofmann 1991, Kulikovskaya 2003, Witt 2001], consistent with the increased calcium sensitivity found in 
myocardium from HCM patients, although this is not limited to individuals with MYBPC3 
mutations. Whether this effect originates directly from loss of MYBPC3 in the sarcomere 
or is an indirect consequence of remodeling is still unclear. However, several of these 
studies observed that N-terminal fragments of MYBPC3 which bind to actin are capable 
of activating force production at low or absent Ca2+ concentrations[Harris 2004, Herron 2006, 
Kampourakis 2014, Razumova 2008, Witt 2001]. Subsequently, Previs et. al. demonstrated that when N-
terminal MYBPC3 fragments are bound to the thin filament, tropomyosin is displaced from 
the blocked position, uncovering the myosin-binding sites on actin in a similar fashion to 
the displacement induced by Ca2+ binding to troponin C[Previs 2012]. This interaction 
potentially explains the effect of MYBPC3 on Ca2+ sensitivity of force. Further, the thin 
filament activating property may serve to equalize activation status near the M-line, the 
furthest point from the location of Ca2+ release units at the Z-disk and the lowest point in 
a Ca2+ concentration gradient across the sarcomere generated after excitation[Previs 2015]. 
Recently, it has also been proposed that through this activating property, MYBPC3 may 
act as a sarcomere length sensor. Skinned myocardium from homozygous MYBPC3 
knockout mice was found to have a blunted length-dependent rate of force 
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redevelopment, implicating MYBPC3 as a major contributor to the length-dependent 
activation mechanism, wherein sarcomere length influences Ca2+ sensitivity and force 
development.[Mamidi 2014, Pfuhl 2012].  
1.2.4 Regulation of MYBPC3 function by phosphorylation. These findings 
provide substantial evidence that MYBPC3 is a significant regulator of both thick and thin 
filament function capable of meticulously fine-tuning contraction. This fine-tuning is further 
controlled by phosphorylation of residues mediated by protein kinase A (PKA), protein 
kinase C (PKC), protein kinase D (PKD), Ca2+/calmodulin dependent kinase II (CaMKII) 
and GSK3β (Figure 1.1A) [Bardswell 2010, Gautel 1995, Hartzell 1984, Kuster 2013, Mohamed 1998, Venema 1993]. 
In fact, phosphorylation is essential for proper MYBPC3 function. The phosphorylation 
sites considered to be most influential in terms of affecting function are found in the 
cardiac-specific sequence within the C1-C2 linker at Ser275, Ser284, and Ser304 
(residue positions represent human MYBPC3). A series of studies from the Sadayappan 
Lab using phosphonull and/or phosphomimetic mutations at these sites underscore the 
importance of phosphorylation to MYBPC3 function and the complexity of its 
consequences on cardiac physiology and disease. Replacement of all three serine 
residues with alanine in a transgenic mouse model, completely abolishing 
phosphorylation at these sites, resulted in significant diastolic dysfunction and dilated 
cardiac morphology comparable to the knockout mouse phenotype, while a full 
phosphomimetic mouse model with all three serines mutated to aspartic acid residues 
displayed no adverse phenotype[Gupta 2013, Sadayappan 2005, Sadayappan 2006]. Surprisingly, 
mimicking phosphorylation at only one site while ablating it at the other two results in 
three distinct phenotypes: normal (S275A/S284D/S304A), dilated 
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(S275D/S284A/S304A), and hypertrophic (S275A/S284A/S304D)[Sadayappan 2011]. 
S275D/S284A/S304D transgenic mice developed a hypertrophic phenotype as well[Gupta 
2013]. These findings imply that each phosphorylation site exerts its own unique effect on 
MYBPC3 function, and that maintenance of cardiac function requires a delicate balance 
of phosphorylation state. This is corroborated by the fact that MYBPC3 total 
phosphorylation has been observed to be significantly decreased in HCM, end-stage 
heart failure, pressure overload-induced right heart failure, and myocardial ischemia[Decker 
2005, El-Armouche 2007, Jacques 2008, Walker 2011]. Baseline phosphorylation levels of MYBPC3 in 
human donor myocardium have been reported to be fairly high, at 4-5mol Pi/mol 
MYBPC3, suggesting a combination of regulatory effects from each phosphoresidue is 
necessary for proper function[Jacques 2008]. The precise molecular mechanism relevant to 
each site remains to be determined, but there is evidence that phosphorylation of these 
sites follows a hierarchical pattern, with phosphorylation of Ser284 significantly enabling 
accessibility of the other two sites to several kinases[Gautel 1995, Sadayappan 2011]. 
Overall, phosphorylation affects MYBPC3 by altering its conformation and spatial 
orientation such that the N-terminal domains interact with either myosin or actin, thus 
affecting myosin conformation[Weisberg 1996]. Current evidence supports a mechanism in 
which unphosphorylated MYBPC3 favors N-terminal interactions with myosin S2 
associated with the “braking” effect, while phosphorylated MYBPC3 favors interactions 
with actin associated with thin filament activation[Gruen 1999, Kulikovskaya 2003, Taylor 2016]. 
Accordingly, phosphorylation blunts the “braking” effect[Previs 2012]. This mechanism is 
supported by in vitro findings indicating that incorporation of phosphonull MYBPC3 into 
isolated thick filaments promotes ordered arrangement of myosin heads consistent with 
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the SRX conformation, while phosphomimetic MYBPC3 produces more disordered 
filaments, suggesting more myosin heads are in the DRX conformation[Kensler 2017]. 
Phosphomimetic MYBPC3 also reduces myofilament Ca2+ sensitivity and enhances the 
length-dependent activation response in skinned myocardium[Kumar 2015]. Thus, 
phosphorylation of MYBPC3 acts as a switch to promote either thick filament inactivation 
or thin filament activation, depending on the prevailing physiological needs.  
1.2.5 Roles of MYBPC3 in whole-organ cardiac physiology. The molecular 
interactions of MYBPC3 with the thick and thin filaments, when translated to the whole 
organ level, produce both inotropic (affecting force of contraction) and lusitropic (affecting 
rate of relaxation) effects on the heart[Pohlmann 2007, Winegrad 1999]. Decreased lusitropy can 
lead to impaired LV filling as less relaxation during diastole allows a reduced volume of 
blood to enter the LV and can increase intraventricular pressure. Diastolic dysfunction 
very frequently develops in HCM, highlighting a critical role for MYBPC3 in modulating 
cardiac lusitropy. MYBPC3’s effects on contraction and relaxation are primarily 
hypothesized to be mediated by changes in the rate of cross-bridge attachment and 
detachment in response to phosphorylation[Moss 2015, Tong 2004]. Phosphorylation of MYBPC3 
by PKA is thought to be a significant contributor the accelerated cross-bridge cycling 
kinetics and enhanced systolic function induced by β-adrenergic stimulus[Gresham 2017, 
Gresham 2016, Tong 2008]. Phosphomimetic constitutive phosphorylation of Ser304 largely 
abolished the positive inotropic effects of dobutamine in vivo, again supporting an 
important role for MYBPC3 in preserving a β-adrenergic contractile reserve [Mamidi 2017]. 
Additionally, papillary muscles from a phosphomimetic mouse model exhibited a faster 
relaxation rate, while muscles from phosphonull mice had a slowed relaxation rate as well 
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as diastolic dysfunction[Rosas 2014]. In a separate study, phosphonull MYBPC3 mice 
exhibited both decreased rates of pressure development in systole and of pressure 
decline in diastole, as determined by in situ pressure-volume analysis[Gresham 2016]. 
Independently of phosphorylation, total loss of MYBPC3 in mice was associated with 
lowered end-systolic pressure and abbreviated systole leading to reduced ejection 
fraction[Nagayama 2007]. As discussed above, MYBPC3 may be involved in length-dependent 
activation. Impaired length-dependent activation has been observed in HCM patient 
myocardial tissue, though again, this is not limited to those with MYBPC3 mutations[Sequeira 
2013, van Dijk 2012, Vikhorev 2018]. Length-dependent activation is the main cellular mechanism 
contributing to the Frank-Starling Law of the heart, which defines the directly proportional 
relationship between end-diastolic volume and stroke volume.  
1.3 Proposed primary pathogenic mechanisms in MYBPC3-linked HCM 
Despite extensive focus on the biophysical, cellular and physiological functions of 
MYBPC3, a definitive mechanism linking the effect of mutations in MYBPC3 to 
hypertrophic myocardial remodeling has not been established. Two hypotheses have 
received significant emphasis in the literature regarding truncating MYBPC3 mutations 
specifically, both of which center on homeostasis of MYBPC3 protein. The first of these 
is the haploinsufficiency hypothesis. Haploinsufficiency occurs when a heterozygous 
mutation results in single functional copy of a gene that is insufficient to maintain normal 
function, and is a primary mechanism underlying many Mendelian diseases such as 
HCM[Deutschbauer 2005]. This hypothesis thus asserts that HCM patients with truncating 
MYBPC3 mutations express reduced MYBPC3 protein in the myocardium, and that 
pathogenesis arises from a relative absence of functional protein. Incorporated 
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sarcomere proteins adhere to strict stoichiometric ratios; therefore, balance between their 
synthesis and degradation must be precisely regulated. However, the mechanisms 
fundamental to this stringent regulation are not yet clear. Experiments using exogenous 
tagged sarcomere proteins have demonstrated the remarkable imperturbability of 
sarcomere stoichiometry. Overexpression of such proteins leads to replacement of 
incorporated endogenous protein within the sarcomere without a change in total 
expression levels or ratios, while excess unincorporated protein is degraded[Gulick 1997, 
Michele 1999, Rust 1999, Sadayappan 2008, Thompson 2014]. These findings make the question of why 
MYBPC3 stoichiometry may not be preserved in MYBPC3-linked HCM all the more 
perplexing. The second hypothesis suggests that truncated mutant MYBPC3 proteins are 
proteotoxic; that is, they are capable of disrupting normal protein quality control (PQC) 
systems through aggregation or overload of rate-limiting PQC elements. An overview of 
the intersecting PQC systems involved in sarcomere protein homeostasis can be found 
in Figure 1.3. In this case, pathogenesis arises from the presence of non-functional 
protein. It should be noted that these hypotheses are not mutually exclusive. However, 
few studies have tried to determine whether either absence of functional protein or 
presence of non-functional protein, in isolation from the other, are necessary or sufficient 
for HCM pathogenesis. Existing evidence for and against each hypothesis will be 
discussed below. 
1.3.1 Evidence for haploinsufficiency of WT MYBPC3. Haploinsufficiency has 
been suspected as a potential pathogenic mechanism in HCM patients with truncating 
MYBPC3 mutations since the first truncating mutations were identified in the mid-
1990s[Andersen 2004, Yang 1998, Yu 1998]. Over the following twenty years, multiple independent 
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studies have failed to detect truncated mutant proteins in myocardial tissue of HCM 
patients[Helms 2014, Jacques 2008, Marston 2009, Rottbauer 1997, Theis 2009, van Dijk 2009, van Dijk 2012]. Most 
importantly, a majority of studies using patient tissue found reduced wild-type MYBPC3 
protein expression (Table 1.1). Allelic imbalance at the mRNA level favoring an increased 
ratio of wild-type to mutant transcript was also reported in some cases[Helms 2014, Marston 2009, 
van Dijk 2009]. The combined results indicate that on average, HCM patients with MYBPC3 
truncating mutations express roughly 70% of wild-type MYBPC3 protein compared to 
control individuals. This suggests a compensatory mechanism that incompletely 
overcomes the loss of mutant allele, but cannot maintain the MYBPC3 sarcomere 
stoichiometry necessary for normal contractile function.  
To test this hypothesis experimentally, several in vitro and in vivo studies have 
been performed to show that replacement of functional MYBPC3 in haploinsufficient 
models can attenuate phenotype, while reduction of functional MYBPC3 can induce 
hypertrophic responses. Cardiomyocytes derived from human induced pluripotent stem 
cells (hiPS-CMs) and embryonic stem cells (hES-CMs) are emerging as a powerful tool 
to study cardiomyopathies in a human model. Though significant variations in 
methodologies should be recognized, these studies broadly suggest reduction of 
MYBPC3 may also be present in both patient-derived and genetically engineered hiPS-
CMs (A summary of MYBPC3 studies in hiPS-CMs and hES-CMs can be found in Table 
1.2). Differentiated cardiomyocyte cultures with reduced MYBPC3 expression showed a 
mixture of phenotypes including cellular hypertrophy, myofibrillar disarray, reduced force 
generation, and Ca2+ dysregulation. In further support of the haploinsufficiency 
hypothesis, gene replacement therapy resulting in increased WT MYBPC3 expression 
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was found to ameliorate hypertrophy and dysfunction in two independent studies within 
stem cell based systems[Monteiro da Rocha 2016, Prondzynski 2017]. However, some hiPS-CM models 
have not exhibited any significant reduction in MYBPC3 expression while still displaying 
phenotypes[Seeger]; therefore it is still unclear whether haploinsufficiency itself is the 
triggering mechanism. 
 Several mouse models carrying null or truncating MYBPC3 mutations exist; 
however, there is considerable variability in severity and onset of phenotype between 
heterozygotes of different models, with some exhibiting very mild to no phenotype[Carrier 
2004, Harris 2002, McConnell 1999, Vignier 2009]. It is possible that this variability is correlated to the 
amount of wild-type MYBPC3 each model expresses. In vivo experiments which have 
utilized approaches to correct or induce haploinsufficiency have helped mechanistically 
dissect whether reduction in MYBPC3 expression is a precursor or downstream 
consequence of cardiac hypertrophy. Heterozygous knock-in mice carrying a G>A 
transition in the last nucleotide of exon 6, which produces multiple products including a 
full-length missense transcript, a transcript terminating in exon 9, and a deletion of exon 
6, express ~80% of control MYBPC3 levels and display diastolic dysfunction[Fraysse 2012, 
Vignier 2009]. Exon skipping of exons 5 and 6 via antisense oligoribonucleotide injection 
increased expression of total MYBPC3 and temporarily rescued cardiomyopathy, though 
only in neonatal mice[Gedicke-Hornung 2013]. The protein product lacking the sequence encoded 
by exons 5 and 6 was stable and functional. In the same mouse model, wild-type 
MYBPC3 gene therapy delivered by adeno-associated virus to neonatal mice was able 
to partially prevent hypertrophic remodeling in a dose-dependent manner[Mearini 2014]. 
Conversely, a tamoxifen-inducible homozygous MYBPC3 knockout mouse model was 
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used to assess the consequences of loss of MYBPC3 expression in adult (12 week-old) 
mice. By 2 weeks after knockdown, MYBPC3 expression was reduced to ~40% of 
controls, and diastolic dysfunction was observed. At 20 weeks after knockdown, with 
MYBPC3 protein at ~10% of controls, left ventricular weight and wall thickness had 
significantly increased, suggesting that a marked reduction in MYBPC3 can induce 
significant functional and structural changes. Similarly, morpholino-mediated knockdown 
of MYBPC3 in d. rerio elicited dose-dependent symptoms consistent with hypertrophic 
remodeling[Chen 2013]. While there is much evidence in the literature that haploinsufficiency 
of MYBPC3 is sufficient to induce hypertrophic remodeling, variability in mouse model 
and hiPS-CM phenotypes leaves open the question of whether a “second hit” caused by 
currently unknown factors is necessary in conjunction with haploinsufficiency.   
1.3.2 Evidence for proteotoxicity of truncated MYBPC3. While truncated 
MYBPC3 proteins have not yet been observed in myocardium from MYBPC3-linked HCM 
patients, it is important not to assume that absence of evidence equals evidence of 
absence. Low or absent truncated protein has been attributed to two different quality 
surveillance mechanisms: i) nonsense-mediated decay (NMD), a process by which 
mRNA transcripts with premature termination codons located 50 or more nucleotides 
upstream of an exon-exon junction are targeted for degradation; and ii) the ubiquitin 
proteasome system (UPS), through which proteins labeled with ubiquitin are targeted for 
degradation by the proteasome, a large macromolecular protease complex[Sarikas 2005, Vignier 
2009]. However, despite allelic imbalance and NMD, mutant mRNA remains present. Our 
lab and others have previously shown that potentially ~16-40% of total MYBPC3 mRNA 
in HCM patient myocardium may originate from the mutant allele, and could provide a 
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template for truncated protein. Western blotting was the most commonly used detection 
method cited in studies which looked for truncated MYBPC3 proteins; in some cases the 
authors established lower detection limits in their experiments varying from 1.5-3.0% of 
total MYBPC3 protein[Marston 2009, Rottbauer 1997, van Dijk 2009]. This leaves open the possibility 
that truncated protein is present at levels below the resolution of techniques reported thus 
far, due to accelerated UPS-mediated degradation. It has been suggested that the need 
to continually degrade any truncated MYBPC3 that is translated over the lifetime of an 
HCM patient could cause chronic stress to the proteasome and affect hypertrophic 
signaling pathways[Carrier 2010, Day 2013]. This hypothesis is supported by findings of UPS 
dysfunction in myocardial tissue from HCM patients. Our lab has reported that the 
chymotrypsin- and caspase-like activities of the proteasome were significantly depressed 
in HCM myocardium, comparably to the activity observed in failing myocardium[Predmore 
2010]. Although not tested in isolation from other genotypes, the majority of samples in 
these experiments were from HCM patients with MYBPC3 truncating mutations. 
Thottakara et. al. also reported a 45% reduction in chymotrypsin-like proteasome activity 
in samples with MYBPC3 mutations exclusively[Thottakara 2015]. Lastly, observation of 
preamyloid oligomers in myocytes from patient myocardium suggests that proteostasis 
may be impaired in HCM[Sanbe 2004]. 
When expressed in several in vitro systems, truncated MYBPC3 proteins have 
reliably been reported to have lower steady state expression and fail to incorporate into 
the sarcomere compared to WT MYBPC3[Bahrudin 2008, Flavigny 1999, Sarikas 2005]. These studies 
have analyzed a range of truncated proteins of varying sizes. Such findings suggest 
truncated MYBPC3 in general is degraded at a faster rate than WT MYBPC3. Accelerated 
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degradation could be a function of several factors including lack of sarcomere 
incorporation, protein folding status, and altered interactions with PQC pathways. 
Furthermore, some in vitro studies have presented evidence that expression of truncated 
MYBPC3 in neonatal cardiomyocytes is sufficient to induce dysfunction of the UPS, as 
determined by reduced chymotrypsin-like activity of the 20S proteasome, increased 
polyubiquitinated proteins, and accumulation of a fluorescent UPS substrate whose 
expression is inversely proportional to UPS function[Bahrudin 2008, Sarikas 2005]. Limited 
evidence also exists that truncated MYBPC3 itself can form ubiquitin-positive aggregates 
of presumably misfolded protein in neonatal cardiomyocytes[Sarikas 2005]. In regards to in 
vivo models, The Carrier Lab reported a compelling series of experiments using both 
heterozygous truncating MYBPC3 knock-in and heterozygous MYBPC3 knock-out mice. 
While both knock-in and knock-out mice showed increases in ubiquitinated proteins at 
baseline, only in the knock-in mice was chymotrypsin-like proteasome activity 
reduced[Schlossarek 2012]. Further, with the additional challenge of isoprenaline and 
phenylephrine to induce adrenergic stress, once again only the knock-in mice displayed 
decreased proteasome activity. In a subsequent study, the MYBPC3 knock-in and knock-
out mice were crossed with a UbG76-GFP UPS reporter line and cardiac phenotype was 
examined at 1 year of age[Schlossarek 2012]. Knock-in mice, but not knock-out, showed 
accumulation of the reporter protein, indicating general impairment of the UPS pathway. 
Additionally, the heart weight/body weight ratio of the knock-in mice was larger than that 
of either wild-type or knock-out mice. These results suggest that not only can expression 
of truncated MYBPC3 exacerbate hypertrophy, but it is necessary to cardiac UPS 
dysfunction in HCM. The caveat to these studies, however, is that truncated protein 
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expression was induced in a haploinsufficient model, making it unclear whether UPS 
dysfunction can be caused by truncated protein expression alone. 
 
1.4 Experimental rationale and approach 
This project consists of experiments designed to address three specific aims: 
(i) Define physical and functional interactions between MYBPC3 and protein quality 
control-related factors. (Chapter 2) 
(ii) Assess proteotoxic effects of truncating MYBPC3 mutations in vitro and in vivo. 
(Chapter 3) 
(iii) Assess mutation locus-dependent protein stability in non-truncating MYBPC3 
mutations. (Chapter 4) 
Each aim seeks to generate a better understanding of pathogenesis in MYBPC3-
linked HCM and on a broader scale to expand our basic knowledge of regarding the 
roles of proteostasis and protein quality control mechanisms in myocardial physiology. 
Chapter 2 presents an unbiased, affinity purification-mass spectrometry screening 
assay developed to identify novel physical interactions between MYBPC3 and protein 
quality control factors. Select proteins which passed our specificity criteria were 
considered candidates for assessment of potential functional interactions. Subsequently, 
a biochemical pulse-chase assay was used to monitor degradation of MYBPC3 in 
response to genetic and pharmacological manipulations of candidate interactors using a 
primary cardiomyocyte culture model. The rationale and significance of this aim was to 
begin to understand the specific regulation of MYBPC3 protein turnover and degradation. 
While specific chaperones, co-chaperones, and E3 ligases have been identified for other 
 
21 
 
important myofilament proteins, literature on MYBPC3 protein quality control has only just 
scratched the surface. 
Chapter 3 presents first a series of experiments using a panel of five disease-
causing truncating MYBPC3 mutations expressed in neonatal rat ventricular 
cardiomyocyte (NRVM) cell culture. These experiments began as an attempt to replicate 
the ubiquitin proteasome system dysfunction reported by a previous study suggesting that 
truncated MYBPC3 protein was sufficient to derail proteostasis in cardiomyocytes. Based 
on findings from Chapter 2, we then expanded these experiments to look at responses of 
heat shock protein kDa (HSP70) molecular chaperones. After this acute expression-
based model system produced no signs of proteostasis being affected, we moved to a 
transgenic mouse model which expresses truncated MYBPC3 against a non-
haploinsufficient background. Chronic, lifetime expression of this mutation was not 
sufficient to disrupt myocardial proteostasis or induce hypertrophic LV remodeling. The 
significance of this aim goes toward determining the relative contributions of the two 
hypothetical pathogenic mechanisms proposed above. 
Chapter 4 presents experiments designed to evaluate the stability of a second 
panel of disease-causing, non-truncating MYBPC3 mutations expressing in NRVMs. The 
stimuli for this study was the observation in Chapter 2 that a non-truncating mutation in 
the C10 domain was subject to extremely rapid degradation, combined with novel patient 
genotype data from the Sarcomeric Human Cardiomyopathy Registery (SHaRe) 
revealing three putative non-truncating mutation clusters in the C3, C6, and C10 domains. 
We used a streamlined cycloheximide pulse-chase assay and localization analysis to 
identify patent indications of protein instability associated with C10, but not C3 or C6 
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mutants. These results provide surprising evidence that some MYBPC3 missense 
mutations, research for which is underrepresented in the literature, may share a common 
pathogenic mechanism with truncating mutations. 
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FIGURE 1.1 
 
Figure 1.1. Structure, localization, and function of MYBPC3. (A) Diagram of MYBPC3 
structure highlighting domains associated with known interactors, cardiac-specific sequences, and key phosphorylation 
sites. References for identification of binding domains: S2:C1-C2[Gruen 1999],LMM:C10[Flashman 2007, Miyamoto 1999]; Actin:C0-
C2[Kensler 2011, Shaffer 2009, Squire 2003, Whitten 2008]; Titin:C8-C10[Freiburg 1996]; FHL1:C6-C10[McGrath 2006]. (B) MYBPC3 localizes 
exclusively to 7-9 transverse stripes in the C-zone of the sarcomere. (C) MYBPC3 modulates contraction by both 
inhibiting acto-myosin interactions when unphosphorylated and activating the thin filament when phosphorylated. 
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FIGURE 1.2 
 
 
Figure 1.2. MYBPC3 mutation landscape. Truncating mutations are more abundant and occur along 
the entire gene. Missense and non-truncating mutations are far less frequent, and may potentially cluster specifically 
in domains C3, C6, and C10. Genotype analysis was accomplished using de-identified data of a cohort of HCM patients 
with MYBPC3 mutations from the Sarcomere Human Cardiomyopathy Registry (SHaRe). 
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FIGURE1.3 
 
 
 
Figure 1.3. Overview of protein quality control pathways for sarcomeric proteins. 
Proteostasis of the sarcomere is maintained by activity of sarcomere-associated chaperones/co-chaperones and 
cytoplasmic chaperone handling of proteins dissociated from the sarcomere. The calpain pathway is thought to facilitate 
myofilament protein dissociation. Terminally misfolded or damaged proteins must be isolated from the myofilaments in 
order to undergo proteasomal degradation through the ubiquitin proteasome system (UPS). Single proteins can also 
be targeted for chaperone-mediated autophagy (CMA) or chaperone-assisted selective autophagy (CASA). Larger, 
multimeric sarcomere fragments and aggregates that are not disassembled are removed by macroautophagy via 
autophagosomes and lysosomal degradation. 
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TABLE 1.1. MYBPC3 haploinsufficiency studies in patient myocardium. 
Study # unique mutations 
% mutant 
MYBPC3 
mRNA 
% MYBPC3 protein 
compared to donors 
p-value 
(protein 
level) 
Protein detection 
method / 
normalization 
[Jacques 2008] 2 Not reported 76±4% not reported 
Immunoblot 
/ actin 
[Marston 2009] 5 ~40% 76±3% not reported 
Immunoblot 
/ actin 
[Theis 2009] 7 Not reported ~200% p<0.001 
Immunoblot 
/ GAPDH 
[van Dijk 2009] 2 ~20% 67±5% p<0.05 Immunoblot 
/ α-actinin 
[van Dijk 2012] 4 Not reported 67±5% p<0.0001 
SDS-PAGE and 
SYPRO stain 
/ α-actinin 
[van Dijk 2014] 3 Not reported 65±5% not reported 
SDS-PAGE and 
SYPRO stain  
/ α-actinin 
[Helms 2014] 15 16±3% 88±6% not significant 
Immunoblot 
/ GAPDH  
[McNamara 2017] 8 Not reported ~68% p<0.05 
Immunoblot  
/ α-actinin 
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TABLE 1.2. MYBPC3 haploinsufficiency studies in hESC-CMs or hiPS-CMs 
Study Model Mutation 
% mutant 
MYBPC3 
mRNA 
 
% MYBPC3 
protein 
compared to 
control 
p-value 
(protein 
level) 
Protein 
detection 
method  
/ normalization 
Phenotype 
[Tanaka 2014] hiPS-CM p.Gly999_Gln
1004del 
Not reported ~80% at day 
60 
p<0.05 Immunoblot  
/ GAPDH 
Cellular 
hypertrophy, 
myofibrillar disarray 
[Birket 2015] hiPS-CM 
c.2373dupG 
p.Trp792Val 
fs*41 
Not reported <50% at day 25 p<0.05 
Immunoblot  
/ α-actinin 
Reduced force 
generation 
No cellular 
hypertrophy 
[Monteiro da Rocha 
2016] hES-CM 
c.2905+1 
G>A 
<10% 
~50% only at 
day 17 of 
differentiation. 
No difference 
at day 30. 
p=0.04 Immunoblot  
/ α-actinin 
Cellular 
hypertrophy, 
sarcomere disarray, 
dysregulated Ca2+ 
homeostasis 
[Prondzynski 2017] hiPS-CM p.Val454Cys 
fs*21 
Not reported ~50% p=0.064 Immunoblot  
/ α-actinin 
Cellular 
hypertrophy 
[Ribeiro 2017] hiPS-CM 
TALEN-
engineered 
KO via stop 
codon in exon 
1 
~50% 
Reduced; 
not quantified 
not 
reported 
Immunoblot  
/ α-actinin 
Contractile defects, 
Reduced force 
generation 
[Seeger] hiPS-CM p.Arg943* 32.7±0.6% 
No difference 
at days 53-50 
 
not 
significant 
Immunoblot  
/ α-sarcomeric 
actin 
No cellular 
hypertrophy, 
elevated diastolic 
Ca2+ 
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TABLE 1.3. Animal models of MYBPC3-linked HCM. 
Model 
(species) 
Genetic 
background Mutation type 
Homozygous 
phenotype 
Heterozygous  
phenotype 
WT MYBPC3 
protein levels 
compared to 
controls 
Mus musculus      
[McConnell 1999] 
[McConnell 2001] 
[Fraysse 2012] 
Black Swiss Truncating  in exon 30 
At 8-12 weeks: 
• Fibrosis  
• Diastolic dysfunction 
• Dilated 
cardiomyopathy 
At >125 weeks: 
• LV wall hypertrophy 
• No functional 
deficits  
+/-: 89.9±8.5% 
-/-: no WT protein 
[Harris 2002] 
[Korte 2003] 
C57/BL6 
 
Truncating  
Removal of exons  
3-10 
At 12 weeks: 
• Ca2+ sensitivity   
• Hypertrophy 
•  Diastolic dysfunction) 
•  accelerated cross-
bridge cycling kinetics 
• No phenotype +/-: no reduction -/-: no WT protein 
[Carrier 2004] 
[Schlossarek 2012] 
[Schlossarek 2012] 
C57/BL6 or 
C57/BL6-
Black Swiss 
mixed 
Transcription start 
site knock out 
At ~14 weeks: 
• Dilated 
cardiomyopathy 
• Diastolic dysfunction 
• Eccentric left 
ventricular hypertrophy 
At 10-11 months: 
• Asymmetric septal 
hypertrophy 
At 10-11 mo 
+/-: ~75% 
-/-: no WT protein 
[Vignier 2009] 
[Fraysse 2012] 
[Gedicke-Hornung 2013] 
[Mearini 2014] 
Black Swiss 
Splice site 
(c.772G>A) 
multiple products. 
truncating and 
non-truncating 
Δexon6 
• Ca2+ sensitivity  
• Hypertrophy 
• Diastolic dysfunction 
• Ca2+ sensitivity  
• Diastolic 
dysfunction 
At 60 weeks 
+/-: 79% of WT 
-/-: 10% of WT 
[Chen 2012] C57/BL6 
Conditional 
truncating 
(tamoxifen 
induces deletion 
of exons 3-5) 
Knockout induced at 12wk. 
By 20wk post tamoxifen (32wk): 
• Myocyte hypertrophy 
• Fibrosis 
Less than 10% of 
vehicle controls by 8 
weeks after tamoxifen 
treatment 
Felis catus      
[Meurs 2005] 
[Carlos Sampedrano 
2009] 
[van Dijk 2016] 
Maine Coon 
cat 
Non-truncating 
Ala31Pro 
• Hypertrophy 
• Sudden death 
• Diastolic dysfunction 
• Hypertrophy 
• Longer lifespan 
than -/- 
Allelic imbalance in 
+/- (WT > A31P). 
Total MYBPC3 
unchanged in both 
+/- and -/- 
Danio rerio     
[Chen 2013]  
Knockdown using 
morpholinos 
against translation 
start site 
At 72hr post fertilization, dose dependent 
increase in: 
• Heart failure  
• Ventricular wall thickness 
• Atrial enlargement 
Extent of knockdown 
not determined 
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CHAPTER 2 
 
Heat Shock 70 kDa-family Molecular Chaperones Regulate  
Degradation of Cardiac Myosin Binding Protein C 
 
2.1 ABSTRACT 
Cardiac myosin binding protein C (MYBPC3) is the most commonly mutated gene 
associated with hypertrophic cardiomyopathy (HCM). Haploinsufficiency of full-length 
MYBPC3 and disruption of proteostasis have both been proposed as central to HCM 
disease pathogenesis. Discriminating the relative contributions of these two mechanisms 
requires fundamental knowledge of how turnover of wild-type and mutant MYBPC3 
proteins are regulated. While MYBPC3 is known to be degraded via the ubiquitin 
proteasome system, little is known of upstream protein quality control mechanisms 
involved in its routine turnover and maintenance of proper stoichiometry within the 
sarcomere. We expressed several disease-causing mutations in MYBPC3 in primary 
neonatal rat ventricular cardiomyocytes. In contrast to wild-type MYBPC3, mutant 
proteins showed reduced expression and failed to localize to the sarcomere. In an 
unbiased co-immunoprecipitation/mass spectrometry screen, we identified HSP70-family 
chaperones as novel interactors of both wild-type and mutant MYBPC3. Heat shock 
cognate 70kDa (HSC70) was the most abundant chaperone interactor. Knockdown of 
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HSC70 significantly slowed degradation of both WT and mutant MYBPC3, while 
pharmacologic activation of HSC70 and HSP70 accelerated degradation. HSC70 was 
expressed in discrete striations in the sarcomere. Together these data suggest that wild-
type and mutant MYBPC3 proteins are clients for HSC70, and that the HSC70 chaperone 
system plays a major role in regulating MYBPC3 protein turnover. 
 
2.2 INTRODUCTION 
 
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, 
is primarily caused by mutations in cardiac-specific sarcomere proteins, which make up 
the basic contractile unit of muscle. HCM typically presents with hypertrophy of the left 
ventricle and intraventricular septum, interstitial fibrosis, and diastolic dysfunction. 
Mutations linked to HCM occur in most major proteins of the contractile apparatus, 
including β-myosin heavy chain, regulatory and essential myosin light chain, α-cardiac 
actin, α-tropomyosin, cardiac isoforms of troponin T and I, and cardiac myosin binding 
protein C (MYBPC3)[Bonne, 1995, Geisterfer-Lowrance, 1990, Kimura, 1997, Olson, 2000, Poetter, 1996, Thierfelder, 1994, 
Watkins, 1995]. Uniquely among other sarcomere genes harboring HCM-linked mutations, 
most MYBPC3 mutations are nonsense, frame-shifts or splice site-affecting, predicted to 
result in truncated proteins[Tardiff, 2005]. These truncating MYBPC3 mutations represent the 
most frequent cause of HCM[Alfares, 2015]. MYBPC3 is thick-filament associated protein with 
both structural and regulatory roles in the sarcomere. It is capable of modulating 
contraction by slowing the rate of cross-bridge cycling within the C-zone of the sarcomere, 
where it is exclusively localized[Craig, 1976, Previs, 2012]. 
An ongoing debate as to the primary pathogenic mechanism in MYBPC3-linked 
HCM has yielded evidence for both a loss-of-function mechanism: haploinsufficiency of 
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functional MYBPC3 in the sarcomere[Marston, 2009, McNamara, 2017, van Dijk, 2009, van Dijk, 2012]; and a 
gain-of-function mechanism: proteotoxicity of truncated MYBPC3 leading to loss of 
myocyte protein homeostasis (proteostasis)[Sarikas, 2005, Schlossarek, 2012, Schlossarek, 2012]. 
Proteostasis involves a complex array of cellular protein quality control systems which 
maintain balance between protein synthesis, folding, repair and degradation. 
Maintenance of proteostasis in the heart is critical to proper cardiac function, and quality 
control of MYBPC3 specifically is an important factor to consider in both putative 
pathogenic mechanisms. Cardiac hypertrophy, fundamentally caused by increased 
myocyte size as opposed to proliferation, is inherently an imbalance between protein 
synthesis and degradation [Willis, 2013]. The post-mitotic cardiomyocyte is particularly 
dependent on precise regulation of contractile protein stoichiometry, folding and repair, 
but mechanisms governing turnover of sarcomere proteins, including MYBPC3, are still 
largely unknown. Recent studies have underscored the importance of protein quality 
control pathways in various etiologies of cardiovascular disease [Li, 2011, Rodriguez, 2009, Sandri, 
2014, Schlossarek, 2014, Yu, 2010]. Defects in proteostasis relating to mutations in genes encoding 
molecular chaperones, a class of proteins which assists in folding nascent or misfolded 
clients and preventing toxic aggregation of proteins, can cause pathological cardiac 
remodeling in human disease. Two notable examples are mutations in the small heat 
shock protein αB-crystallin and the co-chaperone BAG3 which cause dilated and 
myofibrillar cardiomyopathy, respectively [Inagaki, 2006, Li, 1999, Norton, 2011]. Therefore, we 
hypothesized that chaperone-client interactions may also play a role in the pathogenesis 
of hypertrophic cardiomyopathy.  
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Multiple chaperones involved in assembly and maintenance of myosin and actin 
monomers and filaments in striated muscle have been identified, whereas chaperones 
known to be associated with critical regulatory myofilament proteins are far fewer in 
number[Carlisle, 2017]. Identifying protein quality control factors specific to individual 
myofilament proteins would lead to a better understanding of their roles in general 
sarcomere maintenance as well as disease mechanisms. We therefore sought to identify 
potential MYBPC3 interactors related to chaperones and protein quality control. Through 
an unbiased co-immunoprecipitation mass spectrometry study, we identified HSP70-
family chaperones as novel MYBPC3 interactors. The heat shock protein 70 kDa (HSP70) 
family, including but not limited to HSP70 and HSC70, is a group of highly ubiquitous 
chaperones with an ATP-dependent catalytic cycle which recognize exposed 
hydrophobic residues on client proteins [Zuiderweg, 2013]. In addition to promoting protein 
folding, the HSP70s participate in guiding proteins toward ubiquitin proteasome system 
(UPS)-mediated degradation through interactions with the E3 ligase carboxyl-terminus of 
HSP70 interacting protein (CHIP) [McDonough, 2003]. MYBPC3 is known to be degraded via 
the proteasome, and truncated MYBPC3 has been reported to cause UPS 
dysfunction[Sarikas, 2005]. This suggests that HSP70 chaperones may regulate proteasomal 
degradation of MYBPC3. Altered interactions with factors upstream of the proteasome, 
such as HSP70s, could contribute to dysfunction. Experimentally, Hspa1a/b-null mice and 
mice null for the HSP70 co-chaperone Hspa4 developed left ventricular hypertrophy and 
fibrosis, suggesting loss of HSP70 chaperone function can lead to a phenotype similar to 
HCM [Kim, 2006, Mohamed, 2012].  
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While critical roles for HSC70 and its co-chaperones in myosin folding and Z-disk 
maintenance have been previously demonstrated, the role of molecular chaperones, 
including the ubiquitous and promiscuous HSP70 family, in handling sarcomeric 
regulatory proteins such as MYBPC3 is underexplored [Arndt, 2010, Hishiya, 2010, Srikakulam, 2004]. 
Given that MYBPC3 protein turnover and degradation are fundamental facets of both 
prevailing hypotheses regarding the primary pathogenic mechanism in MYBPC3-linked 
HCM, elucidating the chaperones and other protein quality control factors which handle 
MYBPC3 would greatly inform future research into targeted approaches for treating HCM. 
We hypothesized that MYBPC3 is a client of HSP70-family chaperones and these 
chaperones play a role in regulating MYBPC3 turnover. To test this, we expressed a panel 
of human MYBPC3 mutations in neonatal rat ventricular cardiomyocytes (NRVMs), and 
explored their physical and functional interactions with HSP70s.  We present our findings 
that both WT and mutant MYBPC3 physically interact with the HSP70 family of molecular 
chaperones, and that modulation of HSC70 expression or activity specifically impacts 
MYBPC3 degradation. Moreover, we show that HSC70 localizes to the sarcomere 
adjacent to MYBPC3. These results represent the first identification of a chaperone for 
MYBPC3, and uncover a new role for HSC70 in sarcomere proteostasis in fully-
differentiated myofibrils. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Isolation and culture of neonatal rat ventricular cardiomyocytes.  
NRVMs were isolated from excised ventricles of 1-3 day old Sprague-Dawley rats 
(Charles River) according to a modified version of the Worthington Neonatal 
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Cardiomyocyte Isolation System (Worthington Biochemical Corporation). Ventricles were 
minced in ice-cold HBSS and pre-digested in 1mg/mL trypsin (Worthington) at 4°C for 6 
hours. Tissue was then digested in 30U/mL purified collagenase (Worthington), dissolved 
in Media 199 (Invitrogen) with Earle’s salts, L-glutamine, 2.2g/L sodium bicarbonate, 2% 
penicillin/streptomycin, 25mM HEPES, and 15% heat inactivated qualified FBS 
(Invitrogen), in a Celstir® 50mL jacketed spinner flask (Wheaton) for 45 minutes at 37°C. 
Digested tissue was triturated and filtered through a 70µm strainer, then incubated for 20 
minutes at room temperature to further digest partially degraded collagen. Cell 
suspension was pre-plated on untreated plastic dishes for 1 hour at 37°C to reduce 
adherent fibroblast contamination, then filtered through a 40µm strainer. NRVMs were 
seeded on plates coated with 5µg/mL bovine fibronectin (Sigma-Aldrich) or on fibronectin-
micropatterned PDMS coverslips (see below) in maintenance media (Media 199 with 
Earle’s salts, L-glutamine, 2.2g/L sodium bicarbonate, 2% penicillin/streptomycin, 25mM 
HEPES, and 5% FBS). Media was changed 24 hours after plating and every subsequent 
48 hours unless otherwise noted. NRVMs undergoing heat shock treatment were 
incubated at 45°C for one hour immediately prior to collection or fixation. 
2.3.2 Micropatterning of PDMS coverslips.  
Micropatterned polydimethylsiloxane (PDMS) stamps with 20μm-wide rows 
spaced 3μm apart were fabricated as previously described with minor modifications 
(Figure 2.1) [Kuo, 2012]. To print fibronectin micropatterns onto 20mm-diameter coverslips 
cut from PDMS sheeting (Specialty Manufacturing, Inc), sterilized stamp surfaces were 
covered in a 1:40 dilution in PBS of fibronectin from human plasma, 0.1% solution (Sigma- 
Aldrich) and incubated at room temperature for 1 hour. Fibronectin solution was aspirated 
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and stamps were dried with compressed nitrogen gas. PDMS coverslips were cleaned by 
sonication in 70% ethanol, placed in 6-well cell culture plates and treated in a UV-ozone 
cleaner (Jelight Company) for 8 minutes prior to stamping. Stamps were inverted onto the 
PDMS circles and then removed. Stamped surfaces were then treated with 1% Pluronic 
F-127® (Sigma-Aldrich) for five minutes to render unstamped areas hydrophobic. 
Coverslips were washed 3 times in PBS and stored at 4°C until plating. 
2.3.3 Expression of FLAG-tagged WT and truncated MYBPC3 constructs via 
recombinant adenovirus.  
MYBPC3 mutants were generated by site-directed mutagenesis using the 
QuikChange II XL Kit (Agilent) from WT human MYBPC3 cDNA. Adenovirus was 
generated with the ViraPower™ Adenoviral Gateway® Expression Kit (Invitrogen) using 
the pAd/CMV/V5-DEST Gateway® vector, and amplified in HEK293A cells. MOI for 
NRVM transduction was optimized to levels at which no ectopic expression of WT 
MYBPC3 was detected by immunofluorescence (MOI 2-10). 
2.3.4 Co-immunoprecipitation of MYBPC3-interacting proteins.  
Un-patterned NRVMS were plated at a density of 1x107 cells per 100mm culture 
dish. Cells were transduced with WT or truncated MYBPC3 adenovirus at MOI 10 24 
hours after plating. Cells were collected 48 hours later by scraping in ice cold PBS with 
Roche protease inhibitor cocktail; cell pellets were stored at -80°C. 2x107 cells were used 
per sample. Nontransduced cells were used as a negative control for the FLAG co-IP. 
Pellets were lysed in RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
150mM NaCl, 10mM Na2PO4 pH 7.2, 1mM NaF, 1mM EDTA, 2.5mM EGTA, 20mM 
(NH4)2MoO4, 100µM Na3VO4, Roche protease inhibitor cocktail) and incubated on ice for 
54 
 
15 minutes. Lysates were then sonicated for four 10 second bursts at 50% amplitude 
using a Branson digital sonifier with cup horn attachment, incubated on ice for a further 
15 minutes, and centrifuged for 10 minutes at 13,000 rpm at 4°C to remove debris. 
Supernatants were recovered and protein concentration was determined by Bradford 
protein assay. This fraction was used as ‘input’ for Western blot analysis of co-IPs. 2mg 
of protein from supernatants was allocated to one FLAG co-IP tube and one normal 
mouse IgG control tube. All samples underwent initial pre-clearing of nonspecific 
interactors by adding 10µg of normal mouse IgG for one hour at 4°C followed by adding 
20µL of a 1:1 mixture of protein A and protein G sepharose bead slurry (Sigma-Aldrich) 
for one hour at 4°C with gentle shaking. Pre-cleared supernatant was retained for IP. 
FLAG co-IP tubes received 20µL anti-FLAG M2-conjugated sepharose beads (Sigma-
Aldrich) while normal mouse IgG control tubes received 10µg normal mouse IgG and 
20µL 1:1 mix of protein A/protein G sepharose beads. Following overnight incubation at 
4°C with gentle shaking, bead fractions were collected and immunoprecipitate was eluted 
by competitive binding in 100µL 100µg/mL 3X FLAG peptide (Sigma-Aldrich). Western 
blot analysis confirmed that FLAG-tagged MYPBC3 bait proteins were not non-
specifically pulled down by normal mouse IgG controls. 
2.3.5 Protein Identification by LC-Tandem Mass Spectrometry.  
30µL of the FLAG immunoprecipitate was separated by SDS-PAGE. Gels were 
stained in Biosafe Coomassie (BioRad) for 1 hour at room temperature and destained in 
ddH2O for 1 hour. Gel lanes were cut into 10-12 fragments and destained with 30% 
methanol for 4 hours. Upon reduction (10mM DDT) and alkylation (65 mM 2-
chloroacetamide) of the cysteines, proteins were digested overnight with sequencing 
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grade modified trypsin (Promega). Resulting peptides were resolved on a nano-capillary 
reverse phase column (Acclaim PepMap C18, 2 micron, 50cm, ThermoScientific) using a 
1% acetic acid/acetonitrile gradient at 300nL/min and directly introduced into Orbitrap 
Fusion Tribrid mass spectrometer (ThermoScientific). MS1 scans were acquired at 120K 
resolution. Data-dependent high-energy C-trap dissociation MS/MS spectra were 
acquired with top speed option (3 sec) following each MS1 scan (relative CE ~32%). 
Data were collected for two independent IP-MS experiments. Peptide-to-spectrum 
assignments (PSMs) were statistically validated and protein lists were generated using 
PeptideProphet [Ma, 2012]. The ABACUS algorithm was used to extract adjusted spectral 
counts, making adjustments for shared peptides among closely homologous proteins 
[Fermin, 2011]. Criteria for identifying MYBPC3 interactors were the following: (i) proteins were 
detected in both experimental replicates, and (ii) proteins showed a calculated fold 
change score (FC-A) in adjusted spectral counts of ≥2 over the non-transduced sample 
in at least one replicate.  FC-A was calculated as described previously [Mellacheruvu, 2013]. 
Spectral counts of interacting proteins were normalized to abundance of the FLAG-
MYBPC3 bait protein by multiplying the adjusted spectral counts by a normalization factor 
equal to the ratio of adjusted spectral counts for FLAG-WT MYBPC3 to adjusted spectral 
counts for the respective FLAG-mutant MYBPC3 in each sample. (𝑆𝑆𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 =  𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎 ∗ 𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎_𝑊𝑊𝑊𝑊
𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎_𝑛𝑛𝑚𝑚𝑚𝑚𝑎𝑎𝑛𝑛𝑚𝑚, where Sadj refers to the adjusted spectral counts retrieved from the Abacus 
algorithm and Snorm refers to the bait-normalized spectral counts.) When comparing 
spectral counts for interacting proteins between WT and mutant MYBPC3, we verified 
that the majority of MYBPC3 peptides detected in each sample could be attributed to the 
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human FLAG-MYBPC3 bait protein as opposed to any endogenous rat MYBPC3 that was 
pulled down non-specifically (Table 2.1). 
2.3.6 Cycloheximide pulse-chase analysis of MYBPC3 degradation rates.  
Un-patterned NRVMs were plated at a density of 2.25x105 cells/well in 24-well 
culture plates. Micropatterned NRVMs used for pulse-chase assays were plated at 
1.5x105 cells/coverslip. Cells were transduced at MOI 2 with WT or truncated MYBPC3 
adenovirus 24 hours after plating. 48 hours following MYBPC3 adenovirus, cells received 
one of the following treatments: 20nM scrambled siRNA (Silencer Select Negative Control 
#1, ThermoFisher Scientific), 20nM rat HSC70 siRNA (Silencer Select s127902, 
ThermoFisher Scientific), 1:1000 DMSO vehicle, or 10µM YM-1 small molecule Hsp70 
activator in DMSO (1:1000 dilution). siRNA was delivered using Dharmafect 1 transfection 
reagent (DharmaCon) in antibiotic-free maintenance media. YM-1 or DMSO vehicle 
control was directly applied to NRVMs. Maintenance media containing 300µg/mL 
cycloheximide (Sigma-Aldrich) to inhibit de novo protein synthesis was added starting 24 
hours after above treatments. Samples were collected in quadruplicate by scraping in 1X 
Laemmli buffer (BioRad) with protease inhibitor cocktail (EDTA-free, Sigma-Aldrich) at 0, 
0.75, 1.5, 3, 6, 9 and 12 hours and stored at -80°C. Abundance of endogenous rat 
MYBPC3 and FLAG-tagged WT and truncated MYBPC3 protein over time was assessed 
by Western blotting. Data from three independent experiments were fit to a first-order 
exponential decay curve [MYBPC3] = [MYBPC3]0e-kt (with [MYBPC3]0 normalized to 1), 
from which reaction constants k and half-lives t½ (calculated as t½ = ln(2)/k) were 
determined. 
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2.3.7 Western Blotting.  
Prior to analysis, sample protein concentration was determined by Lowry (for 
samples collected in Laemmli buffer) or Bradford (for samples collected in RIPA buffer) 
protein assays. Final sample preparation was in 1X Laemmli buffer with 5% β-
mercaptoethanol. Samples were boiled for 5 minutes at 95°C, separated on 18- or 26-
well precast Tris-HCl 4-20% gradient gels (BioRad), and transferred to nitrocellulose 
membranes. Following transfer, gels were stained in Biosafe Coomassie for 1 hour at 
room temperature and destained in ddH2O. Membranes were blocked in 5% non-fat dry 
milk in PBS for 1 hour at room temperature. Primary and secondary antibody solutions 
were made in 5% milk in PBS-T (0.03% Tween-20). Antibody conditions were as follows: 
MYBPC3, rabbit polyclonal 1:10000 (custom, provided by Samantha Harris, University of 
Arizona, Tucson, AZ)[Harris, 2002]; FLAG M2, mouse monoclonal 1:1000 (Sigma-Aldrich 
F1804); FLAG, rabbit polyclonal 1:500 (Sigma-Aldrich F7425) HSC70, mouse 
monoclonal 1:500 (Enzo Life Sciences ADI-SPA-815); Hsp70, mouse monoclonal 1:200 
(Enzo Life Sciences ADI-SPA-810); α-actinin, mouse monoclonal 1:5000 (Sigma-Aldrich 
A7811); cardiac myosin heavy chain [BA-G5], mouse monoclonal 1:1000 (AbCam 
ab50967), GAPDH, rabbit polyclonal 1:1000 (Millipore ABS16); IRDye® 680RD goat anti-
mouse IgG 1:5000 (LI-COR 926-68070); IRDye® 800CW goat anti-rabbit IgG 1:5000 (LI-
COR 925-32211). Primary antibody incubations were either for 1 hour at room 
temperature or overnight at 4°C. Secondary antibodies were incubated for 1 hour at room 
temperature protected from light. For myosin heavy chain blots, blocking and antibody 
buffers were made using Odyssey blocking solution (LI-COR) with 0.2% Tween-20. Blots 
and gels were scanned on an Odyssey® CLx Imaging System (LI-COR) and analyzed 
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with LI-COR Image Studio™. For images of blots in figures, all lanes presented are from 
the same individual blot, but a solid line between adjacent lanes signifies the image is not 
contiguous. Omitted lanes were of additional experimental replicates. 
2.3.8 Immunofluorescence of NRVMs.  
NRVMs plated on glass or PDMS coverslips were washed in PBS, fixed for 15 
minutes at room temperature in 4% paraformaldehyde (Sigma-Aldrich), and 
permeabilized in 0.2% Triton X-100 (Sigma-Aldrich) for 10 minutes. Cells were blocked 
in 5% normal goat serum (Vector Biolabs) in PBS for 30 minutes at room temperature. 
Primary and secondary antibody solutions were made in 5% normal goat serum in PBS. 
Antibody and staining conditions were as follows: MYBPC3, rabbit polyclonal 1:1000 
(custom, Samantha Harris, University of Arizona, Tucson, AZ); FLAG M2, mouse 
monoclonal 1:500 (Sigma-Aldrich F1804); HSC70, mouse monoclonal, 1:200 (Enzo Life 
Sciences ADI-SPA-815); AlexaFluor 488 phalloidin, 1:1000 (ThermoFisher Scientific); 
goat anti-mouse IgG Alexa Fluor 594, 1:500 (ThermoFisher Scientific A11005); goat anti-
rabbit IgG Alexa Fluor 488. 1:500 (ThermoFisher Scientific A11008). In samples dually 
stained for MYBPC3 and FLAG, primary antibodies were incubated sequentially for 1 hour 
each at room temperature; first with FLAG antibody, then with MYBPC3 antibody, to 
reduce antibody cross-reactivity. Secondary antibodies and phalloidin were incubated for 
30 minutes at room temperature, protected from light. Following antibody incubations, 
cells were incubated with 200ng/mL DAPI in PBS for 10 minutes at room temperature, 
protected from light. Lastly, coverslips were mounted onto slides with ProLong Diamond 
Antifade (ThermoFisher Scientific) and cured overnight prior to imaging. PDMS coverslips 
were mounted face-up and topped with glass coverslips. 
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2.3.9 Assessment of HSC70 sarcomere periodicity. 
 Untreated patterned NRVMs plated at a density of 1.5x105 cells/coverslip were 
fixed and immunostained as described above for HSC70 and phalloidin. Images of three 
random fields per coverslip from three biological replicates were acquired with a 60X 
objective using a Nikon Eclipse Ti-E inverted fluorescence microscope. Using NIS-
Elements software, fluorescence intensity profiles for HSC70 and phalloidin were 
obtained from longitudinal line-scans of 2-4 individual cells per field. Line-scans were set 
to 32 pixels wide (~20μm) to cover the entire width of the cardiomyocyte. Baseline 
correction, fast Fourier transforms and cross-correlation analysis of fluorescent intensity 
traces was done using MatLab software. Median periods of both HSC70 and phalloidin 
signals were determined. 
2.3.10 Quantitative reverse transcription PCR.  
qRT-PCR was used to validate knockdown of Hspa8 transcript in NRVMs. RNA 
was isolated from cells using the standard Qiagen RNeasy Mini kit. The Qiagen 
Omniscript RT kit was used for generation of cDNA by reverse transcription. TaqMan™ 
gene expression assays for rat Hspa8 and GAPDH were used in conjunction TaqMan® 
Fast Advanced Master Mix and samples were analyzed using an Applied Biosystems® 
7500 Fast Real-Time PCR system. Data were analyzed as previously described [Pfaffl, 2001]. 
2.3.11 Statistics 
Statistical analysis was done using GraphPad Prism software. Kruskal-Wallis 
nonparametric one-way ANOVA with Dunn’s post hoc test for multiple comparisons were 
used for comparisons among control, WT MYBPC3 and mutant MYBPC3 groups. Outliers 
excluded from analysis were identified using GraphPad Prism’s ROUT method with a Q 
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coefficient of 1%. Cycloheximide chase data analysis was performed by fitting data to a 
first-order exponential decay curve as described above and determining if control and 
treatment data could be explained by identical or differing fit parameters (i.e. reaction 
constant k). p-values of <0.05 were considered statistically significant. Data is reported 
as mean±SEM unless otherwise noted. 
 
2.4 RESULTS 
2.4.1 MYBPC3 mutants are unstably expressed and mislocalized.  
We created WT and five mutant human MYBPC3 constructs with N-terminal FLAG 
epitope tags to express in NRVMs via adenoviral transduction. The mutations chosen 
have been identified as pathogenic in patients with HCM [Helms, 2014, Walsh, 2017] and occur at 
several loci along the MYBPC3 protein (Figure 2.2A).  The Ile154Leufs*5, c.2905+1G>A, 
Asp1076Valfs*6, and Trp1098* mutations are nonsense, resulting in truncated proteins, 
while the Gly1248_Cys1253dup mutation contains an in-frame duplication near the C-
terminus resulting in a full-length protein. Gly1248_Cys1253dup was included because 
unlike other MYBPC3 non-truncating mutations, the mutant protein appears to be 
unstable and is not detectable in human HCM tissue, similar to MYBPC3 truncating 
mutations [Helms, 2014]. We performed immunofluorescence of NRVMs on fibronectin-
micropatterned PDMS coverslips to determine the subcellular localization of MYBPC3 
mutants. This micropatterning technique constrains the NRVMs to 20μm-wide rows, 
inducing elongated rectangular morphologies more similar to adult cardiomyocyte 
geometry, and thus enabling precise analysis of sarcomere structure and protein 
localization (Figure 2.1). FLAG-WT MYBPC3 localized correctly to the C-zone, in the 
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characteristic doublet pattern flanking the M-line. In contrast, none of the MYBPC3 
mutants exhibited sarcomere incorporation, instead localizing diffusely to the cytosol and 
in the case of Ile154Leufs*5, to the nucleus (Figure 2.3A, B). Select MYBPC3 mutants 
also showed significantly decreased expression compared to WT as assessed by 
Western blot of NRVM whole lysate (Figure 2.2B, D). However, total MYBPC3 protein 
levels (sum of endogenous rat and adenovirally-expressed protein) were unchanged, 
indicating that overall sarcomere stoichiometry of MYBPC3 was maintained (Figure 2.2C, 
E, F). 
2.4.2 MYBPC3 associates with HSP70 chaperone proteins.  
In order to identify MYBPC3 interacting proteins, we purified WT, Ile154Leufs*5, 
and Trp1098* FLAG-MYBPC3 and binding partners from NRVM lysates by co-
immunoprecipitation (Figure 2.4A) and analyzed them by LC-MS/MS. Two independent 
IP-MS experiments were performed. Interactors were defined as those proteins with ≥2 
assigned peptides detected in both experiments, and with a calculated fold-change in 
spectral counts (FC-A score) of ≥2 compared to the non-transduced NRVM sample in at 
least one of the two experiments.  Gene ontology enrichment analysis of 37 proteins 
identified as WT interactors (Figure 2.4B) analyzed against a background list of all 515 
proteins detected in the samples transduced with WT FLAG-MYBPC3 identified an 
annotation cluster for chaperones, unfolded protein binding, and protein folding as the 
most enriched category of proteins (For full results and analysis of interactors, see Table 
2.2). Among these, members of the HSP70 family of molecular chaperones were the most 
abundant chaperones identified, with heat shock cognate 70kDa (HSC70/Hspa8) 
exhibiting the highest spectral counts among chaperones in both experiments. The 
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stress-inducible cytosolic HSP70 (Hspa1a), endoplasmic reticulum-specific binding 
immunoglobulin protein (BiP/Hspa5), and mitochondrial HSP70 (Hspa9), were also 
identified as interacting proteins. The abundance of peptides corresponding to each 
HSP70 chaperone was mutation-specific: the Ile154Leufs*5 mutant had the lowest 
spectral counts for HSP70 and HSC70, while Trp1098* had the highest spectral counts 
relative to WT MYBPC3 (Figure 2.4D). Sarcomere proteins known to bind to MYBPC3 
(i.e. α- and β- myosin heavy chains) were identified in WT immunoprecipitates, and were 
less abundant or absent in mutant MYBPC3 samples, reflecting loss of binding domains 
and lack of sarcomere incorporation (Figure 2.4F). While α-cardiac actin (Actc1), a known 
major binding partner of MYBPC3, was detected in both IP-MS replicates, it did not meet 
the requisite threshold for an interacting protein due to the presence of high spectral 
counts in the non-transduced samples. This was likely due to non-specific binding of 
Actc1 to the sepharose beads or IgG, as actin isoforms are known common contaminants 
in affinity purification assays[Mellacheruvu, 2013]. Additionally, Acta1 (α-skeletal muscle), Acta2 
(aortic smooth muscle), Actb and Actg1 (cytoplasmic) were also detected. Due to the high 
sequence homology among different actin isoforms, it is also possible that some peptides 
assigned to cardiac actin originated from the other forms of actin, and vice-versa. Other 
potentially novel interacting proteins associated with the myofilament and cytoskeleton 
were also identified (e.g. FLNA, FLNC, CSRP3, LDB3 and SORBS2) as were several 
proteins involved in other cellular functions, including metabolism and translation (Figure 
2.4B, Table 2.2). 5 proteins retained interaction with WT, Trp1098* and Ile154Leufs*5 
MYBPC3: polyubiquitin-C, Hspa1a, Hspa5, Hspa8, and Hspa9 (Figure 2.4C). Both 
mutants showed an overall loss of interaction with non-HSP70 chaperones and other 
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protein quality control related factors compared to WT. For example, we identified a loss 
of interaction with the small heat shock proteins αB-crystallin (Cryab) and HSP27 (Hspb1) 
for both MYBPC3 mutants (Figure 2.4E).  
2.4.3 HSC70 knockdown slows degradation rate of WT and mutant MYBPC3.  
Both HSC70 and HSP70 act upstream of proteasomal degradation by interacting 
with UPS substrates and the E3 ubiquitin ligase CHIP, thereby facilitating ubiquitination 
[McDonough, 2003]. Because the affinity-purification mass spectrometry experiment 
demonstrated the strongest evidence for an MYBPC3-HSC70 interaction, we focused 
initially on HSC70. We hypothesized that if MYBPC3 is a client for HSC70, modulating 
expression or activity of HSC70 would affect its degradation. To investigate this, we 
measured the degradation rates of WT and mutant MYBPC3 by cycloheximide (CHX) 
pulse-chase assay. First, NRVMs were treated with either non-specific scrambled control 
siRNA or siRNA directed against the gene encoding HSC70 (Hspa8). 24 hours of siRNA 
treatment produced significant (>50%) knock-down of both HSC70 transcript and protein 
compared to scrambled control (Figure 2.5A-C). NRVMs were then incubated in media 
containing CHX to block de novo protein synthesis and allow measurement of the rates 
of degradation for individual proteins by Western blot. Scrambled siRNA treatment did not 
significantly affect the endogenous rat MYBPC3 degradation rate compared with the 
untreated condition (Figure 2.7F). For endogenous rat MYBPC3, FLAG-WT, and 
Trp1098*, t½ was significantly longer in cells treated with HSC70 siRNA versus scrambled 
siRNA, while the effect of HSC70 knockdown on Ile154Leufs*5 and 
Gly1248_Cys1253dup MYBPC3 was not significant (Figure 2.7A-E, Table 2.3, 
representative Western blots can be found in Figure 2.8). The Gly1248_Cys1253dup 
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mutant exhibited a very rapid rate of degradation, and earlier time points post CHX 
treatment (45 and 90 minutes) were added to better capture its degradation kinetics. The 
Z-disk protein α-actinin and myosin heavy chain (Figure 2.7G) did not degrade at the 
same rate as MYBPC3, demonstrating that the degradation kinetics we observed are 
specific to MYBPC3 and do not simply reflect general turnover of all sarcomere proteins. 
Lastly, we demonstrated that FLAG-MYBPC3(WT) is primarily degraded through the 
proteasome rather than autophagy by treating NRVMs with CHX in conjunction with either 
the proteasome inhibitor lactacystin or the autophagy inhibitor bafilomycin. At 12 hours 
post CHX, MYBPC3 expression in lactacystin treated cells was not significantly different 
from levels in untreated cells, while levels in bafilomycin treated cells were reduced to a 
similar extent as cells treated with CHX alone (Figure 2.6). 
2.4.4 HSP70 activator YM-1 accelerates degradation of WT and mutant MYBPC3.  
YM-1 is a small-molecule activator which stabilizes the ADP-bound conformation 
of HSP70 chaperones including but not limited to HSC70, resulting in tighter substrate 
binding. YM-1 has previously been shown to promote degradation and clearance of 
misfolded clients [Wang, 2013]. Addition of YM-1 did not affect HSP70 or HSC70 protein levels 
(Figure 2.5D-F). DMSO itself prolonged the half-lives of WT and mutant MYBPC3 relative 
to scrambled siRNA control in the previous experiment (Table 2.3, Figure 2.7F). This is 
likely because DMSO can non-specifically disrupt protein-protein interactions. However, 
the addition of DMSO was necessary to maintain the solubility of YM-1 and therefore was 
used in the control buffer for this set of experiments. YM-1 significantly accelerated 
degradation of both endogenous rat WT and FLAG-WT MYBPC3 as well as Trp1098* 
and Ile154Leufs*5, compared to DMSO vehicle control (Figure 2.7A-D). 
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Gly1248_Cys1253dup was not significantly affected (Figure 2.7E). Representative 
Western blots can be found in Figure 2.8.  
2.4.5 HSC70 localizes to the sarcomere M-line and Z-disk in NRVMs.  
HSC70 is expressed in both the cytosol and nucleus in most cell types, but the 
precise localization of HSC70 in cardiac myocytes has not been previously reported to 
our knowledge. We observed HSC70 signal localizing to prominent striations within the 
sarcomere of NVRMs. To precisely assess localization patterns of HSC70 in the 
sarcomere, we analyzed aligned micropatterned NRVMs by immunofluorescence. In 
untreated cells, fluorescence intensity traces from line-scans of individual NRVMs 
showed that sarcomere HSC70 signal appeared in an alternating pattern compared to 
phalloidin (actin) staining (Figure 2.9A,B) The center of the area of phalloidin signal 
demarks the Z-disk, indicating that HSC70 peaks occur at the M-line. A weaker HSC70 
band which colocalized with phalloidin was also visible. Fast Fourier transform analysis 
of HSC70 intensity traces, which quantitatively determined the period of HSC70 signal, 
confirmed that local HSC70 maxima occurred once every ~1μm, in comparison to 
phalloidin, with maxima once every ~1.75μm (Figure 2.9C). The fact that the periodicity 
of HSC70 is slightly greater than twice the periodicity of phalloidin may be explained by 
the relative weakness of the Z-disk signal compared to the more prominent M-line signal. 
This places HSC70 in immediate proximity to the C-zone. 
 
2.5 DISCUSSION 
The major findings of this study are the following: (i) MYBPC3 interacts with the 
molecular chaperones HSP70 and HSC70; (ii) decreasing the pool of HSC70 prolonged 
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the half-life of both WT and mutant MYBPC3, while pharmacological activation of 
HSP70/HSC70 shortened half-life; and (iii) a fraction of the HSC70 pool is positioned 
within the sarcomere adjacent to the C-zone. These data provide evidence that 
proteasomal degradation of MYBPC3 is mediated by HSC70. To our knowledge, our 
study is the first to identify a chaperone for which MYBPC3 is a client. HSC70 has 
previously been shown to be involved in assembly of myosin intermediates in skeletal 
muscle myoblasts, regulation of actin capping machinery, and turnover of filamin C at the 
Z-disk in response to mechanical stress [Arndt, 2010, Hishiya, 2010, Srikakulam, 2004]. However, the 
role of HSC70 in routine sarcomere protein turnover in fully differentiated cardiac 
myofibrils has not been explored previously. By showing that HSC70 regulates 
degradation of MYBPC3, we reveal an essential role for this chaperone family in cardiac 
sarcomere protein homeostasis, and provide a proof of concept for therapeutic 
manipulation of chaperone-client interactions to regulate sarcomere protein turnover in 
HCM. 
The extent to which MYBPC3 nonsense mutations produce loss of functional 
protein is governed by regulation of MYBPC3 expression and degradation. Exploration of 
MYBPC3’s binding partners has previously been focused almost exclusively on its 
sarcomeric interactors. Yet, in an unbiased screen, we found that the most enriched 
category of interactors for WT MYBPC3 were chaperones and protein quality control-
related partners. Most abundant among these were HSP70 molecular chaperones, 
supporting a role in the degradation pathway of MYBPC3. Furthermore, HCM-related 
mutations may affect the specificity of MYBPC3-HSP70/HSC70 interactions. HSC70 and 
HSP70 co-immunoprecipitated with WT, Ile154Leufs*5, and Trp1098* MYBPC3. 
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However, normalized spectral counts for both chaperones were substantially reduced for 
Ile154Leufs*5 compared to WT, suggesting decreased interaction for that particular 
mutant. Consistent with these findings, HSC70 knockdown had no significant effect on 
degradation of the Ile154Leufs*5 mutant, although YM-1 did accelerate degradation of 
Ile154Leufs*5. The effect of YM-1 on Ile154Leufs*5 could be explained by activation of 
other HSP70 isoforms in addition to HSC70. Conversely, spectral counts for HSP70 and 
HSC70 were increased for the Trp1098* mutant compared to WT. Since expression of 
Trp1098* did not upregulate HSP70 or HSC70, we speculate that either a larger pool of 
the mutant protein is associated with HSP70 chaperones or that the binding is more avid 
for the mutant than for the wild-type protein. However, the effects of HSC70 knockdown 
and YM-1 on the t½ of the Trp1098* mutant were similar to the effects on FLAG-WT 
MYBPC3. Interestingly, neither the Ile154Leufs*5 nor Trp1098* truncated mutants 
showed a significantly shorter t½ at baseline than that of FLAG-WT MYBPC3. In fact, 
Ile154Leufs*5 had a longer t½, which could be explained by its aberrant nuclear 
localization. On the other hand, degradation of the Gly1248_Cys1253dup mutant was 
significantly accelerated, despite exhibiting similar cytosolic localization to Trp1098*. 
While the Gly1248_Cys1253dup mutation encodes for a full-length protein, the protein 
has not been detected in myocardium from HCM patients, suggesting that this mutation 
renders it highly unstable. Although it was degraded via the UPS in the same manner as 
WT and Trp1098* MYBPC3, neither HSC70 knockdown nor YM-1 affected the t½ of 
Gly1248_Cys1253dup. This could imply that this particular mutation disrupts interaction 
with HSP70 chaperones, but does not affect its ability to be targeted for proteasomal 
degradation. Together, these results imply differential effects on MYBPC3-HSP70 
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chaperone interactions based on mutation locus within MYBPC3. Specificity of a given 
MYBPC3 mutant’s interaction with HSP70 chaperones could potentially be dictated by its 
subcellular localization, presence or absence of binding domains, protein length, or 
folding state. 
Because the HSP70 family interacts with a very broad range of clients and 
because HSC70 participates in many critical cellular functions, it is unknown whether 
direct targeting of these chaperones would be possible without adversely affecting 
turnover of other proteins or other cellular processes. Therefore, further elucidation of the 
mechanism by which HSC70 facilitates degradation of MYBPC3 and identification of 
potential co-chaperones involved is warranted as it could open new therapeutic avenues 
to address haploinsufficiency of MYBPC3 in HCM. HSC70 interacts with the E3 ubiquitin 
ligase CHIP, which links it to UPS-mediated degradation. A recent study identified a 
potential interaction between MYBPC3 and the HSC70 co-chaperone BAG3 [Judge, 2017]. 
BAG3 localizes to the Z-disk and participates in both proteasomal and chaperone-
assisted autophagic degradation pathways, most notably in a complex with HSC70, 
CHIP, and HSPB8 [Arndt, 2010, Minoia, 2014, Norton, 2011, Ulbricht, 2013]. However, clients of this 
complex undergo chaperone assisted selective autophagy, while MYBPC3 seems 
primarily to be degraded by the proteasome. BAG3 and HSC70 have also been found to 
form a complex with the actin capping protein CapZ at the Z-disk in NRVMs, which is 
consistent with the sarcomeric localization of HSC70 we observed [Hishiya, 2010]. We found 
that HSC70 also localized prominently to the M-line in NRVMs. This localization pattern 
is consistent with a regulatory role of HSC70 in the turnover of MYBPC3, which is 
localized as a doublet within the A-band of the sarcomere, adjacent to the M-line on either 
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side. We speculate that this juxtapositioning of HSC70 relative to MYBPC3 within the 
sarcomere facilitates its mobilization to degrade MYBPC3 as the protein is being released 
from the sarcomere. It is also possible that a pool of non-sarcomere-bound MYBPC3 
interacts with HSC70 prior to sarcomere incorporation or after it has been fully 
disengaged from the sarcomere. It is notable that FLAG-WT MYBPC3 had a shorter t½, 
and higher expression after addition of lactacystin compared to endogenous MYBPC3. A 
higher rate of proteasome-mediated degradation is consistent with the existence of a 
larger pool of newly synthesized FLAG-WT MYBPC3 that is not yet incorporated into the 
sarcomere. This could also explain why HSC70 knockdown elicited a lesser magnitude 
change in protein t½ for the FLAG-WT MYBPC3 compared to endogenous MYBPC3 (~2 
fold vs ~12 fold, Table 1). Conversely, YM-1 accelerated degradation of FLAG-WT 
MYBPC3 to a greater extent than endogenous MYBPC3 (~4.5 fold vs ~2.5 fold, Table 1) 
which could be explained by a greater contribution of HSP70 cytosolic chaperones to its 
degradation.  
Several other chaperones and protein quality control-related proteins were 
identified in the co-immunoprecipitation experiments as interacting with WT MYBPC3, 
including the small heat shock proteins (sHSPs) αB-crystallin and HSP27 (Hspb1). A 
subset of sHSP family members are highly expressed in striated muscle and some have 
been found to be cardioprotective against ischemia/reperfusion injury [Golenhofen, 2004, 
Hollander, 2004, Martin, 1997]. Mutations in αB-crystallin, which are hypothesized to alter its 
interactions with its client protein desmin, result in a dilated cardiomyopathy characterized 
by the presence of desmin aggregates [Inagaki, 2006, McLendon, 2011, Perng, 1999]. Both αB-crystallin 
and HSP27 may also act to prevent aggregation of unfolded titin domains [Kotter, 2014]. In 
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this study, we observed a substantial loss of interaction between these sHSPs and 
truncated MYBPC3 mutants in co-IP/MS experiments. Given the importance of these 
sHSPs in maintaining cardiomyocyte proteostasis by preventing aggregation of 
intermediate filament and myofilament proteins, further studies are warranted to define 
the potential role they play in the folding and turnover of MYBPC3. 
Our model system of expressing mutant MYBPC3 proteins in NRVMs has some 
limitations. Because truncated MYBPC3 protein has not been detected in human 
myocardium samples from patients with nonsense MYBPC3 mutations, the levels at 
which FLAG-MYBPC3 mutant proteins are expressed are supra-physiological. However, 
in our model the total expression levels of mutant MYBPC3 are relatively low compared 
to the endogenous protein without affecting total MYBPC3 stoichiometry. Furthermore, 
this expression system enabled quantification and modulation of the degradation kinetics 
of each individual mutant protein relative to WT MYBPC3.  
Most existing therapeutic interventions for HCM address symptoms but do not 
modify the progression of the underlying disease substrate. Recent clinical and preclinical 
trials targeting calcium flux and contractility have shown promise [Coppini, 2013, Ho, 2015, Nag, 
2015], but it is not apparent whether such therapies will be effective for all genetic subtypes 
of HCM. If haploinsufficiency is the major underlying mechanism in MYBPC3-linked HCM, 
restoring normal sarcomere levels of MYBPC3 would be attractive as a targeted therapy. 
In demonstrating interactions between HSP70/HSC70 and MYBPC3, we have identified 
a new mechanism by which MYBPC3 degradation, and thereby turnover, could be 
modulated.   These findings further our understanding of disease mechanisms in the most 
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common genetic form of HCM, and contribute a piece to the longstanding puzzle of 
sarcomere protein turnover and maintenance of stoichiometry. 
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FIGURE 2.1 
 
 
 
Figure 2.1. Fibronectin micropatterning technique constrains immature NRVMs to 
a rod-like morphology. (A) Micropatterned stamps with 20µm-wide rows spaced 3µm apart were used to print 
fibronectin onto PDMS coverslips prior to plating of NRVMs. NRVMs adhered only within the 20µm-wide rows. (B) 
Representative immunofluorescent micrographs of NRVMs stained for MYBPC3 showing an example of amorphous 
morphology and non-parallel sarcomeres of an unpatterned cell (left) versus rod-like morphology and aligned Z-disks 
of a patterned cell (right). 60X magnification.   
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FIGURE 2.2 
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Figure 2.2. FLAG-tagged WT and mutant MYBPC3 constructs were expressed in 
NRVMs via adenovirus. (A) FLAG-MYBPC3 protein schematic showing the 11 domains and locations of 
mutations. (B,C) Representative Western blots of FLAG-MYBPC3 and total MYBPC3, respectively, from NRVMs 
expressing WT or truncated FLAG-MYBPC3. Shorter truncated mutants and Gly1248_Cys1253dup are more unstably 
expressed compared to WT MYBPC3 or longer truncated mutants. (D) Quantification of FLAG-MYBPC3 expression 
for WT and mutants.  n=6, Kruskal-Wallis one-way ANOVA p<0.0001. *p<0.05 vs WT, Dunn’s multiple comparisons 
test. Mean±SEM. (E) Effect of truncated FLAG-MYBPC3 on full-length MYBPC3 levels. Higher expression of truncated 
mutants tended to suppress expression of endogenous MYBPC3. Note that FLAG-WT and FLAG-
Gly1248_Cys1253dup were not sufficiently separated from endogenous MYBPC3 by SDS-PAGE, and therefore 
quantification for these conditions includes both endogenous and FLAG-MYBPC3. n≥5, Kruskal Wallis one-way 
ANOVA p=0.0282. *p<0.05 vs WT, Dunn’s multiple comparisons test. Mean±SEM. (F) Quantification of total MYBPC3 
(endogenous and FLAG-MYBPC3) demonstrated that overall stoichiometry of MYBPC3 was maintained when FLAG-
MYBPC3 mutants were expressed. n≥5, Kruskal Wallis one-way ANOVA p=0.565. *p<0.05 vs WT, Dunn’s multiple 
comparisons test. Mean±SEM. (G) Comparison of abundance of FLAG-MYBPC3 mutants as a percent of total 
MYBPC3 shows a potential relationship between fragment size and expression stability. 
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FIGURE 2.3 
 
 
Figure 2.3. Localization of truncated MYBPC3 mutants. (A) FLAG-WT MYBPC3 is correctly 
expressed in the sarcomere C-zone in patterned NRVMs, while MYBPC3 mutants show diffuse aberrant signal in the 
cytosol or nucleus (Ile154Leufs*5) with little to no sarcomere localization. Immunofluorescence micrographs, 60X 
magnification. Scale bar=10μm. (B) Immunofluorescence micrographs and corresponding intensity traces sarcomeres 
from patterned NRVMs treated with FLAG-MYBPC3 adenovirus. FLAG-WT shows proper C-zone periodicity, while 
FLAG-mutants show no significant sarcomere periodicity. Scale bar = 20μm.  
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FIGURE 2.4 
 
 
 
Figure 2.4. Interactions between MYBPC3 and molecular chaperones. (A) Western blot 
showing co-IP of HSC70 and HSP70 with FLAG-tagged WT and mutant MYBPC3. Shorter MYBPC3 truncated proteins 
show loss of this interaction. (B) Summary of WT MYBPC3-interacting proteins manually categorized by function. All 
interactors were detected in both IP-MS experiments and showed a calculated fold change (FC-A) in spectral counts ≥ 
2 over non-transduced myocytes in at least one independent experiment. Interactors within dark boxes showed an FC-
A ≥ 2 over background in both experiments. (C) Venn diagrams showing overlap of interacting proteins (left: all 
interactors; right: protein quality control interactors) identified in immunoprecipitates for WT, Ile154Leufs*5, and 
Trp1098* MYBPC3. MYBPC3 mutants show loss of interaction with protein quality control-related proteins. (D-F) 
Normalized spectral counts for a subset of MYBPC3 interacting proteins from two independent IP-MS experiments. 
Adjusted spectral counts were normalized to abundance of FLAG-MYBPC3 bait protein. (D) HSC70 and HSP70 were 
more abundant in FLAG-Trp1098* samples, but less abundant in FLAG-Ile154Leufs*5 samples compared to FLAG-
WT; while small heat shock proteins (E) showed loss of interaction with both mutants. (F) MYBPC3 mutants also 
showed reduced association with known binding partners myosin heavy chains α and β.   
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FIGURE 2.5 
 
 
 
Figure 2.5. Validation of HSC70 siRNA efficacy and effect of YM-1 on HSP70/HSC70 
expression. (A) NRVMs treated with 20μM siRNA directed against the rat Hspa8 gene for 24hr show reduced 
HSC70 transcript compared to treatment with 20μM non-specific scrambled siRNA. (B) HSC70 protein is also reduced 
24hr after siRNA treatment. Mean±SEM, *p<0.05 vs scrambled, student’s t test. (C) Representative Western blot and 
total protein from siRNA-treated cells. Black line between lanes indicates noncontiguous samples from the same blot. 
(D and E) YM-1 treatment does not affect protein levels of HSP70 or HSC70, respectively. Mean±SEM. (F) 
Representative Western blot and total protein from YM-1 and DMSO vehicle-treated cells.  
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FIGURE 2.6 
 
 
Figure 2.6. MYBPC3 is primarily degraded through the proteasome rather than 
autophagy. Quantification of MYBPC3 and representative Western blot from NRVMs treated with 300µg/mL CHX 
for 12 hr. Addition of 25µM of the proteasome inhibitor lactacystin (Lac) along with CHX prevented degradation of 
MYBPC3, while addition of 50nM of the autophagy inhibitor bafilomycin (Baf) along with CHX did not. Kruskal-Wallis 
one-way ANOVA p=0.0001, *p<0.05 Dunn’s test for multiple comparisons. Mean±SEM. n=12.  
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FIGURE 2.7 
 
Figure 2.7. Degradation rates of WT and mutant MYBPC3 are affected by HSC70 
knockdown and small molecule HSP70 activator YM-1. (A-E, left panel) MYBPC3 degradation 
was slowed in NRVMs treated with HSC70 siRNA (open triangles, dashed line) compared to scrambled control siRNA 
treatment (closed circles, solid line). (A-E, right panel) MYBPC3 degradation was accelerated in NRVMs treated with 
10μM YM-1 (open diamonds, dashed line) compared to DMSO vehicle control (closed circles, solid line). n≥7, 
Mean±SEM, p values represent significance of comparison of reaction constant k between conditions. Dotted lines 
show 95% confidence intervals for k. (F) Scrambled siRNA and DMSO vehicle control degradation curves (as in A) for 
endogenous MYBPC3 compared to degradation of endogenous MYBPC3 in untreated NRVMs. While scrambled 
siRNA has no effect on the normal degradation rate, DMSO treatment significantly slowed degradation, p<0.05 vs. no 
treatment. (G) Degradation of endogenous MYBPC3 in untreated NRVMs (as in F) as compared to degradation of 
myosin heavy chain and α-actinin. MYBPC3 degrades at a rate independent of other thick filament or Z-disk 
components, p<0.05 vs myosin heavy chain and α-actinin.  
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FIGURE 2.8 
 
Figure 2.8. Representative Western blots for MYBPC3 cycloheximide experiments 
shown in Figure 2.5. (A) Endogenous rat WT MYBPC3, (B) FLAG-WT MYBPC3, (C) FLAG-Ile154Leufs*5 
MYBPC3, (D) FLAG-Trp1098* MYBPC3, (E) FLAG-Gly1248_Cys1253dup MYBPC3. MYBPC3 or FLAG band strength 
was normalized to Coomassie-stained total protein signal from the corresponding gel. α-actinin is shown to verify 
MYBPC3 band is reflective of its own intrinsic degradation rate and not general sarcomere degradation. Blots are 
representative of three independent experiments per condition. Black line between lanes indicates noncontiguous 
samples from the same blot. Lanes omitted were additional replicates of conditions shown. 
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FIGURE 2.9 
 
 
 
Figure 2.9. HSC70 is expressed in the sarcomere in NRVMs. (A) Representative 
immunofluorescence micrograph of untransduced NRVM. HSC70 localizes in sarcomeric striations in row-patterned 
NRVMs, occurring in a prominent band at the M-line and a weak band at the Z-disk (arrowheads). M-line signal exhibits 
an alternating pattern with phalloidin (actin) staining. Scale bar = 20µm. Scale bar in insert = 5µm. 60X magnification. 
(B) Representative baseline-corrected fluorescence intensity profiles for HSC70 and phalloidin taken from a line-scan 
of the cell pictured in (A). Strong HSC70 peaks coincide with phalloidin (Z-disk) troughs; weak HSC70 peaks coincide 
with phalloidin peaks. (C) Median frequency of HSC70 and phalloidin peaks as determined by fast Fourier transform 
analysis of intensity profiles from n=18 cells. HSC70 signal repeats every 1µm, approximately twice as often as 
phalloidin, reflecting both M-line and Z-disk localization. Mean±SEM, *p<0.0001, Wilcoxon signed-rank test. 
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TABLE 2.1. Overlap in matching peptides for bait vs. endogenous MYBPC3. 
IP-MS Set 1 Bait-unique MYBPC3 peptides 
common 
peptides 
Endogenous-unique 
MYBPC3 peptides 
Total 
peptides 
Control 86 57 0 143 
WT 1709 949 24 2682 
Ile154Leufs*5 409 0 58 467 
Trp1098* 1350 808 17 2175 
  
IP-MS Set 2 Bait-unique MYBPC3 peptides 
common 
peptides 
Endogenous-unique 
MYBPC3 peptides 
Total 
peptides 
Control 38 41 3 82 
WT 333 263 9 605 
Ile154Leufs*5 85 0 52 137 
Trp1098* 188 146 20 354 
 
  
83 
 
TABLE 2.2. MYBPC3 interacting proteins for WT, Trp1098*, and Ile154Leufs*5. 
Co-immunoprecipitated proteins with FC-A ≥ 2 in one or both replicates 
Uniprot ID  
(rattus norvegicus) Gene Name WT Trp1098* Ile154Leufs*5 
P63039 Hspd1    
P19945 Rplp0    
P06761 Hspa5    
P23928 Cryab    
Q07936 Anxa2    
G3V6D3 Atp5b    
P35435 Atp5c1    
G3V936 Cs    
G3V7U0 Csrp3    
P32551 Uqcrc2    
G3V6P2 Dlst    
P05197 Eef2    
P85834 Tufm    
C0JPT7 Flna    
A0A0H2UHR7 Flnc    
P04797 Gapdh    
G3V913 Hspb1    
P0DMW0 Hspa1a    
P63018 Hspa8    
A0A0G2JTG7 Hnrnph1    
P61980 Hnrnpk    
B5DEN4 Ldha    
Q62667 Mvp    
G3V885 Myh6    
G3V8B0 Myh7    
A0A0G2JSH9 Prdx2    
Q9EPH8 Pabpc1    
G3V9N0 Pabpc4    
F1LML2 Ubc    
Q6IFU9 Krt16    
A0A096MJ01 Ldb3    
P11507 Atp2a2    
P29457 Serpinh1    
P06685 Atp1a1    
F1LPM3 Sorbs2    
F1M953 Hspa9    
Q7TPB1 Cct4    
Q6P502 Cct3    
P46462 Vcp    
Q60587 Hadhb    
84 
 
TABLE 2.3. Kinetic fit parameters for cycloheximide pulse-chase data. 
 
treatment t½ (hr) t½ 95% CI (hr) k (hr-1) ± SE R2 p value for k comparison 
rat MYBPC3(WT) 
scrambled siRNA 6.29 4.81 to 9.06 0.110±0.017 0.34 
<0.0001* 
HSC70 siRNA 75.6 18.5 to 460 0.0179±0.0089 0.02 
DMSO vehicle 20.2 14.6 to 32.8 0.0343±0.0067 0.13 
<0.0001* 
10μM YM-1 7.59 8.83 to 14.4 0.0913±0.011 0.33 
FLAG-MYBPC3(WT) 
scrambled siRNA 5.04 4.21 to 6.37 0.137±0.014 0.57 
0.0001* 
HSC70 siRNA 10.7 7.80 to 16.8 0.0651±0.012 0.26 
DMSO vehicle 13.6 9.71 to 22.8 0.0508±0.010 0.24 
<0.0001* 
10μM YM-1 3.04 1.45 to 3.88 0.329±0.057 0.44 
FLAG-MYBPC3 
(Ile154Leufs*5) 
scrambled siRNA 23.7 12.3 to 87.6 0.0293±0.011 0.06 
0.323 
HSC70 siRNA 17.9 12.6 to 31.1 0.0388±0.0083 0.15 
DMSO vehicle 21.1 10.2 to 99.0 0.0328±0.014 0.05 
0.0063* 
10μM YM-1 7.21 5.33 to 11.1 0.0961±0.017 0.23 
FLAG-MYBPC3 
(Trp1098*) 
scrambled siRNA 4.43 3.43 to 6.24 0.157±0.023 0.35 
0.002* 
HSC70 siRNA 11.4 6.38 to 24.5 0.0611±0.019 0.10 
DMSO vehicle 17.6 11.1 to 42.0 0.0394±0.011 0.09 
<0.0001* 
10μM YM-1 2.20 1.70 to 3.09 0.316±0.046 0.72 
FLAG-MYBPC3 
(Glu1248_Cys1253dup) 
scrambled siRNA 0.548 0.334 to 0.854 1.27±0.25 0.57 
0.693 
HSC70 siRNA 0.498 0.396 to 0.619 1.39±0.14 0.81 
DMSO vehicle 1.58 1.07 to 2.33 0.439±0.070 0.33 
0.0539 
10μM YM-1 0.849 0.485 to 1.41 1.23±0.16 0.32 
Abbreviations. t½: half-life; k: reaction constant; CI: confidence interval; SE: standard error 
 
*p<0.05 for parameter k in first-order decay reaction fit for scrambled vs. HSC70 siRNA or DMSO vehicle vs. 10μM 
YM-1 
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CHAPTER 3 
 
Expression of truncated MYBPC3 mutants in the context of normal WT MYBPC3 
stoichiometry is not associated with proteotoxicity or hypertrophic remodeling 
 
3.1 ABSTRACT 
 Although mutations in cardiac myosin binding protein C (MYBPC3) have been 
known to cause familial hypertrophic cardiomyopathy (HCM) for two decades, debate 
over the primary pathogenic mechanism in MYBPC3-linked HCM continues. Evidence 
exists in support of two non-mutually exclusive hypotheses: haploinsufficiency of 
functional MYBPC3 within the sarcomere, and a “poison peptide” effect of truncated 
mutant MYBPC3 proteins associated with impaired ubiquitin proteasome system (UPS) 
function. While haploinsufficient knock-out animal models with no expression of truncated 
proteins have demonstrated that haploinsufficiency of MYBPC3 is sufficient to cause 
HCM, few studies have evaluated the “poison peptide” effect in isolation from 
haploinsufficiency or its consequences on cardiomyocyte protein homeostasis 
(proteostasis) beyond the proteasome. To determine whether truncated MYBPC3 
expression alone directly affects proteostasis and induces hypertrophic left ventricular 
remodeling, we utilized a neonatal rat ventricular cardiomyocyte (NRVM) culture model 
and a MYBPC3 transgenic mouse model to identify effects of acute and chronic lifelong 
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expression of truncated MYBPC3, respectively. We expressed disease-associated 
truncating MYBPC3 mutations of varying lengths in NRVMs but observed no changes in 
UPS function or HSP70-family chaperone stress responses associated with any of the 
five mutants. Further, expression of a ~75kDa truncated protein in transgenic mice was 
not associated with proteasome dysfunction or deranged proteostasis, and was not 
sufficient in the context of normal MYBPC3 stoichiometry to produce a hypertrophic 
cardiac phenotype. Therefore, neither acute nor chronic expression of truncated MYBPC3 
protein were capable of disrupting cardiomyocyte proteostasis. These results challenge 
evidence for the “poison peptide” hypothesis and support the necessity of MYBPC3 
haploinsufficiency in HCM pathogenesis. 
3.2 Introduction 
 Hypertrophic cardiomyopathy (HCM), characterized by left ventricular 
hypertrophy and fibrosis, is the most common monogenetic form of inherited heart 
disease affecting ~1 in 500 individuals. Patients with HCM are predisposed to heart 
failure, outflow tract obstruction, arrhythmias, and sudden cardiac death.  The most 
frequently mutated gene in HCM is cardiac myosin binding protein C (MYBPC3), 
accounting for >50% of cases in which the causative gene has been identified [Alfares, 2015]. 
MYBPC3 is a 150kDa myofilament protein found in the C-zone of the thick filament that 
interacts with both myosin and actin, acting as a molecular ‘brake’ on cross-bridge cycling 
[Previs, 2012]. In contrast to other sarcomere genes which primarily harbor missense 
mutations, over 90% of MYBPC3 mutations are nonsense, resulting in premature 
termination and predicted to yield truncated proteins [Alfares, 2015, Tardiff, 2005]. Yet, multiple 
studies have failed to identify the presence of mutant truncated MYBPC3 in myocardium 
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from HCM patients [Jacques, 2008, Marston, 2009, van Dijk, 2009]. Consequently, the most widely 
accepted hypothesis regarding the primary pathogenic mechanism in MYBPC3-linked 
HCM is haploinsufficiency. Nonsense mutant MYBPC3 transcript has been shown to 
undergo nonsense-mediated decay (NMD), suggesting the majority of mutant transcript 
is degraded [Vignier, 2009]. However, we have previously shown that in myocardium from 
patients with MYBPC3-linked HCM, transcript originating from the mutant allele of 
MYBPC3 is still detectable in sufficient quantities to provide a template for mutant protein 
synthesis [Helms, 2014]. While the absence of truncated proteins supports a disease 
mechanism arising from insufficient full-length MYBPC3 within the sarcomere, a 
contribution from mutant protein expression has not been conclusively excluded.  
 In several studies using both cell and animal models, expression of 
truncated mutant MYBPC3 protein was associated with impairment of the ubiquitin 
proteasome system (UPS), one of the major cellular protein degradation pathways [Sarikas, 
2005, Schlossarek, 2012, Schlossarek, 2012]. Deficits in the ubiquitin proteasome system (UPS) have 
been previously linked to human HCM particularly when caused by truncating mutations 
in MYBPC3 [Predmore, 2010, Thottakara, 2015]. UPS dysfunction is one indicator that protein 
homeostasis, or proteostasis, is disrupted. Proteostasis is maintained by several 
intersecting protein quality control (PQC) networks, and is essential to maintenance of 
the sarcomere, whose function relies on conservation of the appropriate protein 
stoichiometry; therefore, proteostasis is critical to cardiac function overall. Where UPS 
dysfunction and loss of proteostasis fit into the molecular progression of disease in HCM 
– whether they are a cause or effect of remodeling - is unknown. In vitro studies suggest 
mutant MYBPC3 is sufficient to disrupt UPS function[Bahrudin, 2008, Sarikas, 2005]; additionally, 
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some in vivo models show that it is necessary for development of UPS dysfunction 
alongside cardiac hypertrophy in heterozygous MYBPC3-mutant mice (but importantly, 
not necessary for hypertrophy alone)[Schlossarek, 2012, Schlossarek, 2012]. Impaired proteasome 
activity preceded structural changes in the hearts of these mice, which would indicate that 
it may be an active contributor to pathogenesis rather than a downstream effect. However, 
several studies have found that proteasome inhibition intervention is beneficial in mouse 
models of left ventricular hypertrophy, including pressure overload-induced (transaortic 
constriction and hypertension), sympathetic stimulation-induced (isoproterenol 
treatment), and genetic (MYBPC3 mutation), ameliorating structural and functional 
deficits[Hedhli, 2008, Meiners, 2008, Schlossarek, 2014, Stansfield, 2008]. These findings argue more towards 
UPS dysfunction being a compensatory effect of hypertrophic remodeling.  
The extent to which, if at all, loss of proteostasis acts as a driving mechanism in 
HCM is an important unanswered question highly pertinent to development of targeted 
therapeutics for patients with truncating MYBPC3 mutations. Limited work has been done 
to identify the effects of truncated MYBPC3 protein expression in a non-haploinsufficient 
model system. Therefore, we sought to determine whether truncated MYBPC3 protein 
expression is deleterious when WT MYBPC3 is present at normal stoichiometric levels. 
We hypothesized that expression of truncated MYBPC3 is sufficient to induce stress 
responses associated with HSP70 chaperones, contributing to UPS impairment and 
defective proteostasis in cardiomyocytes. To test this hypothesis, we expressed a panel 
of human MYBPC3 mutations in neonatal rat ventricular cardiomyocytes (NRVMs), and 
determined effects on HSC70/HSC70 chaperone stress responses and UPS function. 
Further, we hypothesized that expression of truncated MYBPC3 protein is sufficient to 
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cause hypertrophic cardiac remodeling in vitro, in the absence of haploinsufficiency. To 
do this, we observed cardiac phenotype over the course of 12 months in transgenic mice 
expressing a 75kDa truncated MYBPC3 protein on a background with two functional WT 
MYBPC3 alleles.   
 We found that expression of truncated MYBPC3 was not associated with 
proteasome dysfunction, induction of HSP70 expression, or stress-induced translocation 
of cytosolic HSC70 to the nucleus. Further, transgenic expression of a truncated MYBPC3 
protein alongside normal MYBPC3 stoichiometry was not sufficient to cause UPS 
dysfunction or hypertrophic remodeling in mice up to 12 months of age. These results 
challenge the hypothesis that HCM-associated truncated MYBPC3 directly disrupts 
proteostasis, and suggest that UPS dysfunction is not a primary pathogenic mechanism 
in MYBPC3-linked HCM, but arises secondarily to haploinsufficiency or hypertrophic 
cardiac remodeling.  
 
3.3 METHODS 
3.3.1 Isolation and culture of neonatal rat ventricular cardiomyocytes.  
 See section 2.3.1 
3.3.2 Micropatterning of PDMS coverslips.  
 See section 2.3.2 
3.3.3 Expression of FLAG-tagged WT and truncated MYBPC3 constructs via 
recombinant adenovirus.  
See section 2.3.3 
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3.3.4 Western Blotting. 
Sample preparation, SDS-PAGE, transfer, blocking, and analysis were performed 
as in section 2.3.7. Primary and secondary antibody solutions were made in 5% milk in 
PBS-T (0.03% Tween-20). Antibody conditions were as follows: MYBPC3, rabbit 
polyclonal 1:10000 (custom, provided by Samantha Harris, University of Arizona, Tucson, 
AZ)[Harris, 2002]; FLAG M2, mouse monoclonal 1:1000 (Sigma-Aldrich F1804); FLAG, rabbit 
polyclonal 1:500 (Sigma-Aldrich F7425) HSC70, mouse monoclonal 1:500 (Enzo Life 
Sciences ADI-SPA-815); Hsp70, mouse monoclonal 1:200 (Enzo Life Sciences ADI-SPA-
810); GAPDH, rabbit polyclonal 1:1000 (Millipore ABS16); IRDye® 680RD goat anti-
mouse IgG 1:5000 (LI-COR 926-68070); IRDye® 800CW goat anti-rabbit IgG 1:5000 (LI-
COR 925-32211). Primary antibody incubations were either for 1 hour at room 
temperature or overnight at 4°C. Secondary antibodies were incubated for 1 hour at room 
temperature protected from light. For images of blots in figures, all lanes presented are 
from the same individual blot, but a solid line between adjacent lanes signifies the image 
is not contiguous. Omitted lanes were of additional experimental replicates. 
3.3.5 Immunofluorescence of NRVMs. 
Plating, blocking, and mounting were performed as in section 2.3.8. Primary and 
secondary antibody solutions were made in 5% normal goat serum in PBS. Antibody and 
staining conditions were as follows: HSC70, mouse monoclonal, 1:200 (Enzo Life 
Sciences ADI-SPA-815); AlexaFluor 488 phalloidin, 1:1000 (ThermoFisher Scientific); 
goat anti-mouse IgG Alexa Fluor 594, 1:500 (ThermoFisher Scientific A11005). Primary 
antibody was incubated for 1 hour at room temperature. Secondary antibody and 
phalloidin were incubated for 30 minutes at room temperature, protected from light. 
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Following antibody incubations, cells were incubated with 200ng/mL DAPI in PBS for 10 
minutes at room temperature, protected from light. 
3.3.6 Flow cytometry analysis of ubiquitin proteasome function.  
Un-patterned NRVMs were plated at a density of 4.5x105 cells/well in 12-well 
culture plates. Cells were transduced with WT or truncated MYBPC3 adenovirus at MOI 
10, 24 hours after plating. 48 hours following MYBPC3 adenovirus, cells were transduced 
with GFPu degron adenovirus (provided by XJ Wang, University of South Dakota, 
Vermillion, SD) at MOI 7.5. GFPu is a fusion protein of the yeast CL1 degron to GFP 
which acts as a UPS substrate and is constitutively degraded under normal physiological 
conditions, but accumulates when the UPS is impaired (26). Positive control wells were 
treated with 25µM proteasome inhibitor lactacystin (Enzo Life Sciences). 24 hours later, 
NRVMs were dissociated in 0.05% trypsin EDTA (Invitrogen) for 10 minutes at 37°C, 
washed twice in ice cold PBS with 5% FBS, fixed in 4% paraformaldehyde, and stored at 
4°C. Cells were analyzed using an LSRFortessa Cell Analyzer (BD Biosciences). Debris 
and events larger than single cells were gated out. GFPu signal was detected using a 
488nm laser (530/30 filter), and data was processed using FlowJo® software. 
3.3.7 Assessment of HSC70 nuclear colocalization.  
To determine if mutant MYBPC3 expression affects compartmental localization of 
HSC70, we performed colocalization analysis of HSC70 and DAPI signals in confocal Z-
stack images of nuclei from patterned immunostained NRVMs. NRVMs were plated at a 
density of 1.5x105 cells/coverslip, fixed and immunostained as described above for 
HSC70 and phalloidin. Z-stack images with a step size of 0.6µm were acquired with a 
60X objective using a Nikon A1 confocal laser microscope system. 5-6 individual nuclei 
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from three random fields per coverslip per condition were subjected to colocalization 
analysis using NIS Elements Confocal imaging software. 
3.3.8 Assessment of HSC70 sarcomere periodicity. 
Untreated patterned NRVMs were prepared as described in section 2.3.9. Images 
of three random fields per coverslip from three biological replicates per condition were 
acquired with a 60X objective using a Nikon Eclipse Ti-E inverted fluorescence 
microscope. Image and data analysis were performed as described in section 2.3.9. 
Image acquisition and data analysis were done under single-blind conditions. Median 
periods of both HSC70 and phalloidin signals were determined.  
3.3.9 Procurement of human heart tissue.  
Intraventricular septum samples from HCM patients were collected from tissue 
excised during septal myectomy, and control tissue was collected from the intraventricular 
septum of unmatched donor hearts, as described previously [Helms, 2016]. Tissue was snap 
frozen in liquid N2 and stored at -80°C. Patient demographic data were recorded at the 
time of tissue collection, including genotype status determined by clinical genetic testing 
performed in CLIA approved laboratories. All MYBPC3 HCM samples came from patients 
with truncating mutations. 
3.3.10 Quantitative reverse transcription PCR.  
qRT-PCR was used to assess transcript abundance of HSPA8/HSC70 and 
HSPA1A/HSP70 in human myocardial tissue. RNA was isolated from tissue using the 
Qiagen RNeasy Fibrous Tissue Mini kit. The Qiagen Omniscript RT kit was used for 
generation of cDNA by reverse transcription. TaqMan™ gene expression assays for 
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human HSPA8, HSPA1A, B2M (β2-microglobulin), and RPL32 (60S ribosomal protein 
L32) were used in conjunction TaqMan® Fast Advanced Master Mix and samples were 
analyzed using an Applied Biosystems® 7500 Fast Real-Time PCR system. β2-
microglobulin and RPL32 were used as internal reference genes; data was analyzed as 
previously described [Pfaffl, 2001]. 
3.3.11 MYBPC3 transgenic mouse model.  
A mouse line expressing a ~75kDa prematurely truncating MYBPC3 transgene on 
the FVB background was acquired as frozen embryos from Dr. Jeffrey Robbins of 
Cincinnati Children’s Hospital Heart Institute. Transgenic males were bred to wild-type 
FVB females to produce both wild-type and transgenic littermates. Animals were 
sacrificed at 3, 6, 9, 12, and 15 months of age, and equivalent numbers of male and 
female mice were used in experiments. Hearts were collected by perfusing sterile PBS 
through the left ventricle to flush out blood, and then excised. Tissue allocated for Western 
blotting and proteasome activity assays was snap frozen in liquid N2 and stored at -80°. 
Tissue allocated for other applications was prepared as stated below. 
3.3.12 Transgene genotyping. 
 Forward primer 5’-TGTCAGCCTTCAACAAGAAGCCAAG-3’ and reverse primer 
5’-CTTCAGGACTTGAGACACTTTCTTC-3’ were used to generate PCR products from 
genomic DNA isolated from tail snips. With electrophoresis using 1% agarose gel, WT 
(Ntg) DNA produced an 800bp product, while MYBPC transgenic (Tg) DNA produced a 
366bp product. 
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3.3.13 Echocardiography.  
Cardiac function in a cohort of wild-type and transgenic animals was assessed by 
echocardiography at 3, 6, 9 ,12, and 15 months of age by the University of Michigan 
Physiology Phenotyping core. 
3.3.14 Histology.  
PBS-perfused murine hearts were preserved in Tissue-Tek™ O.C.T.embedding 
medium (Sakura Finetek USA) at -80°. Heart tissue was sectioned at a thickness of 5µm 
and mounted on glass slides. Haematoxylin & Eosin staining was used to determine 
myocyte cross-sectional area, and Masson Trichrome staining was used to mark areas 
of interstitial fibrosis. Level of fibrosis was determined in ImageJ using a binary mask with 
a set background threshold to detect blue-stained depositions of collagen. Extent of 
fibrosis was defined as the percent area of the field of view above the set threshold for 
detection. Images were acquired using a Nikon Ti-E Inverted microscope with color 
camera and taken at 20X magnification. For fibrosis quantification, ImageJ software was 
used to generate a binary mask over blue-stained fibrotic regions, from which the masked 
area as a percent of the total image was calculated. 
3.3.15 Electron Microscopy.  
To prepare tissue for EM, mice were first perfused with PBS and then with a 
solution of 2% glutaraldehyde (EM grade, Sigma-Aldrich) and 2% paraformaldehyde (EM 
grade, Sigma-Aldrich) in 0.1M Sorensen’s phosphate buffer, pH7.4. Fixed hearts were 
excised and submerged in glutaraldehyde/paraformaldehyde fixative solution. 1mm3 
pieces of tissue were dissected from the left ventricular free wall and intraventricular 
septum and stored in fixative solution at 4°C prior to further processing. Samples were 
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rinsed three times in 0.1M Sorensen’s phosphate buffer for 15 minutes each, followed by 
post fixation in 1% osmium tetroxide in 0.1M Sorensen’s buffer for one hour at room 
temperature. After three additional 15-minute rinses in 0.1M Sorensen’s buffer, samples 
were dehydrated in increasingly concentrated acetone solutions for 5 minutes (1x25, 
1x50, 1x70, 1x95, 2x100% acetone). Tissue was embedded using Embed 812 resin 
(Thermo Fisher) and polymerized at 60°C for 24 hours. 70nm sections were cut using an 
ultra-microtome, placed on 200 mesh fine bar hex grids and stained with uranyl acetate 
and lead citrate. Tissue was imaged using a Jeol JEM-1400 transmission electron 
microscope. 
3.3.16 Proteasome chymotrypsin-like activity assay.  
 Mouse myocardial tissue (50-60mg) was homogenized in proteasome assay buffer 
(50mM HEPES pH7.5, 20mM KCl, 5mM MgCl2, 1mM Dithiothreitol), on ice. Homogenate 
was centrifuged for 10 minutes at 10,000g at 4°C. Supernatant was retained and used to 
determine protein concentration using the Bradford assay (Bio-Rad). Serial dilutions of 
ATP were prepared in 25mM HEPES pH7.5 (50, 28, 14, 7 and 3.5µM). Each sample was 
analyzed in triplicate in an opaque black 96-well plate with 200µL assay buffer, 10uL ATP 
dilution, and 20µL protein sample. 10µL 0.45mM lactacystin proteasome inhibitor (Enzo 
LifeSciences) was used to determine background non-proteasomal signal. 10µL of 
0.45mM Suc-LLVY-AMC substrate (Enzo LifeSciences) was mixed with each reaction 
well and plate was protected from light until analysis. A SpectraMax® multi-mode 
microplate reader programmed to read 380nm excitation/440nm emission data every 
minute for 45 minutes at 37°C was used to collect results. Background signal was 
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subtracted from the averaged signal from triplicate wells. Data is reported as relative 
fluorescence vs. [ATP]. 
3.3.17 Statistics 
Statistical analysis was done using GraphPad Prism software. Kruskal-Wallis 
nonparametric one-way ANOVA with Dunn’s post hoc test for multiple comparisons were 
used for data with ≥3 groups. Student’s t test was used for data with 2 groups. Outliers 
excluded from analysis were identified using GraphPad Prism’s ROUT method with a Q 
coefficient of 1%. p-values of <0.05 were considered statistically significant. Data is 
reported as mean±SEM unless otherwise noted. 
 
3.4 RESULTS 
3.4.1 Expression of mutant MYBPC3 in NRVMs does not disrupt ubiquitin 
proteasome system function.  
Expression of truncated mutant MYBPC3 in vitro has been previously shown to 
impair UPS function[Sarikas, 2005]. We used the fluorescent degron reporter GFPu to assay 
the effect of mutant MYBPC3 expression on UPS function. GFPu accumulates when the 
UPS is impaired[Kumarapeli, 2005]. The proteasome inhibitor lactacystin was used as a positive 
control. While some MYBPC3 mutants showed increased GFPu signal compared to 
untransduced NRVMs, none of the MYBPC3 mutants significantly induced GFPu 
accumulation compared to cells expressing WT MYBPC3 (Figure 3.1A,B). Lactacystin 
treatment clearly blocked degradation of adenovirally-expressed MYBPC3 proteins 
(Figure 3.1C), but there was no apparent direct effect of mutant MYBPC3 on UPS 
function.  
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3.4.2 Mutant MYBPC3 expression is not associated with stress-induced 
HSP70 expression or HSC70 nuclear translocation.  
HSP70 chaperones have well-characterized roles in cellular stress responses, 
most notably in the cytoplasmic heat shock response [Kregel, 2002]. In order to determine 
whether mutant MYBPC3 expression affected established signs of protein folding stress 
associated with HSP70 chaperones, we assessed HSP70 and HSC70 expression levels 
and localization following WT and mutant MYBPC3 expression. Elevation of HSP70 
mRNA and protein levels occurs as part of the heat shock response pathway and during 
other challenges to proteostasis [Kregel, 2002]. We found no significant differences in HSP70 
protein in NRVMs expressing mutant MYBPC3. HSP70 exhibited very low expression 
levels in NRVMs and was only significantly elevated in cells heat shocked for 1 hour at 
45°C (Figure 3.2A). HSC70 protein was not significantly affected by either mutant 
MYBPC3 expression or heat shock (Figure 3.2B). While HSC70 is constitutively 
expressed under both baseline and stress conditions, it is known to undergo nuclear 
translocation in response to heat stress [Adhikari, 2004, Kodiha, 2005]. HSC70 has been shown to 
translocate in complex with heat shock factor 1 (HSF-1) and regulates HSF-1 mediated 
transcriptional activity [Ahn, 2005]. We performed colocalization analysis of HSC70 and DAPI 
signals using confocal microscopy to determine if mutant MYBPC3 expression affected 
compartmental localization of HSC70. In both control and mutant MYBPC3-expressing 
cells, HSC70 was present in concentrated areas within nuclei, likely nucleoli (Figure 3.3). 
However, nuclear localization of HSC70 significantly increased only in heat shocked 
NRVMs (Figure 3.2C,D). Overall, mutant MYBPC3 was not associated with the typical 
responses of HSP70 and HSC70 to protein folding stress.  
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3.4.3 Sarcomere localization of HSC70 in NRVMs expressing truncated 
MYBPC3 
We previously determined that HSC70 is expressed in the sarcomere in NRVMs 
and occurs at approximately 1µM intervals, corresponding to the M-line and Z-disk (see 
section 2.4.5). and HSC70 was not disrupted by expression of mutant MYBPC3, 
suggesting no effect on the periodicity of HSC70 localization in the sarcomere (Figure 
3.4). 
3.4.4 Transcript and protein abundance for HSP70 and HSC70 are not 
upregulated in human HCM.  
 Our in vitro studies did not indicate a direct effect of acute truncated MYBPC3 
expression on levels of HSP70 chaperone proteins. However, because HCM is a chronic 
disease, expression of these chaperones could be altered over time as a secondary effect 
of the primary pathogenic mechanism. To determine whether HSP70 chaperones may be 
upregulated in HCM patients with MYBPC3 mutations, we measured transcript and 
protein abundance of HSP70 and HSC70 in patient myocardial tissue samples collected 
following surgical myectomy of portions of the intraventricular septum. MYBPC3 mutation 
samples, which all came from patients with truncating mutation genotypes, to tissue from 
healthy donors, were compared to MYH7 mutation samples and samples with 
undetermined mutations not in any sarcomere protein. Transcript levels were normalized 
two separate housekeeping genes: β-2 microglobulin (B2M) and 60S ribosomal protein 
L32 (RPL32). No change in HSPA1A transcript was observed among the experimental 
groups when normalized to either housekeeping gene (Figure 3.5A). HSPA8 transcript 
also showed no change when normalized to B2M; however, when normalized to RPL32, 
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transcript abundance in all three HCM groups was significantly reduced to approximately 
50% of donor controls (Figure 3.5B). Protein expression of neither HSP70 nor HSC70 
was significantly affected in any HCM group as measured by Western blot (Figure 3.5C-
E) and mass spectrometry (Figure 3.5F). 
3.4.5 Stable expression of a truncated MYBPC3 protein does not induce a 
hypertrophic cardiac phenotype in mice.  
 Previous animal studies have explored the effect of MYBPC3 mutations on whole 
heart physiology in a context of haploinsufficiency or complete absence of WT MYBPC3. 
This has made it difficult to tease out which effects, if any, may result from the potential 
presence of truncated protein rather than pure MYBPC3 haploinsufficiency. To explore 
whether the presence of truncated MYBPC3 is sufficient to cause hypertrophic 
remodeling, we utilized a murine model expressing a mutant MYBPC3 transgene under 
control of the αMyHC promoter on a background of full WT MYBPC3 expression. The 
transgene produces stable cardiac-specific expression of a 75kDa truncated MYBPC3 
protein which is readily detectable by Western blot and is not rapidly cleared as in human 
HCM. Cardiac performance in a cohort of both male and female transgenic (MYBPC3 Tg) 
and nontransgenic (Ntg) mice was assessed by echocardiography at three-month 
intervals, starting at 3 months and ending at 12 months of age. A complete summary of 
the echocardiogram data can be found in Table 3.1. Parameters indicative of ventricular 
hypertrophy such as intraventricular septum thickness, LV posterior wall thickness, and 
LV mass showed no statistically significant differences between Ntg and MYBPC3 Tg 
mice at any age, demonstrating absence of hypertrophic remodeling (Figure 3.6A-F). In 
fact, LV posterior wall thickness was slightly but significantly lower in MYBPC3 Tg mice 
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versus Ntg mice. The ratio of heart weight to body weight determined at time of sacrifice 
(12 months) was also unchanged. Additionally, functional measures including ejection 
fraction and fractional shortening were not significantly affected at any age, although both 
parameters showed a trend toward decreasing in MYBPC3 Tg mice at 12 months 
(p≈0.07) (Figure 3.6G,H). Finally, the left atrium showed a slight trend toward increased 
size in 12-month old MYBPC3 Tg mice (p≈0.085) (Figure 3.6I). Although not statistically 
significant, these three parameters may be indicative of the beginnings of diastolic 
dysfunction, a key symptom in HCM. Nevertheless, these findings overall suggest 
expression of truncated MYBPC3 protein is insufficient on its own to be a primary 
pathogenic mechanism in hypertrophic cardiomyopathy. 
3.4.6 Transgenic expression of truncated MYBPC3 in mice is not associated 
with tissue- or ultrastructural-level disarray.  
 We sought to ascertain whether hallmarks of HCM could be present at the tissue 
and subcellular level despite the absence of a whole-organ phenotype in MYBPC Tg 
mice. Pursuant to this goal we assessed cardiomyocyte size, myocardial disarray, and 
interstitial fibrosis in histological sections of myocardium from MYBPC3 Tg and Ntg mice 
at 9. Cardiomyocyte size and disarray were observed from hæmatoxylin & eosin-stained 
sections, while fibrosis was quantified using Masson trichrome-stained sections. We 
found no differences in any of these aspects between MYBPC3 Tg and Ntg mice from 
ages 3 to 12 months (Figure 3.7A). Next, ultrastructural sarcomere organization was 
observed using transmission electron microscopy. Myofibrillar disorganization and 
misalignment of Z-disks has been observed previously in HCM[Maron, 1979, Razzaque, 2013]. 
Images were collected from myocardium of two male and two female mice of each 
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genotype aged 9 months (Figure 3.7B). Both MYBPC3 Tg and Ntg mice had neatly 
packed sarcomeres and few out-of-register Z-disks. Furthermore, no conspicuous 
granular or filamentous cytosolic aggregates were seen in MYBPC3 Tg myocardium, as 
are observed in desmin- or α-B crystallin-associated cardiomyopathy[Inagaki, 2006, McLendon, 
2011, Perng, 1999]. The tissue and ultrastructural findings indicate that expression of the 
truncated MYBPC3 protein is also insufficient to cause pathological tissue or myofibrillar 
disorganization consistent with hypertrophic remodeling or loss of sarcomere 
proteostasis. 
3.4.7 Ubiquitin proteasome function is not impaired in truncated MYBPC3 
transgenic mice. 
  Lastly, we aimed to determine whether expression of the truncated MYBPC3 
transgene was associated with impaired proteasome activity similar to that observed in 
previous studies of human HCM myocardium[Predmore, 2010, Thottakara, 2015]. We utilized an 
optimized assay to measure proteasome activity in tissue homogenate by detecting 
cleavage of a fluorophore from a short peptide substrate by the chymotrypsin-like catalytic 
proteasome subunit (PSMB5/β5)[Powell, 2007]. Ventricular myocardium of n=18 MYBPC3 Tg 
mice and n=14 Ntg mice aged 9-12 months was homogenized. Proteasome activity in 
MYBPC3 Tg ventricular myocardium was not significantly different from activity in Ntg 
myocardium (Figure 3.7). Therefore, chronic expression of a substantial amount of 
truncated MYBPC3 protein in vivo does not reproduce the proteasome dysfunction found 
in HCM patients.  
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3.5 DISCUSSION 
 The major findings of this study are the following: (i) expression of truncated mutant 
MYBPC3 in NRVMs did not induce UPS dysfunction, heat-shock response-associated 
HSP70 expression, or HSC70 nuclear translocation; (ii) stable expression of a truncated 
MYBPC3 mutant without accompanying haploinsufficiency in vivo is not sufficient to elicit 
cardiac hypertrophy in mice; and (iii) expression of HSP70 chaperones is not altered in 
myocardium from HCM patients. These results challenge previous findings that truncated 
MYBPC3 protein is sufficient to disrupt proteostasis in cardiomyocytes, and that truncated 
MYBPC3 may be directly responsible for UPS dysfunction observed in HCM 
patients[Bahrudin, 2008, Sarikas, 2005, Schlossarek, 2012, Schlossarek, 2012]. Instead, they suggest that 
defective proteostasis and proteasome impairment in HCM are downstream 
consequences of cardiac remodeling, most likely induced by haploinsufficiency of WT 
MYBPC3. 
 Two non-mutually exclusive hypotheses to explain pathogenesis in HCM caused 
by nonsense mutations in MYBPC3 have been proposed: haploinsufficiency of functional 
MYBPC3[Marston, 2012], and a “poison peptide” effect associated with truncated 
MYBPC3[Schlossarek, 2014]. Evidence supporting the existence of MYBPC3 haploinsufficiency 
in patients is strong, but a precise mechanism tying haploinsufficiency to activation of 
hypertrophic signaling and remodeling is less so. To date, truncated MYBPC3 mutant 
protein has not been identified in myocardial tissue from HCM patients [Jacques, 2008, Marston, 
2009, van Dijk, 2009]. Furthermore, several studies have identified reduced expression of WT 
MYBPC3 in patients with nonsense mutations in MYBPC3 [Marston, 2009, van Dijk, 2009, van Dijk, 
2012]. Functionally, ablation of MYBPC3 in cardiac muscle fibers causes destabilization of 
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the myosin super-relaxed conformation[McNamara, 2017, McNamara, 2016], and increased 
myofilament calcium sensitivity [Stelzer, 2006], which has been linked to diastolic dysfunction 
both in patient studies and mouse models of HCM [Fraysse, 2012, van Dijk, 2012]. These findings 
suggest that in patients with MYBPC3 nonsense mutations, truncated MYBPC3 is absent 
and WT MYBPC3 levels may be insufficient to maintain normal contractile function, 
energy balance, and calcium sensitivity, leading to diastolic dysfunction, a defining feature 
of HCM. It is known that nonsense mutant transcript is removed by via nonsense-
mediated decay (NMD) [van Dijk, 2009, Vignier, 2009]. However, we have previously found that 
some nonsense MYBPC3 transcripts escape NMD to varying degrees across individual 
patients [Helms, 2014]. Therefore, any truncated protein that is translated is likely degraded 
soon after. Consistent with prior studies [Sarikas, 2005, Vignier, 2009], we observed that truncated 
MYBPC3 is degraded by the UPS, and that several mutants maintained significantly lower 
steady-state expression compared to WT MYBPC3. 
Evidence for truncated MYBPC3 exhibiting a “poison peptide” effect has been 
suggested based on observations of UPS dysfunction in human HCM [Predmore, 2010, Thottakara, 
2015], mutant MYBPC3 mouse models [Schlossarek, 2012, Schlossarek, 2012], and in vitro expression 
of truncated MYBPC3 [Sarikas, 2005]. Whether UPS dysfunction is directly associated with a 
burden imposed on protein quality control by truncated MYBPC3 or indirectly due to 
adverse remodeling in HCM is unresolved. Our in vitro experimental system allowed us 
to study the acute effect of mutant MYBPC3 on UPS function in a context of normal total 
MYBPC3 expression and intact sarcomere structure, in the absence of remodeling. We 
found that expression of mutant MYBPC3 did not induce UPS dysfunction when 
compared to expression of FLAG-WT MYBPC3 in NRVMs. This is in contrast with a 
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previous finding which observed accumulation of a UbG76V-DSRed degron reporter 
associated with expression of a 40kDa truncated MYBPC3 protein in NRVMs, despite 
similar experimental conditions [Sarikas, 2005]. Several differences between this and the 
present study may explain the divergent results.  First, of the two mutants tested in the 
prior study, which both localized to the cytosol, only the shorter one (truncation in C1) 
caused degron accumulation as measured by flow cytometry. The mutant we tested 
which was most similar (truncation in the C0-C1 linker) showed primarily nuclear 
localization, and may not be degraded by cytosolic UPS machinery. Additionally, the prior 
study showed formation of ubiquitin-positive cytosolic MYBPC3 aggregates in some 
NRVMs expressing the shorter mutant, while we did not observe aggregates associated 
with any of the five mutants tested. Therefore, proteasomal burden of mutant MYBPC3 
may be dependent on the severity of truncation and subcellular localization.  
HSP70 expression can be induced in myocytes by hypertrophic stimuli, and can in 
turn regulate hypertrophic signaling, for example by activating histone deacetylase-2[Kee, 
2008, Osaki, 1998]. Therefore, elevated HSP70 as a result of protein folding stress associated 
with truncated MYBPC3 could contribute to remodeling. However, we also found no 
correlation between expression of mutant MYBPC3 and changes in expression or 
subcellular localization of HSP70 and HSC70. These findings indicate that expression of 
truncated MYBPC3 by itself, even well above the sub-threshold expression in human 
HCM, likely does not represent an acute challenge to proteostasis, at least in the 
presence of WT MYBPC3. It is notable that even the highest expression levels of WT or 
mutant MYBPC3 did not induce UPS dysfunction, HSP70 induction or HSC70 nuclear 
translocation, suggesting that the source of proteasome insufficiency in HCM is not direct 
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effect of mutant MYBPC3 expression. Additionally, the absence of any marked protein 
folding stress response suggests that the interaction between MYBPC3 and HSC70 
explored in Chapter 2 is important for normal physiologic regulation of MYBPC3 
expression. Nevertheless, it is possible that proteotoxic effects may arise from long-term 
expression over the course of a patient’s lifetime. Indeed, UPS impairment in mutant 
MYBPC3 knock-in mice was not observed until one year of age [Schlossarek, 2012]. However, 
these heterozygous knock-in mice expressed MYBPC3 at ~80% of WT control levels, and 
thus did not allow differentiation between effects associated with reduced MYBPC3 
expression versus presence of a truncated protein. 
 To further dissect the possible contribution of a “poison peptide” mechanism in 
MYBPC3-linked HCM over a longer period of time, we utilized a mouse model carrying a 
truncating MYBPC3 mutant transgene along with two functioning endogenous WT 
MYBPC3 alleles. This model was previously characterized and the ~75kDa transgene 
product was found to be stable and expressed at levels similar to endogenous MYBPC3, 
with poor sarcomere incorporation[Yang, 1998]. We initially hypothesized that high expression 
of the truncated protein without a decrease in WT MYBPC3 would be associated with left 
ventricular remodeling, preceded by UPS dysfunction, implying that loss of proteostasis 
is an instigating mechanism in HCM. However, after comprehensive echocardiographic, 
histological and ultrastructural analysis, we observed neither cardiac remodeling nor UPS 
dysfunction in this mouse model at 9-12 months of age. Only non-significant trends in 
ejection fraction, fractional shortening, and left atrial diameter at 12 months hinted at any 
phenotype. As such, while this data reinforces the findings from our in vitro model system, 
we can make no conclusions from this study about whether impaired myocyte 
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proteostasis is a cause or effect of cardiac hypertrophy. The study by Schlossarek et. al. 
reported reduced chymotrypsin-like proteasome activity in heterozygous knock-in mice at 
1 year, while HW/BW ratio was already significantly larger compared to WT mice at 9 
weeks. Interestingly, also at 9 weeks steady-state levels of ubiquitinated protein were 
elevated and chymotrypsin-, trypsin- and caspase-like proteasome activities were 
increased.  Additionally, proteasome activity showed positive correlation with HW/BW 
ratio. One explanation put forward for increased proteasome activity occurring early in 
disease development suggests that proteasome subunits are upregulated in order to 
facilitate increased protein turnover during hypertrophy as well as routine maintenance of 
proteostasis[Su, 2010]. This hypothesis suggests initiation of hypertrophic remodeling places 
an additional burden on the UPS and other PQC pathways, which ultimately disrupts 
proteostasis and overloads the proteasome as HCM progresses over many years. It also 
leaves open the possibility that the necessity to degrade any translated truncated 
MYBPC3 proteins could exacerbate this burden and contribute to pathogenesis, though 
likely only subsequent to haploinsufficiency-induced hypertrophy. Overall, our in vivo data 
are more supportive of the idea that UPS dysfunction in HCM is an indirect consequence 
of pathological cardiac remodeling as has been observed for other forms of 
cardiomyopathy and heart failure[Day, 2013, Fessart, 2014, Gilda, 2017]. 
Finally, we investigated transcript and protein expression of HSP70 and HSC70 in 
myocardium from HCM patients with truncating MYBPC3 mutations. Our lab has 
previously observed significant UPS impairment in patients with similar genotypes[Predmore, 
2010]. Nonetheless, expression of upstream chaperones was unchanged compared to 
healthy donor hearts or myocardium from HCM patients with non-sarcomere gene 
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mutations. This may indicate that in cardiomyocytes, the UPS is particularly vulnerable to 
functional insufficiency compared to other branches of PQC pathways such as the 
chaperone network, because the proteasome is responsible for degradation of most 
major sarcomere proteins[Mitch, 1996, Solomon, 1996]. However, the HSP70-family represents 
only one class of chaperones involved in cardiomyocyte proteostasis, and other groups, 
such as the small heat shock proteins, may be more significantly affected. 
In conclusion, the results of this study challenge the viability of the “poison peptide” 
hypothesis of HCM pathogenesis. In contrast to previously reported findings, expression 
of truncated MYBPC3 did not compromise proteostasis in vitro or in vivo. Furthermore, 
we found that truncated MYBPC3 expression alone is not sufficient to provoke a 
hypertrophic cardiac phenotype in mice and is likely not a key root of pathogenesis. The 
mechanistic origin of UPS dysfunction in HCM remains unknown, and further studies are 
required to understand the role of proteostasis in this enigmatic disease. 
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FIGURE 3.1 
 
 
 
Figure 3.1. Expression of MYBPC3 mutants does not significantly affect ubiquitin 
proteasome function as assessed by the degron reporter GFPu. (A) Representative flow 
cytometry density plots. x-axis: GFPu fluorescence; y-axis: side scatter area (SSC-A). Data in the boxed area indicates 
GFP-positive cells. (B) Quantification of GFPu expression. Data is normalized to % GFPu-positive cells for control 
(untransduced) NRVMs. Mean±SEM, n≥11. Kruskal-Wallis one-way ANOVA p<0.0001. *p<0.05 vs control, Dunn’s test 
for multiple comparisons. (C) Representative Western blot of NRVMs expressing MYBPC3 constructs ± treatment with 
25μM proteasome inhibitor lactacystin. Black line between lanes indicates noncontiguous samples from the same blot. 
Lactacystin treatment resulted in significant accumulation of FLAG-MYBPC3, while endogenous rat WT MYBPC3 levels 
were not significantly affected. This indicates that the ubiquitin proteasome system is able to handle a high rate of 
truncated FLAG-MYBPC3 turnover without being impaired. 
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FIGURE 3.2 
 
Figure 3.2. Mutant MYBPC3 expression in NRVMs does not induce HSP70 upregulation or HSC70 nuclear 
translocation. (A) Quantification and representative Western blot for HSP70 (stress-inducible). HSP70 protein levels 
were only significantly elevated in NRVMs heat shocked for 1 hour at 45°C. n≥6, Kruskal-Wallis one way ANOVA 
p=0.003. *p<0.05 vs control, Dunn’s test for multiple comparisons. Mean±SEM. (B) Quantification and representative 
Western blot for HSC70. HSC70 protein levels were consistent across all conditions. n≥6, Kruskal-Wallis one-way 
ANOVA p=0.48. Mean±SEM. (C) Immunofluorescence-based Quantification of HSC70 signal localized to DAPI-positive 
areas as a percent of total signal. Only heat shocked cells showed significantly increased nuclear localization of HSC70. 
n≥5 fields of view, Kruskal-Wallis one way ANOVA p=0.021. *p<0.05 vs control, Dunn’s test for multiple comparisons. 
Mean±SEM. (D) Mander’s correlation coefficient between DAPI and HSC70 signals for n=36 nuclei per condition. 
Kruskal-Wallis one-way ANOVA p<0.0001. *p<0.05 vs control, Dunn’s Dunn’s test for multiple comparisons. 
Mean±SEM. Black line between lanes indicates noncontiguous samples from the same blot. 
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FIGURE 3.3 
 
Figure 3.3. Representative confocal images with Z-projections of patterned NRVMs 
immunostained for HSC70. Z-plane step size of 0.6μm. Scale bar = 20μm, 60X magnification. Only heat 
shock caused marked nuclear translocation of HSC70. 
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FIGURE 3.4 
 
 
 
Figure 3.4. Mutant MYBPC3 protein expression does not alter HSC70 sarcomere 
periodicity. (A) Frequency of HSC70 and phalloidin peaks in untreated control vs. FLAG-MYBPC3 adenovirus 
treated and heat shocked NRVMs, determined by fast Fourier transform analyses on fluorescent intensity profiles. 
HSC70 frequency was not significantly affected by mutant MYBPC3 protein expression or heat shock. (B) Only cells 
expressing the c.2905+1G>A mutant showed a significantly altered ratio of HSC70 frequency to phalloidin frequency 
when compared to untreated cells, but not FLAG-WT treated cells. Kruskal-Wallis one-way ANOVA with Dunn’s test 
for multiple comparisons, *p<0.05. Mean±SEM. n≥16 cells per condition. 
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FIGURE 3.5 
 
 
Figure 3.5. HSP70 and HSC70 transcript and protein are not upregulated in human 
MYBPC3-linked HCM.  (A) HSP70 (HSPA1A) transcript and (C) protein abundance in human myocardial tissue 
from donor controls and HCM patients (septal myectomy samples). HSPA1A mRNA abundance was normalized to two 
different internal reference genes (β2-microglobulin/B2M and 60S ribosomal protein L32/RPL32). No significant 
differences in HSP70 mRNA or protein were observed in tissue samples from HCM patients with MYBPC3 mutations 
compared to controls or HCM patients with no identified sarcomere gene mutations. Mean±SEM, Kruskal Wallis one-
way ANOVA p>0.05. (B) HSC70 (HSPA8) mRNA and (D) protein abundance. No differences in HSC70 protein 
expression were observed. HSPA8 mRNA was significantly reduced in both MYBPC3 and sarcomere-mutation 
negative HCM samples when normalized to RPL32, but not B2M. Mean±SEM, Kruskal Wallis one-way ANOVA; 
*p<0.0001, Dunn’s test for multiple comparisons. (E) Representative Western blots for HSP70 and HSC70. Black line 
between lanes indicates noncontiguous samples from the same blot. For transcripts, healthy control n=11, MYBPC3 
mutations n=11, non-sarcomere mutations n=12. For HSP70 protein, healthy control n=7, MYBPC3 mutations n=10, 
non-sarcomere mutations n=18. For HSC70 protein, healthy control n=7, MYBPC3 mutations n=6, non-sarcomere 
mutations n=7. (F) Quantitative mass spectrometry of key chaperones from MYBPC3-linked and sarcomere gene 
mutation-negative HCM myectomy samples. Bars represent fold change in spectral counts over mean abundance in 
healthy control samples, indicated by dotted line. 
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FIGURE 3.6 
 
Figure 3.6. Echocardiograms show absence of hypertrophic phenotype in 
truncated MYBPC3 transgenic mice compared to non-transgenic mice.  (A) Heart weight 
to body weight ratios and (B) uncorrected heart weight as determined upon sacrifice at 12 months. (C) Left ventricular 
mass as determined by echocardiogram at three-month intervals over a total of 12 months. Salient structural 
parameters (D) intraventricular septum width during diastole, (E) left ventricle posterior wall width during diastole, and 
(F) left ventricular diameter during diastole showed no significant differences between MYBPC3 tg and ntg mice. 
Functional parameters (G) ejection fraction and (H) fractional shortening were also unaffected. (I) Left atrial diameter 
was mildly but non-significantly (p=0.086) increased in mutant MYBPC3 tg mice at 12 months. Mean±SEM, Ntg n=10, 
Tg n=12. 
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FIGURE 3.7 
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Figure 3.7. 9 month-old MYBPC3 transgenic mice do not develop interstitial fibrosis 
or myofibrillar disarray. (A) Masson-Trichrome stained myocardial tissue sections from 9 month-old Ntg and 
MYBPC3 Tg mice. Collagen appears as blue while cytoplasm appears pink. Inset shows magnified fibrotic regions with 
an example of the binary mask used to quantify fibrosis; red areas were counted toward % area fibrosis. 20X 
Magnification. (B) Electron micrographs from myocardium (LV free wall) of 9 month-old Ntg and MYBPC3 Tg mice. No 
significant myofibrillar disorganization or misalignment of Z-disks was observed in either line (left). Both lines had 
infrequent occurrence of amorphous, non-membrane-bound structures but no distinct granular or fibrous protein 
aggregates (right). m=mitochondrion; M=sarcomere M-line, arrowhead; Z=sarcomere Z-disk, arrow. 
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FIGURE 3.8 
 
 
Figure 3.8. 9 month-old MYBPC3 transgenic mice do not exhibit proteasome 
dysfunction in ventricular myocardium. A fluorogenic substrate-cleavage assay specific for 
chymotrypsin-like proteasome activity was performed using murine myocardial tissue homogenate.  Signal from activity 
not inhibited by lactacystin (non-proteasomal) was subtracted from total. No significant difference in chymotrypsin-like 
activity was observed between hearts from non-transgenic mice (closed circles, solid line) and MYBPC3 transgenic 
mice (open triangles, dashed line). Mean±SEM; Ntg n=14, MYBPC3 Tg n=18; p>0.05 for all concentrations of ATP, 
student’s T test. 
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TABLE 3.1. Echocardiographic assessment of heart structure and function in 12 month-
old non-transgenic vs. MYBPC3 mutant transgenic mice. 
 12 months 
sex M F 
genotype ntg MYBPC3 tg ntg MYBPC3 tg 
n 5 6 5 6 
BW (g) 33.16 ± 1.20 35.49 ± 0.709 29.40 ± 0.300 28.33 ± 0.918* 
HR (bpm) 490.7 ± 28.6 525.4 ± 12.2 465.3 ± 39.0 420.7 ± 24.1 
HW:BW (mg/g) 4.291 ± 0.0855 3.917 ± 0.143 3.927 ± 0.166 3.750 ± 0.0877 
LV mass (mg) 176.3 ± 15.2 163.1 ± 13.4 139.4 ± 4.792 117.8 ± 11.6 
IVSd (mm) 1.018 ± 0.0589 1.008 ± 0.0405 0.9900 ± 0.0230 0.8810 ± 0.0695 
IVSs (mm) 1.564 ± 0.0464 1.547 ± 0.0730 1.500 ± 0.0303 1.238 ± 0.0865* 
IVSth (%) 0.5475 ± 0.0566 0.5350 ± 0.0359 0.5171 ± 0.0345 0.4161 ± 0.0643 
LVDd (mm) 4.118 ± 0.0644 4.038 ± 0.116 3.675 ± 0.0969 3.688 ± 0.0823 
LVDs (mm) 2.650 ± 0.124 2.712 ± 0.0890 2.354 ± 0.0393 2.484 ± 0.115 
PWd (mm) 1.036 ± 0.0247 0.9562 ± 0.0464 0.9900 ± 0.0493 0.8592 ± 0.0415* 
PWs (mm) 1.454 ± 0.0369 1.238 ± 0.0783* 1.327 ± 0.0444 1.216 ± 0.0761 
PWth (%) 0.4130 ± 0.0578 0.2895 ± 0.0278 0.3429 ± 0.0513 0.4198 ± 0.0657 
LVVd (uL) 75.43 ± 4.17 72.00 ± 3.50 57.49 ± 2.39 58.31 ± 4.50 
LVVs (uL) 26.27 ± 3.20 27.62 ± 2.24 19.39 ± 0.804 22.44 ± 2.67 
LA (mm) 2.733 ± 0.127 3.080 ± 0.118 2.672 ± 0.0563 2.778 ± 0.1437 
EF (%) 0.6559 ± 0.0227 0.6157 ± 0.0259 0.6609 ± 0.0169 0.6189 ± 0.0223 
FS (%) 0.3575 ± 0.0159 0.3282 ± 0.0188 0.3578 ± 0.0132 0.3276 ± 0.0157 
Abbreviations. BW: body weight; HR: heart rate; HW:BW heart weight to body weight ratio; LV: left ventricle; IVSd: 
diastolic intraventricular septum width; IVSs: systolic intraventricular septum width; IVSth: % change in 
intraventricular septum thickness from systole to diastole; LVDd: diastolic left ventricle diameter; LVDs: systolic left 
ventricle diameter; PWd: diastolic posterior wall width; PWs: systolic posterior wall width; PWth: % change in 
posterior wall thickness from systole to diastole; LVVd: diastolic left ventricle volume; LVVs: systolic left ventricle 
volume; LA: left atrial diameter; EF: ejection fraction; FS: fractional shortening. 
*p<0.05 vs. nontransgenic mice of same sex 
Mean ± SEM 
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CHAPTER 4 
 
MYBPC3 missense mutation locus influences protein stability in vitro 
 
4.1 ABSTRACT 
 Mutations in cardiac myosin binding protein C (MYBPC3) are a frequent cause of 
hypertrophic cardiomyopathy (HCM), the most common inherited heart disease. Patient 
genotyping has uncovered two categories of pathogenic MYBPC3 mutations: truncating 
and non-truncating. Uniquely among other sarcomere genes harboring HCM-associated 
mutations, most MYBPC3 mutations are truncating and there is no evidence that mutation 
locus affects pathogenic mechanism. However, we identified three groups of non-
truncating mutations that potentially represent mutation clusters within the C3, C6, and 
C10 domains of MYBPC3. While C3 and C6 mutant proteins make up a significant amount 
of total MYBPC3 in patient myocardium, at least one C10 mutant was undetectable in two 
unrelated patients, suggesting it does not directly affect sarcomere function and may act 
through a separate mechanism. We expressed C3, C6, and C10 non-truncating MYBPC3 
mutations in neonatal rat ventricular cardiomyocytes to determine whether mutation locus 
influences subcellular localization and protein stability. All three individual C10 mutants 
we tested followed a pattern of cytosolic mislocalization, low expression, and accelerated 
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degradation, while the majority of C3 and C6 mutants behaved similar to WT MYBPC3. 
This data supports the hypothesis that mutation locus can significantly affect 
characteristics of non-truncating MYBPC3 mutants, potentially resulting in divergent 
pathogenic mechanisms. 
4.2 INTRODUCTION 
  Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease 
and is generally considered a “sarcomeropathy.” Characterized by left ventricular (LV) 
hypertrophy and fibrosis, HCM predisposes patients to heart failure, arrhythmias, and 
sudden cardiac death. Hundreds of individual causative mutations have been identified, 
yet underlying pathogenic mechanisms remain poorly understood. The most frequently 
mutated gene in HCM is MYBPC3, encoding cardiac myosin binding protein C 
(MYBPC3). MYBPC3 localizes in the sarcomere A-band, has both structural and 
regulatory function, and acts as a molecular “brake” on cross-bridge cycling[Previs, 2012]. 
Much of the literature has focused on truncating mutations and their physiological 
consequences rather than the significantly fewer in number non-truncating mutations. 
Non-truncating mutations merit further study because while there are many fewer 
individual missense vs. truncating mutations, they are not quite as rare in HCM patients. 
Although nonsense, frame-shift and splice-site mutations make up >90% of HCM-
associated mutations in MYBPC3[Alfares, 2015], the Arg502Trp mutation represents the 
single most common mutation in HCM[Page, 2012, Saltzman, 2010]. As non-truncating mutations 
are likely associated with distinctly different pathogenic mechanisms (dominant-negative 
vs. haploinsufficiency), we sought to understand whether the primary mechanism is 
dependent on mutation locus. 
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 Genotype analysis of HCM patients using the Sarcomeric Human Cardiomyopathy 
Registry (SHaRe) found that while truncating mutations occur throughout the MYBPC3 
gene, missense mutations may potentially cluster in regions encoding specific domains 
(unpublished data). Specifically, groups of missense mutations were found in the C3, C6, 
and C10 domains (See figure 1.2). The C10 domain is known to interact with light 
meromyosin and titin and is part of the binding region essential to sarcomere A-band 
incorporation of MYBPC3[Flashman, 2007, Freiburg, 1996, Gilbert, 1999, Miyamoto, 1999]. The C3 and C6 
domains, however, have no definitive binding partners or functions associated with them.  
 We previously found that the in-frame duplication mutation Gly1248_Cys1253dup 
in C10 is extremely unstable in a neonatal rat ventricular cardiomyocyte (NRVM) culture 
system compared to WT MYBPC3 and even some truncated mutants (See Chapter 2, 
Figures 2.2 and 2.7)[Glazier, 2018]. It also failed to localize to the sarcomere despite retaining 
domains necessary for A-band localization (See Figure 2.3). Interestingly, the mutant 
protein could not be detected in myocardium from two unrelated HCM patients, in contrast 
to an Arg495Gln C3 mutant which made up ~70% of total MYBPC3 protein[Helms, 2014]. This 
C10 mutation most likely interrupts sarcomere binding, potentially making the mutant 
protein subject to rapid clearance from the cytosol. These characteristics are more 
consistent with truncating mutants, and may result in a loss-of-function mechanism rather 
than the dominant-negative mechanism generally associated with MYBPC3 missense 
mutations. We therefore hypothesized that the additional C10 mutants Leu1238Pro and 
Asn1257Lys would also fail to localize properly and have accelerated degradation rates. 
Conversely, we hypothesized that C3 and C6 mutants could incorporate properly and 
have similar degradation rates to WT MYBPC3.  
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 To test these hypotheses and better understand whether the locus of non-
truncating mutations dictates divergent molecular mechanisms of pathogenesis, we 
expressed MYBPC3 proteins with mutations in the relevant domains in NRVMs and 
determined their localization, stability, and degradation kinetics. Our results showed that 
C10 mutants had a consistent pattern of cytosolic mislocalization, low expression levels, 
and markedly fast degradation rates, while C3 and C6 mutants localized normally and 
tended to have comparable expression and degradation rates to WT MYBPC3. These 
results suggest that primary pathogenic mechanisms in HCM may not be universal in all 
missense mutation patients, which will be an important consideration when developing 
targeted therapies. Further, identification of the effects these groups of missense 
mutations have on the properties of MYBPC3 may help clarify the roles of domains C3 
and C6 in regulating contraction. 
 
4.3 METHODS 
4.3.1 Isolation and culture of neonatal rat ventricular cardiomyocytes.  
 See section 2.3.1 
4.3.2 Micropatterning of PDMS coverslips.  
 See section 2.3.2 
4.3.3 Expression of FLAG-tagged WT and missense MYBPC3 constructs via 
recombinant adenovirus.  
See section 2.3.3 
4.3.4 Immunofluorescence of NRVMs.  
See section 2.3.8 
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4.3.5 Cycloheximide pulse-chase assay.  
NRVMs plated in 96-well plates at a density of 4x104 cells/well were treated with 
FLAG-WT or FLAG-MYBPC3 missense adenovirus for 48 hours. Four wells in each plate 
were reserved as FLAG-negative controls and received no virus. Following viral 
treatment, media in quadruplicate wells of cells was changed with maintenance media 
containing 300µg/mL cycloheximide (CHX) (Sigma-Aldrich). Timepoints 0, 0.5, 1, 3, 6, 9 
and 12 hours post addition of CHX were collected simultaneously. This was achieved by 
adding CHX at the appropriate time prior to completion of the timecourse (i.e., wells for 
the 3 hour timepoint received CHX 9 hours after the beginning of the timecourse with 
addition of CHX to wells for the 12 hour timepoint). Following CHX pulse chase, wells 
were rinsed three times with sterile PBS. Cells were then lysed in 1X AlphaLISA lysis 
buffer (PerkinElmer) by adding 50uL of lysis buffer per well and vigorously shaking the 
cell culture plate for 20 minutes at room temperature, followed by scraping. Samples were 
stored at -80°C in the original culture plate, sealed with an adhesive cover (MicroAmp® 
optical adhesive film, Applied Biosystems).  
4.3.6 Optimization of AlphaLISA assay conditions.  
To verify that experimental conditions resulted in data within the AlphaLISA 
assay’s linear range of detection, we tested serial dilutions of lysate from cells transduced 
at MOI 10 for WT MYBPC3 and each missense mutation. Duplicate wells were analyzed 
for each condition. We found that for WT MYBPC3, C3 (Arg495Gln, Arg502Trp, 
Phe503Leu), and C6 (Trp792Arg, Arg810His) mutants, a 1:6 dilution resulted in an 
optimal signal-to-noise ratio while still within the linear range. For these proteins, the 
AlphaLISA assay was performed with a 1:6 dilution of lysate for all timepoints. However, 
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the C10 mutants (Gly1248_Cys1253dup, Leu1238Pro and Asn1257Lys) were only 
expressed at approximately 25% the level of WT MYBPC3, and dilution of these samples 
resulted in suboptimal signal-to-noise ratio. For C10 mutants, undiluted lysate remained 
within the linear range, and therefore these samples were not diluted in the AlphaLISA 
assay. These serial dilution curves were performed alongside each individual experiment 
to control for potential variability in adenoviral dosage within and between experiments.  
4.3.7 AlphaLISA assay to detect degradation rates of MYBPC3 missense 
mutants.  
To conjugate primary antibodies to AlphaLISA beads, antibodies were diluted 
1:1000 in 1X AlphaLISA assay buffer with a 1:100 dilution of the appropriate bead (10:1 
ratio of bead to antibody) and incubated for 1 hour at room temperature, protected from 
light. Mouse FLAG M2 antibody was incubated with anti-mouse AlphaScreen donor 
beads (PerkinElmer), while a rabbit polyclonal MYBPC3 antibody (custom, provided by 
Dr. Samantha Harris, University of Arizona) was incubated with anti-rabbit AlphaScreen 
acceptor beads (PerkinElmer). The AlphaLISA assay was carried out in an opaque white 
half-area 96 well plate (Corning). Each reaction well consisted of 5µL of cell lysate (diluted 
as described above), 10µL of FLAG antibody-conjugated donor beads, and 10µL of 
MYBPC3 antibody-conjugated acceptor beads. Conjugated beads were added to the 
wells under dimmed lighting conditions. The complete assay plate was covered with an 
adhesive foil seal and centrifuged for 1 minute at 1,000 rpm to eliminate bubbles. The 
plate was then incubated in the dark at room temperature for 18 hours. Data was collected 
using an EnVision 2105 multimode plate reader (PerkinElmer) with an excitation 
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wavelength of 680nm and emission detected at 615nm. Two independent experiments 
were completed. 
4.3.8 Cycloheximide chase data analysis.  
Background was defined as the average signal from the four FLAG-negative wells 
in each plate, and was subtracted from the raw signal. The fit of the linear range of serial 
dilution data for each mutant (1:4 through 1:32 dilutions for WT, C3 and C6 mutants, entire 
range for C10 mutants) was used to determine the quantity of FLAG-MYBPC3 in each 
sample. For each condition, the time 0 data were normalized to 1 to give a curve 
describing the relative abundance of FLAG-MYBPC3 over time. Data from two 
independent experiments were fit to a first-order exponential decay curve [MYBPC3] = 
[MYBPC3]0e-kt (with [MYBPC3]0 normalized to 1), from which reaction constants k and 
half-lives t½ (calculated as t½ = ln(2)/k) were determined. 
4.3.9 Statistics 
Statistical analysis was done using GraphPad Prism software. Kruskal-Wallis 
nonparametric one-way ANOVA with Dunn’s post hoc test for multiple comparisons were 
used for comparisons among WT MYBPC3 and mutant MYBPC3 groups. Outliers 
excluded from analysis were identified using GraphPad Prism’s ROUT method with a Q 
coefficient of 1%. Cycloheximide chase data analysis was performed by fitting data to a 
first-order exponential decay curve as described above and determining if WT vs 
missense mutant data could be explained by identical or differing fit parameters (i.e. 
reaction constant k). p-values of <0.01 were considered statistically significant. Data is 
reported as mean±SEM unless otherwise noted. 
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4.4. RESULTS 
4.4.1 Subcellular localization of MYBPC3 missense mutants in NRVMs is 
mutation locus-dependent.  
 Eight MYBPC3 missense mutations identified in HCM patients were engineered 
into the human MYBPC3 gene with an N-terminal FLAG epitope. These mutations: three 
in the C3 domain, two in the C6 domain, and three in the C10 domain, are located in 
regions which may represent previously unidentified mutation clusters in MYBPC3 (Figure 
4.1A). We then inserted these constructs into a mammalian expression vector for use in 
adenovirus. NRMVs were transfected with adenovirus at MOI 2. Immunofluorescence 
was performed on patterned NRVMs to determine whether the missense mutants 
localized correctly to the sarcomere (Figure 4.1B). Compared to FLAG-WT MYBPC3, all 
C3 and C6 mutants incorporated similarly into the sarcomere at the C-zone, colocalizing 
with endogenous MYBPC3. However, the three C10 mutants failed to show any 
sarcomere incorporation, instead localizing diffusely in the cytosol. This subcellular 
localization resembles the behavior of the truncating mutants discussed in Chapter 2, 
despite the presently tested mutants being full-length proteins.  
4.4.2 Missense mutation locus influences steady-state expression of mutant 
protein. 
 We previously observed that the in-frame full-length Gly1248_Cys1253 mutation 
had unexpectedly low expression levels, an accelerated degradation rate, and did not 
localize to the sarcomere when expressed in NRVMs. Based on similar subcellular 
localization of other C10-domain mutants Leu1238Pro and Asn1257Lys, we 
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hypothesized that these mutants would also be expressed unstably, while C3- and C6-
domain mutants would not. NRVMs expressing WT or missense mutant MYBPC3 were 
lysed and the AlphaLISA assay was used to detect steady-state FLAG-MYBPC3 signal. 
The AlphaLISA assay allows precise quantification of protein expression in a high-
throughput format by using beads conjugated to two antibodies raised in different species 
which recognize the same target protein at separate epitopes. One antibody is conjugated 
to a “donor” bead while the other is conjugated to an “acceptor” bead. Excitation of the 
donor bead only when it is in proximity to the acceptor bead yields a light emission signal 
proportional to the quantity of target protein. This reduces spurious signal due to antibody 
cross-reactivity with other proteins. Antibodies against MYBPC3 and the FLAG epitope 
were used to specifically detect FLAG-MYBPC3 proteins. We found that all three C10 
mutations consistently showed significantly reduced expression levels, at approximately 
~25% of WT levels (Figure 4.2). In contrast, C3 and C6 mutations showed a general 
pattern of expression levels unchanged from that of WT MYBPC3, with the exception of 
the C3 mutant Phe503Leu, which was also had significantly reduced expression. Aside 
from Phe503Leu, steady-state protein expression of missense MYBPC3 mutants 
correlates with subcellular localization to the sarcomere, with non-incorporating mutants 
exhibiting reduced expression compared to WT.    
4.4.3 Missense mutations in the C3 and C6 domains of MYBPC3 tend not to 
affect degradation rate. 
 We performed cycloheximide (CHX) pulse-chase analysis in NRVMs expressing 
MYBPC3 missense mutations to test whether mutation locus affected protein degradation 
rates and t½. CHX was used to inhibit de novo protein synthesis in NRVMs. FLAG-
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MYBPC3 quantity was determined in NRVM lysates at time points up to 12 hours post 
addition of CHX to the culture media using the AlphaLISA assay. First, we compared C3 
mutants to WT-FLAG MYBPC3. Arg495Gln, Arg302Trp, and Phe503Leu were found to 
have half-lives not significantly different from that of WT MYBPC3 (5.50, 5.82, and 3.24hr 
vs 5.06hr, respectively) (Figure 4.3). Phe503Leu had the lowest t½ out of the C3 mutants, 
which may be related to its decreased expression in relation to WT MYBPC3 (Figure 
4.3D). C6 mutants Trp792Arg and Arg810His were found to have diverging effects on 
degradation. Trp792Arg had a t½ which was reduced but not significantly different from 
that of WT (3.41hr) (Figure 4.4B). On the other hand, the Arg810His mutant significantly 
increased protein t½ (8.92hr) (Figure 4.4C). Overall, C3 and C6 mutants were not 
associated with altered protein stability. See Table 4.1 for degradation curve fit 
parameters. 
4.4.4 Missense mutations in the C10 domain of MYBPC3 are associated with 
significantly accelerated degradation rates. 
 We hypothesized that C10 mutants Leu1238Pro and Asn1257Lys would degrade 
significantly faster than WT or C3/C6 mutant MYBPC3, similarly to 
Glys1248_Cys1253dup as observed in Chapter 2. CHX pulse-chase with AlphaLISA 
analysis supported this hypothesis. All three C10 mutants had significantly decreased t½ 
compared to WT MYBPC3, in the range of ~10-20 fold lower (Gly1248_Cys1253dup: 
0.44hr, Leu1238Pro: 0.27hr; Asn1257Lys: 0.24hr) (Figure 4.5A-D). These findings 
correlate with the significantly reduced protein expression and lack of sarcomere 
incorporation we observed in C10 mutants. See Table 4.1 for degradation curve fit 
parameters. 
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4.5 DISCUSSION 
 The main findings of this study are (i) analysis of SHaRe registry data uncovered 
clusters of pathogenic missense mutations in the C3, C6, and C10 domains of MYBPC3 
and (ii) protein localization and stability of MYBPC3 missense mutations are influenced 
by mutation locus. We also verified that the t½ of WT FLAG-MYBPC3 we observed from 
Western blot data in Chapter 2 (see Figure 2.7) was similar when measured by a different 
method and demonstrated the efficacy of the AlphaLISA assay to accurately detect 
FLAG-MYBPC3 at levels below the resolution of Western blotting. Based on these data, 
we speculate that C10 mutations may actually be associated with haploinsufficiency of 
MYBPC3, similarly what is observed in patients with truncating mutations[Jacques, 2008, 
Marston, 2009, van Dijk, 2012]. Conversely, C3- and C6-domain mutants are likely associated with 
a dominant-negative effect that alters contraction and the critical regulatory functions of 
MYBPC3. 
 The presence of pathogenic mutation clusters in C3 and C6 imply those loci 
contain residues important to function, binding or folding of MYBPC3. Yet despite the 
frequency of the Arg502Trp mutation and the apparent importance of the C3 and C6 
domains, their roles of these domains remain unclear. Structural characterization of the 
C3 mutation Arg502Trp suggests the mutation alters the electrostatic properties of the 
domain, and the arginine 502 residue was found to be highly conserved across 
species[Zhang, 2014]. While there is no direct evidence that C3 binds to actin, transmission 
electron microscopy analysis of F-actin decorated with a C0-C3 fragment of MYBPC3 
indicates they are in close proximity[Mun, 2011]. Mutations in C3 could potentially disrupt key 
interactions of the N-terminus of MYBPC3 with actin, or alter the flexibility of the protein, 
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which could both seriously impact function. Our results suggest that C3-domain mutations 
do not affect sarcomere incorporation and are stably expressed, which is in line with the 
hypothesis that altered function of full-length MYBPC3 can drive HCM pathogenesis 
through a dominant-negative mechanism causing contractile dysfunction. 
 Arginine 820 in the C6 domain is also conserved in mammals, and a naturally 
occurring Arg820Trp mutation causes feline HCM[Meurs, 2007]. Arg820Trp and Arg820Gln 
mutations have been identified in humans, but they were more associated with left 
ventricular non-compaction and dilated cardiomyopathy, respectively[Konno, 2003, Ripoll Vera, 
2010]. The Trp792Arg mutation changes another highly conserved residue. Recently, 
Smelter et. al. analyzed this mutation in an engineered mouse cardiac tissue model and 
found it to be expressed at significantly lower levels compared to WT MYBPC3, 
suggesting instability despite correct sarcomere localization[Smelter, 2018]. They hypothesize 
that introduction of a charged arginine residue into the hydrophobic core of C6 causes 
misfolding of this fibronectin-like domain. These results conflict with our observations, 
which showed no significant signs of Trp792Arg being unstable compared to WT 
MYBPC3. This discrepancy could be explained by the use of different model systems with 
different genotypes: our experiments were performed using a monolayer of neonatal rat 
cardiomyocytes with full expression of endogenous MYBPC3, while Smelter et. al. 
generated 3D tissue cultures from MYBPC3 knockout neonatal mouse cardiomyocytes. 
Both studies used adenovirus to introduce mutant MYBPC3. Despite these differences, 
these encouraging findings support the idea that certain missense mutations result in 
instability of MYBPC3 and a loss-of-function based mechanism. 
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 We observed significant instability of not C6 but C10 mutant proteins. The C10 
domain has well-established binding partners and is necessary to anchor the C-terminus 
of MYBPC3 to the rod of the thick filament[Gilbert, 1999, Gilbert, 1996]. This corresponds with the 
failure of all three C10 mutants to incorporate into the sarcomere, which is probably a 
result of abolished MYBPC3 and light meromyosin/titin interactions. Aberrant cytosolic 
expression of C10 mutant MYBPC3 without protection from the sarcomere is a likely 
explanation for its susceptibility to rapid degradation and low expression levels. We 
therefore conclude that mutations in the putative C10 cluster are more likely to act by a 
mechanism distinct from other missense mutations. Ascertaining the precise mechanism 
associated with C10 mutations should be of high priority as personalized medicine moves 
forward, namely due to an extremely prevalent deletion mutation that is found in 
approximately 4% of the South Asian population, and potentially up to 1% of the entire 
population[Kuster, 2014]. This pathogenic variant replaces most of C10 with novel sequence 
and like the Gly1248_Cys1253dup mutation, it was not detectable in septal myectomy 
samples from two different HCM patients[Dhandapany, 2009]. We speculate that this mutant 
protein would also show accelerated degradation kinetics. Clearly, differentiating between 
molecular mechanisms associated with stable vs. unstable MYBPC3 mutations will be 
vital to development of targeted therapies for some of the most frequently occurring 
mutations in HCM. 
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FIGURE 4.1 
 
 
 
146 
 
Figure 4.1. C3 and C6-domain mutants localize to the C-zone, while C10-domain 
mutants mislocalize to cytoplasm. (A) Location of C3, C6 and C10 missense mutations within MYBPC3, 
showing potential mutation cluster regions. (B) Neonatal rat cardiomyocytes (NRVMs) were transiently transfected with 
FLAG-MYBPC3 adenovirus and immunofluorescence was performed on patterned NRVMs. FLAG-WT MYBPC3 and 
endogenous MYBPC3 correctly co-localize to the C-zone. This likewise occurs for C3 and C6-domain mutations. 
However, C10 domain mutations appear diffuse in the cytosol with little to no sarcomere localization. All conditions 
were tested at minimum in triplicate. Endogenous MYBPC3 (green), FLAG (red), DAPI (blue). Immunofluorescence 
micrographs, 60X magnification. Scale bar = 10µm.  
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FIGURE 4.2 
 
 
 
Figure 4.2. Expression levels of missense MYBPC3 mutants versus WT. The AlphaLISA 
assay was used to determine steady-state levels of adenovirally-transfected FLAG-MYBPC3 in NRVMs. C3- and C6-
domain mutation levels were similar to WT levels, with the exception of F503L. Expression of all three C10-domain 
mutations was significantly reduced compared to WT, corresponding with their cytosolic mislocalization. Two 
independent experiments; Mean±SEM, n≥6. Kruskal-Wallis one-way ANOVA p<0.0001. *p<0.0001 vs control, Dunn’s 
test for multiple comparisons. 
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FIGURE 4.3 
 
 
 
Figure 4.3. MYBPC3 missense mutations in the C3 domain do not significantly alter 
protein t½. (A) Overlaid cycloheximide pulse-chase analysis of the C3 mutants Arg495Gln (squares), Arg502Trp 
(triangles), Phe503Leu (diamonds), compared to FLAG-WT MYBPC3 (open circles, solid line) Gray dotted lines show 
95% confidence intervals for WT fit. (B-D) Individual curve fits for mutants with 95% confidence interval. For each data 
point, n≥8 technical replicates from two independent experiments. Mean±SEM, p values represent significance of 
comparison of reaction constant k versus WT-FLAG MYBPC3. *p≤0.01. Dotted lines show 95% confidence intervals 
for k. 
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FIGURE 4.4 
 
 
Figure 4.3. MYBPC3 missense mutations in the C6 domain do not significantly alter protein 
t½. (A)  Overlaid cycloheximide pulse-chase analysis of the C6 mutants Trp792Arg (squares) and Arg810His (triangles), 
compared to FLAG-WT MYBPC3 (open circles, solid line). WT data shown previously in Fig. 4.3. (B-D) Individual curve 
fits for mutants with 95% confidence interval. For each data point, n≥8 technical replicates from two independent 
experiments. Mean±SEM, p values represent significance of comparison of reaction constant k versus WT-FLAG 
MYBPC3. *p≤0.01. Dotted lines show 95% confidence intervals for k. 
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FIGURE 4.5 
 
 
 
Figure 4.5. MYBPC3 missense mutations in the C10 domain severely reduce protein 
t½. (A)  Overlaid cycloheximide pulse-chase analysis of the C10 mutants Gly1248_Cys1263dup (squares), 
Leu1238Pro (triangles), and Asn1257Lys (diamonds), compared to FLAG-WT MYBPC3 (open circles, solid line). WT 
data shown previously in Fig. 4.3. (B-D) Individual curve fits for mutants with 95% confidence interval. For each data 
point, n≥11 technical replicates from two independent experiments. Mean±SEM, p values represent significance of 
comparison of reaction constant k versus WT-FLAG MYBPC3. *p≤0.01. Dotted lines show 95% confidence intervals 
for k. 
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TABLE 4.1. Kinetic fit parameters for AlphaLISA cycloheximide pulse-chase data. 
Domain Protein t½ (hr) t½ 95% CI (hr) k (hr-1) ± SE 
p value for k 
comparison 
vs. WT 
 WT 5.06 4.15 to 6.50 0.137 ± 0.030  
C3 
Arg495Gln 5.50 3.95 to 9.06 0.126 ± 0.049 0.7174 
Arg502Trp 5.82 4.35 to 8.81 0.214 ± 0.062 0.5087 
Phe503Leu 3.24 2.51 to 4.56 0.119 ± 0.040 0.0442 
C6 Trp792Arg 3.41 2.58 to 5.04 0.203 ± 0.053 0.0826 Arg810His 8.92 6.46 to 14.4 0.0777 ± 0.030 0.0081* 
C10 
Leu1238Pro 0.27 0.16 to 0.89 2.57 ± 1.8 <0.0001* 
Gly1248_Cys1253dup 0.44 0.32 to 0.66 1.58 ± 0.56 <0.0001* 
Asn1257Lys 0.24 0.18 to 0.37 2.89 ± 0.99 <0.0001* 
Abbreviations. t½: half-life; k: reaction constant; CI: confidence interval; SE: standard error 
 
*p<0.01 for parameter k in first-order decay reaction fit for WT vs. respective mutant 
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CHAPTER 5 
 
DISCUSSION 
 
5.1 Summary of thesis work 
 A wealth of research over the years has cemented the assessment of cardiac 
myosin binding protein C (MYBPC3) as a critical regulator of contraction with significant 
roles in cardiac physiology. Despite its long-recognized status as the most frequently 
mutated gene in the most common inherited cardiomyopathy, definitive disease 
mechanisms associated with MYBPC3 mutations have not been firmly established. The 
overarching goal of this project was to work toward a better understanding of 
pathogenesis in MYBPC3-linked HCM. The work presented in this dissertation is pursuant 
to three specific aims: (i) to identify protein quality control-related factors involved in the 
handling and turnover of MYBPC3; (ii) to clarify whether pathogenic truncating MYBPC3 
mutants are directly proteotoxic, and whether truncating mutations are sufficient to cause 
left ventricular remodeling in the absence of MYBPC3 haploinsufficiency; and (iii) to 
determine if protein stability, and therefore potential pathogenic mechanism, is dependent 
on mutation locus in non-truncating MYBPC3 mutants. These three questions are tied 
together around the central concept of sarcomere protein homeostasis. The conclusions 
drawn from our results accomplish the overarching goal and also offer insight into the 
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complex and incompletely understood subject of sarcomere maintenance and its 
physiological roles at the molecular, cellular, and organismal levels. To finish this 
dissertation, we will discuss the implications of this study on potential therapies and future 
directions in HCM research. 
5.1.1 Novel interactions between MYBPC3 and molecular chaperone proteins 
 In Chapter 2, we used an unbiased affinity purification-mass spectrometry screen 
to detect MYBPC3 interacting proteins in NRVMs transduced with adenovirus to express 
FLAG-epitope tagged WT and mutant MYBPC3. Surprisingly, gene ontology analysis 
identified protein quality control-related interactors as the most enriched protein category, 
rather than myofilament proteins. This category included several molecular chaperones, 
proteins which assist in folding, repair and degradation of client proteins, most 
prominently the inducible and constitutive isoforms of heat shock protein 70kDa (HSP70 
and HSC70, respectively). MYBPC3 is known to be degraded via the ubiquitin 
proteasome system (UPS)[Sarikas, 2005, Vignier, 2009], but mechanisms which target it for 
ubiquitination are unknown. After demonstrating physical interaction between MYBPC3 
and HSP70 chaperones, we were also able to demonstrate functional interactions by 
using cycloheximide pulse-chase experiments to observe the effects of modulating 
HSP70/HSC70 expression and activity on the degradation kinetics of WT and mutant 
MYBPC3. Suppression of HSC70 expression and activation of HSP70 resulted in 
significant changes in protein t½, strongly implying HSP70s act upstream of the UPS to 
target MYBPC3 for degradation through interactions with E3 ligases like C-terminus of 
HSC70 interacting protein (CHIP)[McDonough, 2003]. To our knowledge these are the first 
chaperones found to interact with MYBPC3. While evaluation of functional interactions 
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between MYBPC3 and chaperone proteins was limited to the HSP70-family in this study, 
we also consider the small heat shock proteins (sHSP) αB-crystallin and HSP27 
compelling candidates for factors involved in MYBPC3 turnover. In contrast to the 
HSP70s, the sHSPs showed loss of interaction with mutant MYBPC3. αB-crystallin and 
HSP27 are among those sHSPs highly expressed in the heart[Golenhofen, 2004, Hollander, 2004]. 
Both of these chaperones have previously established interactions with titin which can be 
induced by mechanical damage and unfolding of immunoglobulin-like domains[Kotter, 2014]. 
These interactions are relevant because MYBPC3 contains eight immunoglobulin 
domains with high structural similarity to those in titin[Otey, 2009]. It is unknown whether 
MYBPC3 immunoglobulin-like domains unfold in response to stretch in vivo, but atomic 
force microscopy experiments suggest they will unfold under relatively modest 
mechanical loads[Karsai, 2011]. Therefore, αB-crystallin and HSP27 could be recruited to 
refold MYBPC3 in a similar fashion to titin. Future studies should address functional 
interactions between MYBPC3 and sHSPs perhaps under both normal and chronic 
stretch conditions. The significance of identifying chaperones and co-chaperones 
associated with MYBPC3 lies in the discovery of pathways that could be targeted to 
control expression of MYBPC3 in disease contexts, particularly to restore expression to 
normal levels in haploinsufficient states. 
 5.1.2 Truncated MYBPC3 is not directly proteotoxic in cardiomyocytes 
 In Chapter 3, we investigated proteostasis at the cellular and whole-organ levels 
by challenging cardiomyocytes with expression of truncated MYBPC3 proteins. Previous 
studies found evidence that expression of truncated mutants was sufficient to disrupt 
proteostasis by causing impaired UPS function and aggregation of ubiquitinated 
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proteins[Bahrudin, 2008, Sarikas, 2005]. Combined with later findings of significantly reduced 
proteasome enzymatic activity in septal myectomy tissue from HCM patients[Predmore, 2010, 
Thottakara, 2015], this data generated the hypothesis that truncated MYBPC3 is inherently 
proteotoxic and a “poison peptide” effect contributes to HCM pathogenesis. In vivo 
modeling of “pure” haploinsufficient mice (heterozygous MYBPC3 knock-out) versus mice 
with both haploinsufficiency and truncated protein expression (heterozygous truncating 
knock-in) seemed to support this hypothesis, as myocardial UPS dysfunction was only 
reproduced in the heterozygous knock-in mice[Schlossarek, 2012, Schlossarek, 2012]. However, this 
premise has been repeatedly called into question by attempts to detect truncated proteins 
in patient tissue which have consistently failed[Jacques, 2008, Marston, 2009, van Dijk, 2009]. The above 
studies showed that truncated MYBPC3 expression may be necessary to induce UPS 
dysfunction, but not ventricular remodeling. Haploinsufficiency without truncated 
MYBPC3 was found to be sufficient to elicit cardiac hypertrophy, but the inverse situation 
had never been tested. We demonstrated that truncated MYBPC3 is in fact not sufficient 
to cause hypertrophic remodeling or disrupt proteostasis in non-haploinsufficient models. 
Using a more diverse panel of mutations than previous studies[Sarikas, 2005], we found no 
evidence of UPS dysfunction, protein aggregates, or HSP70-related protein folding stress 
responses in NRVMs with acute expression of truncated mutants. Neither were UPS 
dysfunction or aggregates present in the hearts of transgenic mice with conserved 
MYBPC3 stoichiometry chronically expressing truncated protein. Finally, rigorous 
structural and functional assessment of transgenic murine hearts over 12 months 
identified no cardiac disease phenotype. These results move toward resolving the 
haploinsufficiency vs. “poison peptide” debate in MYBPC3-linked HCM. Future studies 
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should try to clarify whether “pure” haploinsufficiency is sufficient to cause UPS 
dysfunction without a “second hit.” The heterogeneity of HCM phenotypes suggests 
influence of unknown modifier genes; variants in proteasome subunits or other protein 
quality control-related genes could affect whether loss of proteostasis develops 
subsequent to hypertrophic remodeling. As mouse models with MYBPC3 mutations 
generally display very mild phenotypes, isogenic induced pluripotent-derived stem cell 
lines or large animal models may be better choices of model systems. A porcine HCM 
model carrying a mutation in MYH7 has been generated and exhibits a robust 
phenotype[del Rio Carlos, 2017, Green Eric, 2017]. Mutations in MYBPC3 would optimistically produce 
a similar phenotype in pigs. 
 5.1.3 Putative missense mutation clusters in MYBPC3 reveal locus-
dependent variability in protein stability. 
In Chapter 3, SHaRe registry patient genotype data revealed three regions of 
potential “hot spots” for non-truncated MYBPC3 mutations in the C3, C6, and C10 
domains. Non-truncating mutations in MYBPC3 make up <10% of individual mutations 
thus far identified[Alfares, 2015], and are generally assumed to share a common dominant-
negative pathogenic mechanism whereby they incorporate into the sarcomere and alter 
contractile function. This assumption has recently been challenged based on a missense 
mutation that significantly alters protein stability and may instead cause 
haploinsufficiency[Smelter, 2018]. Additionally, in Chapter 2 we found that an in-frame 
duplication mutation had an extremely accelerated degradation rate compared to WT 
MYBPC3, and was unable to localize to the sarcomere[Glazier, 2018]. In patients the mutant 
protein was not detectable, as is consistently seen with truncating mutations[Helms, 2014]. 
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We assessed the subcellular localization and expression levels of three C3, two C6, and 
three C10 non-truncating mutants adenovirally-transduced into NRVMs. We next used a 
streamlined, microplate-based version of the cycloheximide pulse-chase method 
employed in Chapter 2 to compare degradation kinetics of the different mutants. Our 
results support the hypothesis that distinct pathogenic mechanisms exist within the 
subcategory of MYBPC3 missense mutations that are dictated by mutation locus. Most 
significantly, all three C10-domain mutants showed cytosolic mislocalization, low 
expression and protein t½ 10- to 20-fold lower than WT MYBPC3. If these characteristics 
are recapitulated in vivo, a dominant-negative mechanism is very unlikely. In general, we 
found the C3- and C6-domain mutants to have expression and protein t½ not significantly 
different from WT MYBPC3, and all five of these localized properly to the C-band. This 
pattern is more in line with the dominant-negative mechanism. Our lab is currently 
expanding this study to include in silico structural analysis of these mutants using Iterative 
Threading Assembly Refinement (I-TASSER)[Yang, 2015] and structure-based prediction of 
protein stability (STRUM)[Quan, 2016] methods to predict protein structure and the Gibb’s 
free energy gap differences between WT and mutant proteins (ΔΔG). Preliminary results 
further distinguish between the two groups of mutations, with C3 mutants predicted to 
have little to no change in stability, while C10 mutants all have ΔΔG≤-1, indicating 
destabilization. Future, more mechanistically-targeted directions should emphasize ruling 
out direct effects on contractile function associated with C10-domain mutants through 
comparison to “pure” haploinsufficient models or by showing that conditional suppression 
of the C10 mutant allele results in no change in phenotype. Being able to predict 
pathogenic mechanisms based on mutation locus will facilitate development of targeted 
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therapies in MYBPC3-linked HCM and make identification of appropriate interventions 
more efficient. 
 
5.2 MYBPC3 mutations and unifying pathogenic mechanisms in HCM 
Despite the range of evidence in support of the two main hypotheses discussed 
previously, an intermediate mechanistic link between haploinsufficiency and/or 
proteotoxicity and whole-organ cardiac remodeling remains undefined, as does a unifying 
pathogenic mechanism across various HCM genotypes. As with HCM caused by a subset 
of mutations in other sarcomere genes, Ca2+ sensitivity of the myofilament is increased in 
MYBPC3-linked HCM[van Dijk, 2009]. Increased Ca2+ sensitivity, potentially leading to 
hypercontractility, impaired relaxation, and alterations in Ca2+-dependent signaling 
pathways, has been suggested as a unifying pathogenic mechanism in HCM. Another 
compelling hypothesis proposes HCM is the result of energetic deficits stemming from 
overuse of ATP by myosin due to altered contractility[Ashrafian, 2003].  
Both of these broader mechanisms are theoretically consistent with 
haploinsufficiency of MYBPC3 being the primary insult. Partial extraction of MYBPC3 
from rat cardiomyocytes has been shown to result in increased Ca2+ sensitivity, and total 
ablation of MYBPC3 is associated with increased Ca2+ sensitivity in some mouse 
models[Fraysse, 2012, Hofmann, 1991]. Haploinsufficiency of MYBPC3 would blunt the “braking” 
function, leading to a higher rate of cross-bridge cycling in the C-zone. This would 
presumably also apply to C10-domain non-truncating mutations. Evidence in support of 
this includes recent findings in both mouse and human cardiomyocytes that MYBPC3 
may stabilize the super-relaxed conformation of myosin, in which actin binding and ATP 
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hydrolysis are severely restricted[McNamara, 2017, McNamara, 2016]. These reports demonstrated 
accelerated ATP turnover and a decrease in the proportion of super-relaxed myosin 
heads in patient cells and MYBPC3-knockout murine cells, respectively. Whether 
proteotoxicity of truncated MYBPC3 or proteasome dysfunction could affect overall 
myocyte Ca2+ homeostasis or energy balance is less straightforward, but many processes 
involved in PQC are ATP-dependent including proteasome-mediated degradation and 
HSP70 chaperone folding cycles, while Ca2+ homeostasis in the endoplasmic reticulum is 
also vital for maintaining ER proteostasis. Another viable hypothesis suggests that UPS 
impairment could block the normal degradation of hypertrophic signaling factors, such as 
calcineurin[Li, 2004], NFAT[Tang, 2010], and MAPK phosphatase-1[Xie, 2009], causing 
inappropriate activation of pro-hypertrophic signaling. Overall, however, our data does 
not support that truncated MYBPC3 can elicit these effects on its own. Given that 
mutations in most other sarcomere genes act by directly altering contractile function, it is 
difficult to place proteotoxicity of truncated MYBPC3 within a hypothetical larger 
framework of converging mechanisms. 
 
5.3 The risk of treating absence of evidence as evidence of absence regarding 
truncated protein expression 
  The evidence increasingly supports haploinsufficiency of MYBPC3 in patient 
myocardium, while truncated mutant proteins remain undetected. Nevertheless, we must 
acknowledge that more sensitive techniques could be employed before accepting the 
current absence of evidence to mean evidence of absence. Published studies typically 
used SDS-PAGE and Western blotting to look for truncated proteins, with lower detection 
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limits established to be 1.5-3.0% of the total MYBPC3 protein[Marston, 2009, Rottbauer, 1997, van 
Dijk, 2009]. Our lab has attempted to detect truncated proteins by cutting out bands from 
polyacrylamide gels at the predicted molecular weight of the given protein and analyzing 
protein composition by mass spectrometry (unpublished data). This method also failed to 
detect any mutant protein, but it is entirely possible that the mutation ran at a different 
weight than predicted. As we have observed, proteasome inhibition blocks degradation 
of MYBPC3 mutants, and could be used to try to bring out expression in patient-derived 
induced pluripotent stem cell-derived cardiomyocytes. We could also take advantage of 
frameshift mutants that produce novel amino acid sequences and use mass spectrometry 
to detect peptides containing these unique sequences. Lastly, the ribo-seq technique 
could identify whether prematurely terminated MYBPC3 transcripts are ever translated by 
sequencing of transcript fragments being actively translated and therefore protected from 
RNase treatment by the ribosome[Ingolia, 2009]. This method has already been successfully 
used to demonstrate that titin truncating variants which were not detected by SDS-PAGE 
were indeed translated[Schafer, 2016]. 
 
5.4 Future Directions 
5.4.1 Potential therapeutic interventions in MYBPC3-linked HCM 
Our study found that truncating MYBPC3 mutations could not produce phenotypes 
when isolated from the haploinsufficiency observed in HCM patients. Recognition that 
haploinsufficiency plays a central role in disease pathogenesis for MYBPC3 mutation-
linked HCM raises interesting possibilities for disease-modifying therapies. Currently, 
medical management is supportive. Treatments include beta blockers, calcium channel 
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blockers, surgical myectomy for symptomatic left ventricular outflow tract obstruction, 
implantable cardiac defibrillators for prevention of sudden cardiac death, and heart 
transplantation for a small subset of patients who progress to decompensated heart 
failure. There is a great interest in exploring therapies that could prevent the emergence 
and/or progression of HCM. MYBPC3 carriers showed the greatest benefit in a small 
randomized trial of the Ca2+ channel blocker diltiazem in sarcomere gene mutation 
carriers, with reductions in LV wall thickness and mass, improved diastolic filling, and 
lower cardiac troponin I levels in those taking diltiazem compared with controls[Ho, 2015]. 
However, correcting the fundamental defect that triggers pathological remodeling in HCM 
is the ultimate goal for disease prevention.  For MYBPC3 mutation carriers, developing 
strategies to normalize MYBPC3 protein levels could hold tremendous promise. In cellular 
and mouse models, increasing WT MYBPC3 levels prevents the development of 
hypertrophy and other HCM phenotypic characteristics[Mearini, 2014, Merkulov, 2012, Monteiro da Rocha, 
2016].  These studies raise the possibility of gene delivery of wild-type MYBPC3 via viral 
vectors into patients with HCM as a potential therapeutic option. Alternatively, with the 
advent of CRISPR technology, gene correction has been proposed as a treatment option. 
As a proof of concept CRISPR-mediated repair of a MYBPC3 mutation was recently 
successful performed in a human embryo[Kaul, 2018] (Figure 5.1A). Another method of gene 
editing is exon skipping. This strategy has been employed successfully for Duchenne 
muscular dystrophy[Aartsma-Rus, 2009, Aartsma-Rus, 2017]. In a mouse model carrying biallelic 
MYBPC3 mutations, antisense oligonucleotide-induced exon skipping produced an 
alternative transcript that restored partial protein expression and function[Gedicke-Hornung, 
2013]. However, this strategy is likely not applicable for heterozygous mutations given that 
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the WT allele would also undergo exon skipping, leaving no full-length WT MYBPC3. 
Despite the obvious enthusiasm for applying gene corrective approaches to the treatment 
of Mendelian diseases like HCM, there are many technical obstacles and safety concerns 
that limit its applicability in the near future. For these reasons, a more attractive approach 
to targeted therapy for HCM is small molecule therapeutics. An allosteric myosin 
modulator (mavacamten) that inhibits myosin ATPase activity has been developed[Green, 
2016, Kawas, 2017] (Figure 5.1D) and is currently in clinical trials in HCM patients. However, it 
is not yet clear whether mavacamten will be effective for those who carry mutations in 
genes other than myosin. For MYBPC3 mutation carriers, the possibility of targeting 
haploinsufficiency therapeutically using small molecules could be very attractive for 
preventing or attenuating disease progression. One potential approach would be to 
employ read-through strategies (Figure 5.1B). Small molecule drugs have been 
developed that enable ribosomal read-through of nonsense mutations in mRNA resulting 
in the production of full length protein. Altaluren, one such small molecule, is being tested 
in phase 3 clinic trials for the treatment of Duchene Muscular Dystrophy[McDonald, 2017].  
5.3.2 Targeting PQC of MYBPC3 as a method to restore normal stoichiometry  
As we uncover a more complete understanding surrounding how nonsense 
mediated mRNA decay, the ubiquitin proteasome system, and molecular chaperones 
regulate and control MYBPC3 protein levels, we may identify novel targets that can be 
regulated to restore wild-type MYBPC3 protein levels (Figure 5.1C). Towards this goal, it 
has already been demonstrated that proteasome inhibition and inhibition of nonsense-
mediated mRNA decay can increase MYBPC3 protein levels[Vignier, 2009]. However, this 
approach could also increase levels of mutant protein which may not incorporate into the 
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sarcomere or have deleterious effects. Thus, the phenotypic consequences of increased 
mutant protein levels must be defined. Further, these systems may change levels of other 
cellular proteins resulting in off-target effects. A potentially more specific approach is to 
alter the activity of specific molecular chaperones. While identification of HSP70/HSC70 
as MYBPC3 chaperones is an important first step towards this, these chaperones are 
highly ubiquitous and involved in numerous critical cell functions and inhibition would also 
affect myriad other protein clients. Identification of specific co-chaperones or E3 ligases 
that assist with HSC70-medated MYBPC3 degradation may allow more finely-tuned 
regulation of MYBPC3 expression. 
5.3.3 Other factors influencing haploinsufficiency of MYBPC3 
5.3.3.1 Correlation between WT MYBPC3 levels and HCM phenotypes 
An interesting unresolved question is whether MYBPC3 mutation carriers remain 
asymptomatic until a certain threshold of haploinsufficiency is reached. As we develop 
modulators of MBYPC3 protein homeostasis, it is also important to recognize that the 
dynamic relationship between MYBPC3 protein levels and HCM phenotypes remains 
undefined. More accurate techniques to measure and quantify mRNA and protein levels 
will facilitate a more refined understanding of this relationship. Some potential useful 
technologies include the use of human SNPs and high-density DNA arrays to detect allelic 
imbalance[Mei, 2000] and quantitative mass spectrometry-based analytical methods[Panuwet, 
2016]. The development of chemical probes that can dynamically control MYBPC3 protein 
levels or allow for the quantification of MYBPC3 protein levels within live cardiac tissue 
could significantly impact on our ability to evaluate how MYBPC3 protein level and 
disease phenotypes are linked.  Identification of modifier genes involved in PQC may help 
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explain some of the phenotypic heterogeneity in HCM. Impairment in protein folding 
stress responses increases with age and, such modifier genes could affect age of disease 
onset. For example, HSP70 polymorphisms have tentatively been shown to influence 
clinical manifestation of HCM in South Asian patient cohorts[Rangaraju, 2014, Rangaraju, 2013]. 
5.3.3.2 Effects of stress on MYBPC3 expression 
Some recent studies have raised the question of whether stress can trigger 
reduction in MYBPC3 levels and remodeling in asymptomatic individuals, which may also 
explain the variable age of onset of MYBPC3-linked HCM[Strande, 2015]. Schlossarek et al. 
found that adrenergic challenge via one week of treatment with isoprenaline and 
phenylephrine induced ventricular hypertrophy and proteasome dysfunction in previously 
phenotype-negative heterozygous MYBPC3 mutant mice[Schlossarek, 2012]. Additionally, 
Barefield et al. observed reduction in wild-type MYBPC3 expression in heterozygous, but 
not wild-type, mice following both transverse aortic constriction surgery and, surprisingly, 
sham surgery[Barefield, 2015]. These findings tentatively suggest that stress may influence 
MYBPC3 expression particularly in truncating mutation carriers. A number of sources of 
cellular stress activate unfolded protein response pathways, including heat stress, 
oxidative stress, inflammation, and metabolic dysfunction[Morimoto, 1993]. Additional studies 
are needed to determine whether stressors such as chronic β-adrenergic stimulation, 
cardiovascular stress separate from HCM, and trauma can exacerbate or even initiate 
maladaptive cardiac remodeling by influencing expression of MYBPC3. 
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5.5 Concluding Remarks 
In summary, this dissertation explored connections between MYBPC3 and 
proteostasis networks in order to better understand how MYBPC3 mutations cause 
hypertrophic cardiomyopathy and what role protein quality control plays in disease 
pathogenesis. Our findings challenge two important hypotheses: first, that truncating 
mutations can cause HCM by disrupting cardiomyocyte proteostasis; and second, that 
non-truncating mutations share a common dominant-negative mechanism that directly 
affects contraction independent of mutation locus. On the contrary, we observed that non-
truncating mutations in the light meromyosin binding C10 domain of MYBPC3 are 
rendered acutely unstable compared to other mutations in C3 and C6, and likely result in 
haploinsufficiency instead. Although we were not able to associate truncated MYBPC3 
expression to proteotoxicity or hypertrophic remodeling, our affinity purification-mass 
spectrometry screen implicated the important molecular chaperone HSC70 as a regulator 
of MYBPC3 degradation, the first chaperone found to be associated with MYBPC3. These 
results de-emphasize the role of proteotoxicity in the pathogenesis of HCM, but open the 
door to new lines of inquiry regarding how therapeutic interventions might restore 
MYBPC3 sarcomere stoichiometry in haploinsufficient hearts. A more detailed 
understanding of the mechanisms which regulate MYBPC3 protein homeostasis could 
potentially lead to a successful treatment strategy for HCM, where natural protein quality 
control mechanisms could be leveraged to selectively restore MYBPC3 protein 
homeostasis and overcome haploinsufficiency.    
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FIGURE 5.1 
 
 
 
Figure 5.1. Potential therapeutic approaches to correcting or ameliorating the 
effects of MYBPC3 haploinsufficiency in HCM at different mechanistic stages. Such 
approaches could include: correction of the mutant allele through gene editing technology, restoring full expression of 
wild-type MYBPC3; stop codon readthrough for truncating mutations, resulting in expression of a mutant but 
functional full-length protein; increasing expression of the wild-type protein by modulating its turnover; and targeting 
of downstream maladaptive mechanisms without affecting MYBPC3 protein expression. 
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